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ABSTRACT OF THE DISSERTATION 
The Role of Actr10 in Nervous System Development and Disease 
by 
Amy Louise Herbert 
Doctor of Philosophy in Biology and Biomedical Sciences 
Developmental, Regenerative, and Stem Cell Biology 
Washington University in St. Louis, 2018 
Professor Kelly Monk, Chair 
Professor Jim Skeath, Co-Chair 
 
The vertebrate nervous system requires myelinating glia for the fast propagation of action 
potentials, as well as for vital trophic support to axons. Myelinating glia produce myelin, which 
is a lipid-rich, multi-lamellar sheath that surrounds axons and allows for rapid electrical 
signaling. In the central nervous system (CNS), myelin is produced by oligodendrocytes, while 
in the peripheral nervous system (PNS), Schwann cells perform this function. Although glia have 
historically been understudied compared to neurons, recent research has uncovered critical roles 
for glia in nervous system development and disease. Disruption to myelin or to the glial cells that 
generate myelin can have severe consequences for human health, as demonstrated by the 
debilitating symptoms of multiple sclerosis (MS) and Charcot-Marie-Tooth disease (CMT). In 
order to improve patient health, it is necessary to determine the etiology of demyelinating 
diseases, which in turn requires a comprehensive understanding of glial cell development and 
myelination. The scientific advances made in our understanding of myelinating glial cell 
development will be discussed in Chapter 1 of this dissertation. Although great progress has been 
 xiv 
achieved, our understanding of the molecular mechanisms that regulate myelination is 
incomplete.  
The zebrafish has emerged as an important model organism for studying myelin. In 
particular, the ability to perform forward genetic screens in zebrafish has greatly increased our 
understanding of the individual genes involved in myelination in both the CNS and the PNS. 
Although several myelin-related forward genetic screens have been previously performed in 
zebrafish, these screens were not done to saturation, potentially leaving essential genes 
unidentified. Our lab therefore performed a large scale forward genetic screen to uncover new 
players in myelin development. The screen was a collaborative effort between students in the 
Monk lab and members of the Solnica-Krezel lab. The myelin screen was highly successful, 
uncovering 31 mutants. The set-up and outcome of the screen is described in more detail in 
Chapter 2.  
One of the mutants identified in the screen was found to be the result of a mutation in the 
gene actin related protein 10 (actr10). Actr10 (or Arp11) is a component of the dynactin 
complex, which is necessary for retrograde transport of cargo by cytoplasmic dynein. Two 
alleles of actr10 zebrafish mutants, actr10stl83 (the allele originally identified in the screen) and 
actr10nl15 (a presumptive null generously shared by the Nechiporuk lab) exhibited reduced 
myelin in the CNS and in the PNS, as well as a punctate expression of myelin basic protein 
(mbp) in the hindbrain. Mbp has important roles in myelin compaction as well as in initiating 
wrapping of myelin around axon segments. Initial characterization of actr10nl15/nl15 mutants 
revealed a reduction in oligodendrocyte precursor cells, fewer myelinated axons by 
ultrastructural analysis, and increased cell division in mutant oligodendrocytes. Moreover, the 
punctate mbp phenotype was reminiscent of another zebrafish mutant in the anterograde kinesin 
 xv 
motor kif1b. Importantly, mbp mRNA is transported and translated locally at the developing 
myelin sheath. I hypothesized that dynein/dynactin regulates anterograde transport of mbp 
mRNA in oligodendrocytes. To test this, I collaborated with another lab and found that indeed, 
mbp mRNA transport was arrested/perturbed in both rat oligodendrocyte cell culture and 
zebrafish in response to dynein inhibition, demonstrating a previously unknown role for 
dynein/dynactin in mbp transport. This published work can be found in its entirety in Chapter 3. 
In addition to myelin defects, actr10 zebrafish mutants exhibited axonal swellings in both 
the CNS and in the PNS. Electron microscopy revealed neurofilament accumulation in the axons 
of mutant animals, which is a hallmark of many neurodegenerative disorders. We therefore 
wondered whether ACTR10 might have a role in human disease. In collaboration with a 
neurologist at Washington University, several patients diagnosed with amyotrophic lateral 
sclerosis (ALS), distal myopathy and CMT were also found to have mutations in ACTR10. Using 
genome editing technologies in zebrafish, we generated a line of zebrafish containing the CMT2 
patient ACTR10 mutant single nucleotide polymorphism (SNP), thereby generating a patient 
specific disease zebrafish model. Current work is ongoing to characterize the zebrafish mutant 
and future experiments could include drug screens to identify compounds that may ameliorate 
CMT mutant phenotypes. Generation of the this CMT zebrafish line and future directions for this 
project are described in Chapter 4.  
From a forward genetic screen to identify novel regulators of myelination to generating 
patient specific mutations in zebrafish, my dissertation has involved a broad range of genetic and 
molecular techniques in the study of nervous system development in general, and myelinating 
glial development in particular. The identification of Actr10 as a player in oligodendrocyte 
development and myelination, as well as a potential regulator of a major human demyelinating 
 xvi 
disorder, demonstrates the power of zebrafish to address both basic and biomedical questions 
directly relevant to human patients. 
 1 
Chapter 1: Introduction 
 2 
Preface: 
Portions of this chapter have been reproduced and adapted from the following 
published manuscript: 
Herbert AL and Monk KR. (2017) Advances in myelinating glial cell 
development. Curr Opin Neurobiol 42:53-60.        
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1.1 The myelin sheath 
In the vertebrate nervous system, the fast conduction of action potentials is potentiated by 
the myelin sheath, a multi-lamellar, lipid-rich structure that also provides vital trophic and 
metabolic support to axons. Myelin is elaborated by the plasma membrane of specialized glial 
cells, oligodendrocytes in the central nervous system (CNS) and Schwann cells (SCs) in the 
peripheral nervous system (PNS). The diseases that result from damage to myelin or glia, 
including multiple sclerosis and Charcot-Marie-Tooth disease, underscore the importance of 
these cells for human health. Therefore, an understanding of glial development and myelination 
is crucial in addressing the etiology of demyelinating diseases and developing patient therapies. 
In this review, we discuss new insights into the roles of mechanotransduction and cytoskeletal 
rearrangements as well as activity dependent myelination and axonal maintenance by glia. 
Together, these discoveries advance our knowledge of myelin and glia in nervous system health 
and plasticity throughout life. 
1.2 Intrinsic factors guiding glial development 
Although both cells produce myelin to insulate and support axons, oligodendrocytes and 
SCs differ early in their genesis. Oligodendrocytes originate from neuroepithelial precursors, 
whereas SCs are derived from the neural crest. Furthermore, one oligodendrocyte can myelinate 
multiple axon segments, but one SC myelinates only a single axon segment (Fig. 1, Fig. 2). This 
is achieved through a process called radial sorting in which cytoplasmic processes from 
immature SCs extend into axon bundles and “select” an axon segment (1). SC development is 
mediated by a host of transcription factors and signaling molecules, including Sox10, which 
persists throughout development and differentiation, activating other transcription factors (1). In 
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pro-myelinating SCs, which have radially sorted axons and wrapped 1-1.5 turns around an axon, 
the G protein-coupled receptor (GPCR) GPR126/Adgrg6 elevates cAMP to promote expression 
of the transcription factor Oct6/Pou3f1 (1). Oct6 and Sox10, along with other factors, activate 
the master regulator of PNS myelination, Krox-20/Egr2, which is essential for expression of 
critical myelin genes, including Myelin basic protein (Mbp) (1).  
Proliferative and migratory oligodendrocyte precursor cells (OPCs) extend and retract 
numerous processes during development (2). Recent work has found that OPCs can migrate 
along blood vessels in a Wnt-dependent manner involving the receptor-ligand pair Cxcr4-
Cxcl12, which are expressed on OPCs and endothelial cells, respectively (3). Oligodendrocyte 
differentiation requires some shared SC factors, including Sox10 and Yin yang 1 (Yy1), in 
addition to the oligodendrocyte specific regulators Olig1, Olig2, Nkx2.2 (2) and Myelin 
regulatory factor, Myrf, which plays an analogous role to Krox-20 (4). Recent work in SCs and 
oligodendrocytes has identified novel roles for signaling molecules, including a suite of GPCRs, 
GPR17, GPR56 and GPR37 in the CNS (5-8)  and GPR44 and the zinc finger Zeb2 in the PNS 
(9-11) . While new myelin regulators remain to be uncovered, elucidating function of known 
molecules and pathways is key to understanding myelination in development and repair.  
1.3 Mechanical regulation of myelinating glial development 
and differentiation 
 
A unique signaling mechanism in SCs occurs via the basal lamina (BL), and recent 
evidence points to the molecular mechanisms by which this structure mechanically regulates 
myelination. In SCs, GPR126 can interact with axonally-derived Prion protein (PrPc) (12) as well 
as two SC-derived components of the BL, collagen IV and Laminin-211 (13,14). Laminin-211 
polymerization was proposed to activate GPR126 mechanically, initiating SC myelination (Fig. 
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1) (13), and SCs respond to mechanical properties of the BL with intracellular molecules such as 
Focal adhesion kinase (FAK) (15). Recently, two Hippo pathway signaling molecules, YAP and 
TAZ (YAP/TAZ), have been implicated as mediators of mechanotransduction during SC 
development. YAP/TAZ respond to mechanical or chemical stimuli and translocate to the 
nucleus to regulate gene transcription. In vitro culture experiments found nuclear localized 
YAP/TAZ during SC spreading, plating on stiffer surfaces, plating on Laminin-211, and 
experimentally applied stretching (Fig. 1). Analysis of mouse mutants demonstrated that 
YAP/TAZ signaling is required for radial sorting and myelination (16). YAP also has a role in 
modulating internode length during development and disease (17). In concert with TEAD 
transcription factors, nuclear YAP activates genes involved in the myelination program, 
including Krox-20/Egr2 and Myelin associated glycoprotein (MAG), Rab11, and Laminin¡1. 
The polarity protein Crb3 inhibits YAP nuclear translocation and knock-down of Crb3 increases 
the length of SC myelin segments (17). Crb3 is therefore thought to modulate YAP activity to 
temper internode length. Interestingly, a dystrophic mouse model of peripheral neuropathy 
exhibited reduced nuclear YAP with shorter internodes, a phenotype which could be rescued by 
manual sciatic nerve elongation via femoral distraction to increase nuclear YAP (17). These data 
suggest that migration of SCs along axons and/or longitudinal nerve growth could activate 
YAP/TAZ signaling during development. Perhaps physical maturation of the BL and GPR126 
activation is similarly linked to developmental YAP/TAZ signaling, as GPCRs are known 
upstream regulators of this pathway (18). Downstream of YAP/TAZ signaling, TEAD1 directly 
regulates Peripheral myelin protein 22 (Pmp22), mis-regulation of which causes Charcot-Marie-
Tooth disease (19).  
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While a role for YAP/TAZ signaling in oligodendrocytes has not been described, these 
cells are also responsive to mechanical stimuli. OPC proliferation and migration can be altered 
by plating on substrates of varying stiffness (20), resulting in differentiation in a density-
dependent manner. Plating at high density with polystyrene beads promoted OPC differentiation, 
demonstrating that this process is mediated by physical space limitations, rather than by 
extracellular signals (21). How might external forces drive oligodendrocyte development? A 
recent report demonstrates that mechanical stimuli interact with the nucleus via the Linker of 
Nucleoskeleton and Cytoskeleton complex (LINC). One LINC complex component in particular, 
SYNE1, which binds the nuclear envelope and actin, was shown to link extracellular stimuli, 
including high density plating with beads and mechanical force using a cell-compression device, 
to nuclear changes (22). The switch from primarily euchromatin to heterochromatin is a hallmark 
of differentiation in oligodendrocytes (23) and requires SYNE1 (22). Histone modifying 
complexes, specifically HDAC1 and HDAC2, affect nuclear reorganization by altering 
chromatin configuration and are essential for oligodendrocyte and SC differentiation. Epigenetic 
regulation of oligodendrocytes and SCs during development and myelination is reviewed in 
greater detail elsewhere (1, 24). 
1.4 Cytoskeletal regulation of myelination 
In a feat of cellular morphogenesis, glial cells massively upregulate production of their 
plasma membrane and spiral it around an axon segment. These dramatic shape changes require 
extensive cytoskeletal rearrangements, and great inroads have been made in understanding how 
such rearrangements drive myelin sheath formation. Using zebrafish in vivo imaging and 3D 
electron microscopic reconstruction, Snaidero and colleagues demonstrated that the plasma 
membrane inner tongue maintains contact with the axon segment as it wraps and progressively 
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spreads out to form the myelin internode. Initial inner tongue movement is aided by the transport 
of critical material, including mRNA and protein, through nanometer wide channels, which 
remain in the mature myelin sheath (24). How is the inner tongue propelled around the axon? 
Two elegant studies suggest actin dynamics as a driving force. Nawaz et al. used zebrafish live 
imaging to determine that F-actin is initially localized to the leading edge, but later excluded 
from the developing membrane. Culture experiments demonstrated that F-actin depolymerization 
by drug treatment increased cell spreading, leading to a model in which the force of actin 
filament disassembly propels the membrane forward (Fig. 2). Interestingly, Zuchero and 
colleagues found that actin disassembly is driven in part by competition of MBP protein for 
binding to PI(4,5)P2, which then releases the actin disassembly factors gelsolin and cofilin (Fig. 
2). The dynamic interplay between actin assembly during development and disassembly during 
myelination highlights a potential form of temporal control. Since actin assembly is necessary for 
OPC development (25), the timing of disassembly must be tightly regulated. What factors could 
influence timing? One possibility is axonal activity. In vitro, vesicular glutamate release from 
axons in response to electrical stimulation phosphorylates Fyn kinase at the oligodendrocyte 
membrane, leading to local translation of Mbp (26). Together, these discoveries implicate axons 
in temporally influencing myelination via actin disassembly. 
A role for actin dynamics has similarly been described in the PNS. Inhibition of F-actin 
formation resulted in delayed SC differentiation (27) and SC-specific deletion of neural Wiskott-
Aldrich syndrome protein (N-WASp), a mechanical transducer that remodels actin via Arp2/3, 
inhibits myelination and causes motor deficits (28, 29). Unlike oligodendrocytes, SCs must sort 
axons prior to myelination. Radial sorting, like myelination, requires dramatic cell shape changes 
that are mediated by proteins regulating the cytoskeleton, including the Rho family GTPases 
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Rac1 and Cdc42 (30, 31). Although these studies point to the importance of cytoskeletal 
rearrangements in SC development, less is known about the forces driving myelination. 
Interestingly, both oligodendrocytes and SCs transport Mbp along microtubules to sites of 
membrane elaboration (32, 33). Whether actin disassembly and local translation of Mbp in SCs 
have roles in driving myelination remains to be determined. 
1.5 Activity-dependent control of myelination and myelin 
maintenance 
 
Oligodendrocytes have intrinsic myelinating capacity and can myelinate fixed axons in 
addition to synthetic nanofibers and micropillars (21, 34, 35) . What prevents oligodendrocytes 
from myelinating dendrites or other cells in the CNS? Using a candidate approach, Redmond et 
al. identified the transmembrane protein JAM2 as a negative regulator of oligodendrocyte 
myelination (Fig. 2). Overexpression of JAM2 attenuated the ability of plated oligodendrocytes 
to myelinate micropillars, and loss of Jam2 in a mouse model caused an increase in myelinated 
neuronal cell bodies, implicating repulsive cues in modulating myelination (36). Another study 
indicates that a component of intrinsic myelination may be hardwired in oligodendrocytes. When 
plated on nanofibers, spinal cord oligodendrocytes produced more myelin than cortex-derived 
oligodendrocytes (37). Are these regional differences due to environmental cues or other factors? 
One possibility is that there are specific subtypes of oligodendrocytes with distinct myelinating 
capacities. To this end, single-cell RNA sequencing was used to characterize cell types in the 
murine hippocampus and cortex. Interestingly, findings from these experiments suggested 7 
distinct subtypes of oligodendrocytes, including OPCs (38). Furthermore, a recent study using 
the same technique to probe oligodendrocyte heterogeneity in more detail proposed 13 distinct 
populations of oligodendrocytes in the mouse brain (39).  
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While negative regulators prevent aberrant myelination in the CNS, variation in myelin 
distribution along single axons of the developing cortex suggests a fine-tuning of myelination 
capacity beyond an intrinsic program (40). Indeed, early work implicated electrical signaling as 
an instructive cue in oligodendrocyte development and myelination (41, 42). How might activity 
influence myelination? Previous work demonstrated that neurons form functional synapses on 
OPCs (43). Recent research suggests, however, that while oligodendrocytes are more likely to 
myelinate electrically active axons, this occurs independently of synapse formation, instead 
relying on vesicular release of glutamate and ATP (44). A critical role for vesicle transport in 
myelination was confirmed in vivo using zebrafish. Mensch and colleagues used tetanus toxin to 
inhibit vesicular release, resulting in fewer sheaths, while increasing activity led to more sheaths 
per oligodendrocyte (45). In a complementary study, Hines et al. found that initial 
oligodendrocyte axon ensheathment is activity independent, but preferential contact is 
maintained on axons releasing vesicles. Processes are either retracted from inactive axons or 
produce shorter myelin sheaths (Fig. 2) (46). However, the necessity of vesicular release is 
differentially regulated in the CNS. This cue is required for myelination by reticulospinal 
neurons but not by commissural primary ascending (CoPA) neurons (47). Why there are 
different regulatory mechanisms depending on neuronal subtype is an area of future 
investigation.  
Rather than a simple static insulator deposited during development, myelin is now 
recognized as a player in nervous system plasticity. Myelination during development and in 
adulthood is modulated by an animal’s social experience (48, 49) and myelin remodeling occurs 
throughout life (50). Furthermore, learning new skills, such as juggling and language acquisition, 
results in changes to myelin (51, 52). How do myelin alterations occur and how do they affect 
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nervous system plasticity? One possibility is that activity stimulates formation of new 
oligodendrocytes. To this end, it was shown that differentiation of oligodendrocytes from 
precursors is necessary for mice to learn a new skill effectively (53), and that neuronal activity 
promotes oligodendrogenesis and concomitant behavior changes (54). What is the role of new 
oligodendrocytes? A recent paper examined the timing of oligodendrogenesis in response to 
learning and found significant formation of new oligodendrocytes in mice learning to navigate a 
complex wheel within the first 2.5 hours. Furthermore, mice unable to form new 
oligodendrocytes exhibit learning deficits as early as 2-3 hours after first encountering the wheel. 
This early necessity for new oligodendrocytes in the learning process indicates a level of active 
involvement (55). Whether this occurs through modifying circuits, providing metabolic support 
or an as yet undetermined mechanism is an area of future investigation.  
1.6 Myelin and metabolism 
In addition to promoting efficient action potential propagation, myelin is also critical for 
trophic and metabolic support of axons (56). To provide metabolites to axons accurately, glia 
must “know” the metabolic requirements of axons. Could electrical activity by axons function as 
a means of communication? NMDA glutamate receptors are present on oligodendrocytes (57, 
58), but were thought to be dispensable for oligodendrocyte development, myelination, and 
injury response (59, 60). However, recent work has implicated these receptors in mediating 
calcium influxes in mature oligodendrocytes (61). Furthermore, NMDA receptors have been 
shown to link electrical activity in axons to the production of lactate by oligodendrocytes, a 
critical energy source for axons. By “learning” via NMDA receptor signaling which axons are 
fast spiking, oligodendrocytes are able to vary lactate production. Loss of NMDA receptors 
specifically in oligodendrocytes, while not critical during development, causes eventual 
 11 
neurodegeneration from reduced metabolism (62). Lactate production and metabolic support of 
axons by SCs is also critical in the PNS (63, 64). The lactate transporter that is used by 
oligodendrocytes, MCT1, is present in SCs and mediates axonal health (65, 66). However, these 
studies did not address a role for electrical activity in SC regulation of axonal metabolism. 
Interestingly, a recent report found that ATP release by electrically active axons mediates 
mitochondrial signaling to promote energy production in SCs and disruption of this signaling 
pathway resulted in hypomyelination (67).  
1.7 Conclusion and outlook 
From static insulating factor to dynamic structure critical in enabling nervous system 
plasticity, our conceptions about myelin have changed dramatically in recent years. However, 
although both SCs and oligodendrocytes produce myelin, the mechanisms by which they do so 
are distinct (Fig. 3). Oligodendrocytes possess an intrinsic ability to myelinate that is fine-tuned 
by environmental cues, such as mechanical stimulation and electrical activity from axons. New 
studies suggest the existence of distinct subsets of oligodendrocytes, raising the possibility that 
such heterogeneity could contribute to differences in innate myelination and re-myelination 
abilities. It will be exciting to uncover the extent to which interplay between the extracellular 
environment and oligodendrocyte heterogeneity influences myelination during development and 
repair. Advances in cellular techniques, including 3D electron microscopic reconstructions and 
live imaging, have contributed to a better understanding of the physical process of myelination 
by oligodendrocytes, including a surprising role for actin dynamics. Further research into the 
cytoskeletal and architectural reorganization of membrane during myelination will help us better 
understand this feat of morphogenesis and elucidate how to promote re-myelination in disease or 
injury.  
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SCs are incapable of myelinating inert structures (37), relying instead on instructive cues. PNS 
myelination also appears to be less finely tuned compared to the CNS, with stricter correlations 
between axon diameter and myelin thickness. Whether PNS myelin undergoes dynamic changes 
similar to CNS myelin has not been well studied. While early work demonstrated a role for 
axonal activity in modulating SC development and myelination (68), this area of research has 
lagged behind progress made in the CNS. The mechanisms by which SCs elaborate a myelin 
sheath are similarly mysterious. One pertinent question is whether actin dynamics, which are 
vital during CNS myelination, play an analogous role in SCs. A current focus in SCs is on 
mechanotransduction, and advances in this area are already guiding future therapeutic 
developments through techniques such as optimal matrices for acellular nerve allografts (69).   
In summary, the studies highlighted in this review demonstrate that myelination in the 
CNS and PNS is distinct while sharing some similar processes. Future work would benefit from 
comparing and contrasting these systems to clarify common or unique aspects of development 
and myelination. Therapeutic advances will be realized through continued investigation into the 
mechanisms and controls of myelination from genesis through maturity.  
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1.9 Figures 
 
Figure 1: Mechanotransduction plays a critical role in Schwann cell development and 
differentiation.  
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Immature SCs migrate and divide along growing axons. The forces associated with migration are 
thought to activate the mechanotransducers YAP/TAZ in SC cytoplasm, which then translocate 
to the nucleus where they interact with the TEAD family transcription factors to drive expression 
of important myelin genes (a). After SCs have formed a “1:1” relationship with axons in the pro-
myelinating stage, maturation of the basal lamina and subsequent polymerization of Laminin-211 
is thought to activate GPR126, which initiates a transcriptional cascade activating Oct6 and 
promoting myelination (b). Eventually, SCs wrap myelin around axon segments to form 
internodes (c). 
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Figure 2: Multiple factors fine tune the myelination potential of oligodendrocytes. 
Oligodendrocytes preferentially myelinate electrically active axons (a) and retract processes from 
inactive axons (b). Furthermore, the intrinsic myelination program is moderated by negative 
regulators, such as JAM2, which are expressed on dendrites (c). Vesicular release from active 
axons initiates a cascade of events, one of which is the translation of locally transported Mbp 
mRNA. MBP then competes with the factors gelsolin and cofilin for binding to PIP2 on the inner 
oligodendrocyte membrane, resulting in release of the two proteins and subsequent actin 
disassembly (d). During wrapping, filamentous actin is located at the leading edge of the inner 
tongue and is proposed to propel the membrane forward by actin disassembly (e) (image adapted 
from Nawaz et al. 2015).  
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Figure 3: Comparing and contrasting Schwann cell and oligodendrocyte development and 
differentiation.  
Although both SCs and oligodendrocytes produce the myelin critical for nervous system 
function, there are important differences in the mechanisms by which they generate myelin. The 
similarities and differences between SCs and oligodendrocytes discussed in this review are 
summarized in the table above. 
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Chapter 2: A forward genetic screen in 
zebrafish to uncover new regulators of 
myelinated axon development 
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2.1 An introduction to zebrafish screens 
Forward genetic screens in model organisms have made seminal contributions to the field 
of developmental biology. The ability to discover new genes involved in regulating 
developmental processes led to the assembly of gene networks and is responsible for our current 
understanding of numerous developmental processes. Early work in C. elegans and Drosophila 
established the importance of forward genetic screens (1, 2). In order to study development in a 
genetically tractable vertebrate system, George Streisinger established the zebrafish as a model 
organism in the 1970s. The rapid generation time, transparent embryonic and larval stages, and 
large clutch size of zebrafish led to their quick adoption as a vertebrate model of choice, and to 
the establishment of forward genetic screens as an important tool (3). Classic studies 
demonstrated that the mutagen used in forward genetic screens in other organisms, Ethyl 
methanesulfonate (EMS), was less efficient than N-Ethyl-N-Nitrosurea (ENU) in introducing 
point mutations in the zebrafish germline (4, 5). In 1996, two groups published seminal work 
describing the first large-scale forward genetic screens performed in zebrafish (6, 7). These 
screens identified a host of new mutant zebrafish with defects in varied processes including 
gastrulation, notochord development, retinal development, craniofacial development, and ear 
development, among others (8-11). 
As the cost of sequencing technology has decreased, it has become increasingly feasible 
to determine the genes responsible for mutant phenotypes extracted from forward genetic 
screens. Moreover, the sequencing of the human and zebrafish genomes has rendered it possible 
to perform comparative analyses between the genes identified in zebrafish screens to orthologues 
in humans. In the field of myelin biology, rodents were initially the model of choice. An 
important study identifying zebrafish orthologues of key myelin proteins, including Myelin 
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protein zero (P0), Proteolipid protein (Plp), and Myelin basic protein (Mbp) set the stage for 
zebrafish to be used as genetic models in investigating myelin development (12). Although there 
are some crucial differences between mammalian and zebrafish myelination, further studies have 
solidified numerous similarities, establishing zebrafish as a model organism at the forefront of 
myelin research (13, 14). To this end, several important myelin screens have been performed in 
zebrafish over the years, yielding critical insights into the regulation of myelin in both the central 
nervous system (CNS) and peripheral nervous system (PNS).  
The discovery of myelin protein orthologues in zebrafish, Mbp in particular, was 
instrumental in facilitating myelin research. Mbp is a small, basic protein (as its name suggests), 
and is critical for compaction of the myelin sheath. Mbp is transported from the cell body to the 
periphery as mRNA, and recent studies have focused on additional roles for Mbp other than 
compaction, including initiation of myelination in oligodendrocytes (15-18). In zebrafish, mbp 
transcripts are initially distinguished beginning at 2 days post fertilization (dpf) in the CNS and 
the PNS and are robustly expressed by 4 dpf. The ability to visualize myelinated axons using 
riboprobes against mbp was particularly useful for forward genetic screens.  
In 2006, two studies published the results of forward genetic myelin screens looking for 
disruptions to mbp mRNA that together uncovered 17 myelin mutants (19, 20). Mapping of the 
mutations identified important new regulators of myelination including Kif1b, Nsf, and Kbp (21-
23). Of particular note was the discovery that two myelin mutants identified from the Talbot lab 
were the result of mutations in a G protein-coupled receptor (GPCR), Gpr126, a member of the 
understudied class of adhesion GPCRs (24). The necessity of cAMP signaling during Schwann 
cell development to facilitate the initiation of myelin production had been known for many years 
(25-27). However, it had been unclear what regulated the timing and production of cAMP. Monk 
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and colleagues demonstrated in zebrafish that signaling by Gpr126 was responsible for triggering 
upregulation of cAMP, which in turn initiated the transcription of a host of myelin genes 
necessary for myelination. Moreover, subsequent studies demonstrated that this critical role of 
Gpr126 was conserved in rodents and humans (28, 29). Since GPCRs are recognized as 
“druggable targets,” research is ongoing in zebrafish to discover small molecules or drugs that 
can modulate Gpr126 activity, with the potential for identifying treatments for human PNS 
myelin disorders (30, 31). From gene discovery to drug screens, this example highlights the 
efficacy of zebrafish as a tractable genetic model organism capable of yielding insights into not 
only development, but also human disease. 
More recently, transgenes have been used in zebrafish myelin forward genetic screens. In 
a screen to identify regulators of oligodendrocyte development, the Appel lab used the transgene 
olig2:EGFP (tg:olig2:EGFP) as a marker of oligodendrocyte precursor cells (OPCs) (32). 
Transgenic approaches circumvent the need to fix zebrafish larvae during the in situ 
hybridization process, allowing researchers to observe phenotypes in live animals. This is 
particularly important today when traditional recombination mapping has been replaced by next 
generation sequencing to determine the lesion responsible for the mutant phenotype. In the 
tg(olig2:EGFP) screen, several mutated genes were uncovered, including in the ubiquitin ligase 
fbxw7, in cytoplasmic dynein, and in the enzyme hmgcs1, which catalyzes cholesterol 
biosynthesis (32-34). Transgenes therefore present a viable option for forward genetic screens in 
zebrafish and should be used to their full advantage in the future. Importantly, the myelin screens 
described above were not performed to saturation and there were likely new genes involved in 
myelination to be uncovered. The Monk lab therefore decided to embark on a forward genetic 
screen to identify remaining myelin mutants that had not been found previously.  
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2.2 Set-up of the “LM” screen 
In collaboration with the Solnica-Krezel lab, members of the Monk lab participated in a 
large-scale forward genetic screen in zebrafish. The purpose of the LM screen, which stands for 
the two transgenes used (see below), was to identify mutants in both gastrulation and 
myelination. Before I joined the Monk lab, the screen was initiated with ENU mutagenesis of 
two founding groups of males, LM1 and LM2, according to standard protocols with the addition 
of tricaine to the water (35). 40 males in the LM1 group were exposed to 3 mM ENU for one 
hour every week during a 6-week period, while 40 males in the LM2 group were exposed to a 
3.5 mM dose for 4 weeks. WT males from the genetic strain SAT, which is a combination of the 
Sanger AB and Tubingen lines, were used. A specific locus test was utilized to determine the rate 
of mutagenesis in the founder males. Mutagenized F0 founder males from both LM1 and LM2 
groups were outcrossed to females of homozygous albino or homozygous albino/golden 
backgrounds, both of which lack pigmentation. F1 progeny from these crosses were screened for 
pigment defects by members of the Monk and Solnica-Krezel labs at 3 dpf to determine the 
mutation rate in the F0 mutagenized males (35).  
F0 mutagenized males were then outcrossed to WT SAT females to produce the F1 
progeny, approximately half of which should have heterozygous mutations in unknown genes. 
F1 animals were grown to adulthood and then crossed to a double transgenic line to produce the 
F2 generation. The double fluorescent reporter line included tg(lhx1a:egfp), which was used by 
the Solnica-Krezel lab to screen for gastrulation defects, and tg(mbp:mcherry-CAAX), which was 
used by the Monk lab to screen for myelin mutants. I became involved with the screen after the 
F2 progeny had reached sexual maturity. During the summer of 2013, we set up two cohorts of 
intercrosses per week, using F2s that had originated from both LM1 and LM2 males. Because of 
 28 
the screen set up, half of the F2 generation should be heterozygous, which allowed us to screen 
for recessive mutations in the F3 generation. We set up 10 pairs per family and screened between 
20-40 F3 larvae per clutch under the fluorescent microscope for perturbations to myelin as 
visualized using tg(mbp:mcherry-CAAX) (Figure 1).  
Unfortunately, weakness of the mCherry fluorescent reporter and differences in transgene 
copy number resulted in difficulty screening by this transgene. To confirm mutants identified by 
transgene, we therefore saved larvae from screened clutches for re-screening using mbp in situ 
hybridization. Eventually, it became clear that screening by transgene was not efficacious, and 
we switched to a purely in situ hybridization screen. Any F2 pairs identified as producing larvae 
with mutant phenotypes were re-crossed and re-screened using in situ hybridization. 
Furthermore, the F3 progeny from these crosses were themselves grown up and then crossed and 
re-screened by ISH to confirm heritability of the mutation. After passing these rigorous tests, 
mutants were considered to be “real” and given allele designations with the prefix stl, which 
stands for “St. Louis.”   
In total, Monk lab members, including myself, screened approximately 4,500 F3 clutches 
from 1,102 F2 families. We identified 31 mutations in total. Of these mutants, 14 were shown to 
be heritable while 5 did not re-screen and were subsequently discarded. We eventually stopped 
re-screening the F4 generation for heritability, and therefore 12 mutants are currently awaiting 
re-screening. 
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2.3 Whole genome sequencing identifies the causative lesions 
responsible for mutant phenotypes 
 
The myelin mutants identified in the LM screen exhibited a variety of phenotypes (Figure 
2). Although there was only one mutant identified with increased mbp expression, stl64, there 
were many mutants exhibiting reduced expression in either the PNS, such as stl72, stl91 and 
stl83, or in the CNS, such as stl90 and stl93 (Figure 2). Transitioning to the in situ hybridization 
screen was also effective for identifying more PNS mutants, as the lateral line had been 
particularly difficult to score using the transgene. The tg(lhx1a:eGFP) also allowed us to 
visualize axon defects, as lhx1a is expressed in a subset of neurons. This led to the identification 
of the stl83 mutant, which exhibited large caliber axon swellings in the CNS and the PNS 
(Figure 2). Mbp in situ hybridization of the stl83 mutant showed reduced expression, indicative 
of potential myelin defects the CNS and PNS, as well as a punctate expression of mbp in the 
hindbrain of the CNS (Figure 2).  
The ability to identify stl83 mutants via the tg(lhx1a:eGFP) transgene meant that DNA 
could be collected from fresh tissue. This was advantageous for mapping purposes because DNA 
from fresh tissue is more amenable to sequencing than crosslinked DNA from tissue that had 
been fixed during the in situ hybridization process. Therefore, stl83 was the first mutant of the 
LM screen to be sequenced. In order to sequence the stl83 genomoe, we performed a map cross 
by crossing the F2 carriers that had produced mutant progeny to SJD, an isogenic strain of 
zebrafish with well characterized markers used for traditional recombination mapping (36). After 
reaching adulthood, F3 progeny from the SJD outcross were intercrossed and screened for the 
stl83 phenotype by transgene. The mutation was successfully passed on to the next generation.  
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From this intercross, I anaesthetized progeny in tricaine and screened for the mutant phenotype 
using the transgene tg(lhx1a:eGFP). 20 phenotypically WT larvae and 20 phenotypically mutant 
larvae were pooled separately in 1.7 ml Eppendorf tubes. 500 µL of Lysis buffer, composed of 
100 µM Tris-HCL (pH 8.5), 5 mM EDTA, (pH 8.0), 0.2% SDS, 200 mM NaCL, was added to 
each tube, and tubes were then heated at 98°C for 10 minutes. Next, 5 µL of 20 mg/mL 
proteinase K was added and both tubes were incubated overnight at 55°C. The next day, samples 
were centrifuged at 14,000 x g for 1 minute. The supernatant was pulled off and placed in a new 
1.7 mL Eppendorf tube. 600 µL of isopropanol was added to each tube, mixed by inversion, and 
allowed to sit for 5 minutes at room temperature. Next, samples were centrifuged at 14,000 x g 
for 5 minutes and supernatant was removed, leaving a pellet containing the DNA. Pellets were 
washed with 500 µL of 70% Ethanol (EtOH), allowed to sit for 5 minutes at room temperature, 
and then centrifuged at 14000 x g for 2 minutes. 70% EtOH was removed, the sample was 
briefly spun again, EtOH again removed, and the sample was allowed to air dry. 100 µL H20 was 
added to both samples and they were then incubated for 1 hour at 60°C, vortexing continuously 
to facilitate resuspension. Finally, the DNA concentration in the samples was obtained using a 
nanodrop.  
1 µg in 50 µL of extracted DNA from mutant and WT samples was sent to the Genome 
Technology Access Center (GTAC) at Washington University. 100 bp paired end sequencing 
using the Hi-Seq Illumina platform was used to sequence samples. Upon receiving the 
sequencing results from GTAC, I worked with Ryan Gray and Thomas O’Reilly-Pol, in the labs 
of Lila Solnica-Krezel and Steve Johnson, respectively, to determine the gene responsible for the 
mutant phenotype. The pipeline established to identify the stl83 mutant was later refined and 
published in a research article from our lab, which can be found in Appendix A of this 
 31 
dissertation (37). In brief, a Perl script was used to first split the sequencing data into 25 separate 
files for each of the zebrafish 25 chromosomes. There were 50 individual files, 25 from the 
mutant sequencing and 25 from the WT sequencing. Another Perl script was then used to 
compute the mutant allele frequency (MAF). By comparing the MAF between siblings and 
mutants, we were able to identify regions of homozygosity where the MAF approached 2. It was 
found that the highest peak from the stl83 sequencing was on chromosome 20 (see Chapter 3).  
A subsequent SNP subtraction analysis was performed on the stl83 data using sequencing 
data from the Solnica-Krezel lab. This narrowed the number of candidate SNPs down to 5, 
including actin related protein 10 (actr10). Importantly, none of the identified SNPs was a 
STOP; rather, all were candidate missense mutations. I then turned to a modified traditional 
recombination mapping approach. I designed genotyping assays that involved PCR and digest 
for several of the SNPs. The SNPs themselves disrupted specific restriction enzyme sites. In this 
way, I was able to narrow down the potential mutant SNPs. As I was using this method of 
mapping, we learned of a mutant identified in another screen for axonal defects that exhibited a 
similar phenotype to stl83 (Figure 4).  
The nl15 mutation was identified at Oregon Health and Science University (OHSU) in a 
forward genetic screen for regulators of axon development as assayed by transgene expression of 
a pan neuronal promoter, neurod, driving GFP expression tg(neurod:egfp). The nl15 mutation 
had been mapped by a post-doctoral fellow in the Nechiporuk lab, Katie Drerup, to the gene 
actin related protein 10 (actr10), which is a component of the dynactin complex that facilitates 
retrograde transport by the molecular motor dynein (38). After receiving actr10nl15 fish from 
OHSU, I performed a complementation test by crossing actr10nl15/+ fish to stl83 carriers. In a 
subset of the progeny, I observed a recapitulation of the mutant phenotype with axonal swellings 
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in the PNS illuminated by the tg(neurod:egfp) transgene (Figure 4). This failure to complement 
confirmed that the stl83 mutation was indeed the result of a mutation in actr10. A description of 
the published work done on the actr10 mutants can be found in Chapter 3 and Appendix B of 
this dissertation. 
I used the analysis protocol to map another mutant identified in the screen, stl91. 
Establishing the gene responsible for the stl83 mutation had been facilitated by the fact that I was 
able to collect DNA from fresh tissue. However, this was not the case for the rest of the myelin 
mutants identified in the LM screen. Therefore, we established a modified extraction protocol to 
collect DNA from larvae that had been fixed during the in situ hybridization process. This 
protocol is detailed in Appendix A of this dissertation. I used this extraction protocol to prepare 
genomic DNA of several other mutants for sequencing, including stl91, a strong PNS 
hypomyelination mutant, stl159, which exhibited axon pathfinding defects, and stl72, a weak 
PNS hypomyelination mutant (Figure 2). I used the sequencing analysis pipeline to determine 
that the likely candidate gene for the stl91 phenotype was a missense mutation in the gene 
exostosin1c (ext1c).  
Ext1c encodes a member of the Exostosin1 protein family that has been expanded in 
zebrafish. While there is only one Ext1 gene in Xenopus and mammals, zebrafish possess ext1a, 
ext1b, and ext1c proteins (39). Exostosin proteins are necessary for the production of heparin 
sulfate proteoglycans (HSPGs), which form part of the extracellular matrix (40). In humans, 
mutations of EXT genes have been shown to cause benign tumors called hereditary multiple 
exostoses (41). Interestingly, a key difference between Schwann cells and oligodendrocytes is 
the presence of a basal lamina surrounding Schwann cells that plays critical roles in signaling 
during development and myelination (42). To this end, our lab showed that Laminin-211, part of 
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the Schwann cell extracellular matrix, was responsible for binding and signaling to Gpr126 (43). 
Moreover, HSPGs were shown to directly affect Schwann cell development via Neuregulin 
signaling (44). A role for ext1c in myelination of the PNS therefore would seem to fit with 
current work. However, when other members of the Monk lab applied a new filter called 
SNPFisher to the sequencing data, which was not available when I originally mapped stl91, it 
was determined that the mutation of interest could reside in either ext1c or another protein, 
angpt1 (Nick Sanchez, personal communication). SNPFisher is a publicly available database that 
is comprised of all known zebrafish SNPs. Complementation testing with other alleles of ext1c 
and angpt1 will therefore be needed in the future to confirm the gene responsible for the stl91 
phenotype. 
In conclusion, the LM screen was highly successful, identifying numerous myelin 
mutants. Two publications have already resulted from work related to the screen, and more 
manuscripts are currently in preparation. Although zebrafish screens have become quite 
common, particularly in recent years, it is clear that there is still much to be learned from a 
forward genetics approach to discovering new genes involved in developmental processes.  
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2.4 Figures 
 
Figure 1: A forward genetic screen in zebrafish to identify regulators of myelination. 
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80 F0 males from the SAT background were mutagenized using ENU. F0 males were then 
outcrossed to SAT females to produce F1 progeny, which in theory should be heterozygous for 
potential mutations of interest. After growing to adulthood, F1 animals were crossed to a 
homozgygous transgenic line with the fluorescent reporters tg(lhx1a:eGFP) and tg(mbp:mCherry-
CAAX), which were used to screen for gastrulation defects and myelin defects, respectively. The 
progeny from this cross, the F2 generation, 50% of which should have the mutation of interest, were 
randomly intercrossed to produce the F3 generation, which were screened by transgene and in situ 
hybridization for alterations to mbp expression. Assuming two F2 siblings heterozygous for a 
mutation of interest were intercrossed, the genotypes of the F3 progeny should be as follows, 
according to Mendelian genetics: 25% WT, 50% heterozygous and 25% mutant for the mutation of 
interest. The transgene inheritance would follow a similar pattern: 25% of the larvae would have no 
transgene, 50% would be heterozygous for the transgenes and 25% would be homozygous for the 
transgenes. 
 
 
 
 
 
 
 
 
 
 
 
 
 36 
 
Figure 2: The screen uncovered myelin mutants with a variety of phenotypes. 
 (A) The tg(lhx1a:eGFP) fluorescent reporter shows normal expression in a WT animal whereas 
in an stl83 mutant (B), there are large caliber swellings in the spinal cord. (C) Mbp mRNA is 
normally expressed in the CNS (arrow) and PNS (arrowheads) of a WT zebrafish larva at 5 dpf. 
(D) The stl64 mutant exhibits increased mbp in the CNS whereas the stl90 mutant (E) has almost 
no mbp in the CNS (arrows). (F) Mbp ISH of the stl83 mutant reveals decreased mbp in both the 
CNS (arrow) and PNS (arrowheads), as well as a punctate phenotype of mbp expression in the 
CNS. (G) The stl93 mutant has reduced mbp in the CNS (arrow) but normal mbp in the PNS, 
whereas the stl72 (H) and stl9 (I) mutants have decreased and nearly absent mbp expression 
(respectively) in the PNS (arrowheads). (J). Finally, the stl159 mutants likely have axon 
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pathfinding defects, as demonstrated by the “wavy” mbp expression in the lateral line of the PNS 
(arrowheads). 
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Figure 3: Whole genome sequencing is used to identify the genes responsible for mutant 
phenotypes.  
F2 stl83 carriers (which are genetically heterozygous for stl83) were outcrossed to the mapping 
strain SJD. The resulting F3 progeny, 50% of which should be heterozygous for the stl83 mutant 
allele, were randomly intercrossed. The F4 larvae were screened by tg(lhx1a:eGFP) for axon 
defects. DNA from 20 phenotypically WT and 20 phenotypically mutant animals was collected 
separately and sent for sequencing at the Genome Technology Access Center. 
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Figure 4: A complementation test confirms that actr10 is the gene responsible for the stl83 
mutant phenotype.  
Heterozygous nl15 animals were crossed to heterozygous stl83 animals. In the transheterozygous 
progeny, there was a recapitulation of the mutant axonal phenotype as visualized using the 
tg(neurod:egfp) fluorescent reporter.  
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Chapter 3: Dynein/dynactin is necessary for 
anterograde transport of Mbp mRNA in 
oligodendrocytes and for myelination in vivo 
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Preface: 
 
This chapter has been reproduced and adapted in its entirety from the following 
published manuscript: 
 
Herbert AL*, Fu MM*, Drerup CM, Gray RS, Harty BL, Ackerman SD, 
O’Reilly-Pol T. Johnson SL, Nechiporuk AV, Barres BA, Monk KR. (2017) 
Dynein/dynactin is necessary for anterograde transport of Mbp mRNA in 
oligodendrocytes and for myelination in vivo. Proc Natl Acad Sci U S A 
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3.1 Significance 
Oligodendrocytes in the brain insulate neuronal axons in layers of fatty myelin to 
facilitate fast electrical signaling. Myelin basic protein (MBP), an important myelin component, 
is transported as mRNA away from the cell body before being translated into protein. In 
zebrafish, the anterograde motor kinesin transports mbp mRNA away from the cell body. We 
now identify myelination defects in zebrafish caused by a mutation in the retrograde motor 
complex dynein/dynactin, which normally transports cargos back toward the cell body. However, 
this mutant displays defects in anterograde mbp mRNA transport. We confirm in mammalian 
oligodendrocyte cultures that drug inhibition of dynein arrests transport in both directions and 
decreases MBP protein levels. Thus, dynein/dynactin is paradoxically required for anterograde 
mbp mRNA transport 
3.2 Abstract 
Oligodendrocytes in the central nervous system produce myelin, a lipid-rich, multi-
lamellar sheath that surrounds axons and promotes the rapid propagation of action potentials. A 
critical component of myelin is myelin basic protein (MBP), expression of which requires 
anterograde mRNA transport followed by local translation at the developing myelin sheath. 
Although the anterograde motor kinesin KIF1B is involved in mbp mRNA transport in zebrafish, 
it is not entirely clear how mbp transport is regulated. From a forward genetic screen for 
myelination defects in zebrafish, we identified a mutation in actr10, which encodes the Arp11 
subunit of dynactin, a critical activator of the retrograde motor dynein. Both the actr10 mutation 
and pharmacological dynein inhibition in zebrafish result in failure to properly distribute mbp 
mRNA in oligodendrocytes, indicating a paradoxical role for the retrograde dynein/dynactin 
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complex in anterograde mbp mRNA transport. To address the molecular mechanism underlying 
this observation, we biochemically isolated reporter-tagged Mbp mRNA granules from primary 
cultured mammalian oligodendrocytes to show that they indeed associate with the retrograde 
motor complex. Next, we used live-cell imaging to show that acute pharmacological dynein 
inhibition quickly arrests Mbp mRNA transport in both directions. Chronic pharmacological 
dynein inhibition also abrogates Mbp mRNA distribution and dramatically decreases MBP 
protein levels. Thus, these cell culture and whole animal studies demonstrate a novel role for the 
retrograde dynein/dynactin motor complex in anterograde mbp mRNA transport and myelination 
in vivo. 
3.3 Introduction 
In the central nervous system (CNS), specialized glial cells called oligodendrocytes wrap 
axons in many layers of plasma membrane to form the myelin sheath. Oligodendrocytes 
originate from neuroepithelial precursors that develop into oligodendrocyte precursor cells 
(OPCs), which are migratory and proliferative, extending numerous processes to sample the 
environment (1). OPCs differentiate into post-mitotic oligodendrocytes, which activate 
expression of mature myelin proteins and ensheathe multiple axon segments with loose 
membrane spirals that are eventually compacted to form a functional myelin sheath (2). 
Disruption of the myelin membrane can cause debilitating human conditions, including multiple 
sclerosis. However, while the clinical applications of myelin research are clear, molecular 
mechanisms regulating basic oligodendrocyte development are not well understood. 
A critical protein generated during oligodendrocyte differentiation is myelin basic protein 
(MBP), which is essential for proper compaction of the myelin sheath. Due to its highly basic 
charge and propensity to promote membrane adherence, Mbp translation is tightly regulated 
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during oligodendrocyte development (3). Mbp mRNA is trafficked to the developing sheath and 
translated locally (4, 5). Translation at the membrane and formation of myelin sheaths is 
stimulated by Fyn kinase, which is phosphorylated in response to axonal electrical activity (6–8). 
In addition, MBP acts as an important spatial and temporal regulator of myelination, by 
triggering disassembly of the actin cytoskeleton to promote initiation of myelin membrane 
wrapping (9, 10).  
Classic experiments in cultured oligodendrocytes demonstrated that Mbp mRNA 
trafficking in the anterograde direction (away from the cell body) relies on microtubules (11). By 
electron microscopy, these microtubules are uniformly oriented with polymerizing plus ends 
directed away from the cell body (12). Two types of motors move along microtubules: a vast 
family of kinesin motors majority of which move toward the plus end and a single cytoplasmic 
dynein motor that moves toward the minus end when bound to the dynactin activator complex 
(13). Previously, a genetic screen in zebrafish identified a kinesin kif1b mutant in which 
anterograde mbp mRNA transport is disrupted, resulting in mislocalization of mbp mRNA in 
oligodendrocyte cell bodies (14). Importantly, another zebrafish genetic screen for myelination 
defects uncovered a dynein mutation that results in decreased mbp mRNA levels in both the 
peripheral nervous system (PNS) and CNS, highlighting the necessity of molecular motors in 
myelination (15, 16).  
Classic transport studies have demonstrated the interdependence of oppositely directed 
motors. Many vesicular cargos are simultaneously associated with both dynein and kinesin 
motors and inhibition or loss of either motor results in transport arrest in both anterograde and 
retrograde directions (17). This has been observed for organelles in squid axoplasm treated with 
anti-dynactin antibodies (16), for synaptic vesicles in axons of Drosophila with mutations in 
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kinesin, dynein, or dynactin (17) and for vesicles and lysosomes in mammalian axons in which 
subunits of kinesin and dynactin have been knocked down (20, 21). Though less is known about 
how opposing motors regulate mRNA transport, one early study in Drosophila S2 macrophage-
like cells showed that dynein knockdown leads to arrested transport in both anterograde and 
retrograde directions of fluorescently tagged fragile X mental retardation protein (FMRP), which 
is an RNA-binding protein (22). However, a role for the interdependence of kinesin and dynein 
motors in mRNA transport has yet to be shown in glial cells. 
Here, we demonstrate in vivo in zebrafish and in mammalian oligodendrocyte cultures 
that dynein/dynactin is required for anterograde mbp mRNA transport. In a myelination screen in 
zebrafish, we discovered a mutation in a subunit of the dynein activator, dynactin. This mutation 
in actr10, which encodes the Arp11 protein, results in dynein/dynactin loss of function 
phenotypes, such as photoreceptor loss and aberrant melanosome distribution in pigment cells. 
Mutants have OPC proliferation defects, fewer myelinated axons by transmission electron 
microscopy (TEM) and reduced levels of mbp mRNA, all of which phenocopy a previously 
published zebrafish dynein mutant (16). Interestingly, of the oligodendrocytes that are present in 
the mutants, we noticed a reduction in mbp mRNA localized to processes, which is similar to the 
previously published kinesin kif1b zebrafish mutant and therefore may be caused by mRNA 
transport defects (14). To test whether dynein/dynactin directly plays a role in mbp mRNA 
transport, we turned to primary rodent oligodendrocyte cultures. Co-immunoprecipitations 
demonstrated that Mbp mRNA granules indeed associate with dynactin and dynein. Furthermore, 
imaging of Mbp mRNA granules in primary oligodendrocytes revealed movement in the 
anterograde direction, as expected; unexpectedly, the granules also move transiently backwards 
in the retrograde direction. To test how dynein activity affects Mbp mRNA transport, we 
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pharmacologically inhibited dynein using ciliobrevin in both zebrafish larvae and cell culture. In 
zebrafish, ciliobrevin treatment reduced mbp mRNA localization in oligodendrocyte processes; 
in primary oligodendrocytes, this resulted in arrested transport in both anterograde and 
retrograde directions and also dramatically reduced MBP protein levels. Taken together, our 
cellular and in vivo data demonstrate a previously unappreciated role for dynein/dynactin in 
anterograde Mbp mRNA transport in developing oligodendrocytes. 
3.4 Results 
actr10 mutations in zebrafish cause reduced mbp mRNA levels. 
In order to investigate the development of myelinated axons, we performed a large-scale 
N-ethyl-N-nitrosourea (ENU)-based forward genetic screen in which we visualized axons using 
the transgenic reporter tg(lhx1a:GFP) (23), then imaged myelin using mbp in situ hybridization 
(ISH). We uncovered a mutant, designated stl83, with both GFP-positive axonal swellings (Fig. 
1A and B) and reduced levels of mbp by ISH (Fig. 1C and D). Whole genome sequencing of 
equimolar pools of mutants and siblings and subsequent analysis using an in-house pipeline 
(Sanchez et al., submitted) were used to determine that the gene of interest likely resided on 
chromosome 20 (Fig. 1E). Further single-nucleotide polymorphism (SNP) subtraction analysis to 
compare this data to other whole genome sequencing data sets reduced the number of candidate 
genes within our mapped locus to five, including one in actr10 (Fig. 1F). To test if the stl83 
mutation was indeed in actr10, we performed a complementation test using a second actr10 
mutant allele (actr10nl15)(24). While the putative actr10stl83 allele results from a G-to-T 
transversion in exon 12 resulting in a glycine to tryptophan amino acid change, the actr10nl15 
allele is a putative null mutation in the start site of actr10 (Fig. 1G and Fig. S1A). 
Complementation analysis confirmed that the stl83 phenotype results from a mutation in actr10, 
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as transheterozygous animals have axonal swellings, which are never seen in either heterozygous 
or wild-type (WT) animals from either genotype (Fig. 1H and I). Although the actr10stl83 
mutation occurs late in the genomic sequence, both mutants are lethal at the larval stage. The 
actr10stl83 mutants are grossly healthier than the actr10nl15 mutants (Fig. S1D), indicating that 
actr10stl83 may be a hypomorphic allele.  
actr10 mutants have fewer myelinated axons. 
To directly observe the ultrastructure of the myelin sheath, we performed TEM of both 
actr10 mutant alleles and counted the number of myelinated axons in a hemi-segment of the 
ventral spinal cord. Of note, heterozygous actr10stl83/+ and actr10nl15/+ animals are viable and 
have no discernable phenotype compared to WT siblings as assessed by tg(neurod:egfp) from the 
complementation cross and number of myelinated axons by TEM (Figure S1E, F) and are 
therefore combined with WT as “controls.” Consistent with our mbp ISH analysis, both actr10 
mutant alleles have significantly fewer myelinated axons compared to control animals by TEM 
at 5 days post-fertilization (dpf) (Fig. 2A–J), demonstrating that dynein/dynactin dysfunction has 
functional consequences for myelin in the CNS.  
actr10nl15/nl15 mutants have fewer OPCs. 
One explanation for reduced myelinated axon numbers in actr10 mutants could be fewer 
OPCs. To test this, we examined spinal cord cross-sections from double transgenic 
tg(olig2:dsred);tg(sox10:mgfp) (25, 26) zebrafish to quantify OPC number in putative null 
actr10nl15/nl15 mutants. olig2 is expressed in OPCs and motor neurons at 3 dpf, sox10 is expressed 
in OPCs, and the tg(olig2:dsred);tg(sox10:mgfp) transgenes combined allow for visualization of 
OPCs with red cytoplasm and green membrane. At 3 dpf, actr10nl15/nl15 mutants had fewer OPCs 
compared to controls (Fig. 3A–C), indicating a role for actr10 in OPC development.  
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In the zebrafish spinal cord, OPCs originate ventrally and then migrate dorsally on either 
side of the neuronal cell bodies located in the center of the spinal cord (27). A population of 
OPCs remains in the ventral cord to differentiate and myelinate ventral axons, while the dorsally 
migrated OPCs differentiate and myelinate axons in the dorsal spinal cord. Dorsal OPCs can be 
visualized using the tg(olig2:dsred) transgene, which are easily distinguished by their elongated 
cell bodies (27). Using this elongated cellular morphology as a metric, we found that the number 
of DsRed-positive elongated cells in the dorsal spinal cord was reduced at 3 dpf in actr10nl15/nl15 
mutants compared to controls (Fig. 3D, E, and H). To determine whether this resulted from a 
delay in migration and maturation, we similarly assayed 4 dpf animals and also found a 
significant reduction at this later time point (Fig. 3F, G, and I). Together, these data demonstrate 
that actr10nl15/nl15 mutants have reduced numbers of OPCs and fewer dorsally migrated OPCs, 
recapitulating early defects described in zebrafish dynein mutants (16). Importantly, however, 
some maturing dorsal OPCs are present in actr10nl15/nl15 mutants, indicating that migration 
defects alone are not the sole cause of the myelination phenotypes observed in mutants. 
OPC proliferation is slower in actr10nl15/nl15 mutants. 
Interestingly, depletion of Arp11 in mammalian COS7 resulted in the striking formation 
of multiple spindles during mitosis (28). To better understand the mechanistic role of Arp11 in 
OPC proliferation and cell division, we performed live imaging using the transgenic line 
tg(nkx2.2a:megfp), which also marks OPCs (1). Transgenic zebrafish were imaged for up to 12 
hours starting at ~57 hours post fertilization (hpf). During this time period in oligodendrocyte 
development, OPCs have been specified and continue to divide and migrate from the ventral to 
the dorsal spinal cord. They continuously extend and retract exploratory processes to sample the 
environment before becoming post-mitotic, and beginning to myelinate (1). Live imaging 
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revealed that mutant nkx2.2a-labeled cells took longer to divide compared to cells in control 
sibling actr10nl15/+ animals (Fig. 4, Movies S1–S4). During division, the nkx2.2a-labeled cells 
retract processes, and become distinctly round before dividing. In the control animals, the time 
from beginning of rounding until division or the end of live imaging, takes an average of 46 
minutes compared to 159 minutes in mutants, suggesting that reduced OPC numbers are in part 
due to slower OPC proliferation.  
Dynein activity is impaired in multiple tissues in actr10nl15/nl15 mutants.  
Previous studies have found that loss of actr10 disrupts the assembly of the dynactin 
complex in mammalian cell culture and in the filamentous fungi Aspergillus nidulans (28, 29). 
Actr10 has recently been shown to have a specific role in retrograde mitochondrial transport in 
peripheral axons without disrupting dynein-dynactin complex integrity (24). We hypothesized, 
however, that oligodendrocyte cell lineage and myelin phenotypes in actr10nl15/nl15 mutants result 
from general disruption to dynein/dynactin function for several reasons. Firstly, mutants have 
defects in OPC development and myelination that are similar to those previously defined in 
zebrafish dynein mutants (16). Secondly, mutants phenocopy the photoreceptor loss observed in 
zebrafish with mutations in other subunits of dynactin, including p150Glued and p50 (30–32) (Fig. 
S2A and B). The photoreceptor defects observed indicated that the fish might be blind. To this 
end, we used the Noldus behavior unit, DanioVision, to assay the response of WT, actr10nl15/+,  
and actr10nl15/nl15 animals during light/dark cycles. Larval zebrafish, unlike their adult 
counterparts, avoid the dark and respond with increased movement (33, 34). The movement of 
larvae in a 96-well plate was tracked during an alternating light/dark cycle. Both WT (Fig. S2G) 
and actr10nl15/+ animals (Het) (Fig. S2H) showed a significant increase in movement in the dark 
compared to the light. However, actr10nl15/nl15 animals (Mut) showed no significant difference in 
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movement between the light baseline and dark response (Fig. S2I), indicating that the observed 
photoreceptor death likely leads to blindness.  
Thirdly, actr10nl15/nl15 animals phenocopy the excessive pigment observed in the dorsal 
head region of zebrafish dynein mutants (Fig, S2C and D)(16) and also have increased pigment 
along the lateral line (Fig. S2E and F). Interestingly, blindness has been shown to cause 
background adaptation in which zebrafish upregulate pigment production in response to constant 
darkness (35). Thus, the increase in basal levels of pigmentation could be connected to 
photoreceptor loss. In addition, pigment cells, called melanophores, can change skin color in 
response to environmental stimuli. This is mediated by release of the hormone epinephrine, 
which triggers intracellular changes in protein kinase A activity that result in increased dynein-
mediated retrograde run lengths, leading to melanosome aggregation toward the melanophore 
cell body (16, 36, 37). Thus, to further test whether dynein activation is perturbed in 
actr10nl15/nl15 mutant melanophores, we performed a classic melanosome aggregation assay (Fig. 
S2J–S). In control animals, 5 minutes of exposure to epinephrine induced noticeable 
melanosome aggregation toward the center of the cell (Fig. S2K) whereas actr10nl15/nl15 mutants 
maintained relatively dispersed melanosomes (Fig. S2P). After 30 minutes, whereas 
melanosomes in all control animals were aggregated (Fig. S2N), mutants continued to exhibit 
widespread pigment distribution (Fig. S2S), indicating that activated retrograde melanosome 
transport is compromised in mutant melanophores.  
Actr10 function in oligodendrocytes can partially suppress myelin defects. 
To understand the function of actr10 in oligodendrocytes, a construct in which the glial 
sox10 promoter drives expression of actr10 tagged with monomeric RFP (sox10:mRFP-actr10) 
was transiently expressed in larvae from a cross between tg(mbp:gfp-caax);actr10nl15/+ and 
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actr10nl15/+ fish. sox10:mRFP-actr10 injected larvae (sox10 injected) exhibit RFP fluorescence, 
which is not seen in uninjected mutants (Fig. 5A–B’’). TEM analysis and quantification at 5 dpf 
showed partial suppression of the mutant phenotype in the dorsal spinal cord. Although 
sox10:mRFP-actr10-injected mutants were not rescued to control levels, sox10:mRFP-actr10-
injected mutants possessed significantly more myelinated axons compared to uninjected mutant 
siblings, demonstrating that glial actr10 rescue can promote proper myelination in vivo.  
 Analysis of a stable transgenic neuronal rescue line in which mRFP-actr10 is driven by 
the neuronal-specific neurod promoter tg(neurod:mRFP-actr10) demonstrates that Actr10 also 
functions in neurons to promote oligodendrocyte myelination (Fig. S3). Given the critical 
functions of dynein/dynactin in all cells, it is not surprising that Actr10 functions in both neurons 
and oligodendrocytes to promote myelination. Of note, injection of sox10:mRFP-actr10 resulted 
in lower levels of actr10 as assayed by RFP fluorescence than were seen in the tg(neurod:mRFP-
actr10) stable line. Thus, one reason a neuronal rescue was more effective could be due to the 
differences between transient injection with weak oligodendrocyte actr10 expression and a stable 
transgenic line with strong actr10 expression. The function of Actr10 in neurons to promote 
myelination forms the basis of future work; here, we focus on the cell autonomous function of 
Actr10 in oligodendrocytes. 
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actr10nl15/nl15 mutants have reduced mbp mRNA localization in oligodendrocyte processes.  
All actr10nl15/nl15 mutants observed have reduced mbp mRNA localization to processes at 
4 dpf (Fig. 6A–F). This phenotype cannot be explained by OPC proliferation defects alone, as 
the observation of dorsal elongating cells in mutants (Fig. 3) indicates that some 
oligodendrocytes are indeed migrating and maturing. Moreover, this phenotype is reminiscent of 
the kinesin kif1b zebrafish mutant in which disruption of anterograde transport results in 
accumulation of mbp mRNA in oligodendrocyte cell bodies (14). This led us to hypothesize that 
dynein/dynactin may play a role in efficient transport of mbp mRNA to distal oligodendrocyte 
processes. 
Dynein and dynactin associate with Mbp mRNA granules. 
 To visualize Mbp mRNA transport, we expressed the MS2 reporter in primary rat 
oligodendrocyte cultures that were purified using the immunopanning technique and are free of 
neuronal contamination (38). MS2 is an RNA-binding protein derived from bacteriophage that 
binds with high affinity to specific RNA sequences that form stem loop structures (39). Using a 
bidirectional construct, we co-expressed two transcripts: 1) Mbp containing 5’UTR, CDS and 
3’UTR followed by MS2-binding stem loops and 2) a GFP-tagged MS2 reporter (Fig. 6G). In 
oligodendrocytes differentiated in culture for four days, MS2-GFP-positive puncta associated 
with Mbp mRNA are distributed throughout the many processes that emanate outward from the 
cell body (Fig. 6H), while in control cells not expressing stem loops, MS2-GFP is retained in the 
cell body (Fig. S4A).  
 We can use this system to biochemically validate the association of the dynein motor and 
its adaptor dynactin to Mbp mRNA granules. Indeed, immunoprecipitations using a GFP 
antibody to isolate MS2-GFP-tagged Mbp mRNA granules also pulls out the dynactin subunit 
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p150Glued, dynein intermediate chain (DIC), and Arp11 (Fig. 6I). Eluates more robustly co-
immunoprecipitated p150Glued than DIC. Interestingly, two bands are visible using the p150Glued 
antibody, which indicates that the lower band is p135, a shorter splice isoform of p150Glued that 
does not contain the N-terminal microtubule-binding domain (40). This was confirmed by 
comparing the p135 band in this anti-GFP immunoprecipitation to another immunoprecipitation 
using an antibody against the N-terminus of p150Glued that preferentially isolates full-length 
p150Glued, but not p135 (Fig. S4B and C). To our knowledge, this is the first description of the 
p135 isoform in oligodendrocytes or associated with mRNA granules. 
Acute dynein inhibition arrests Mbp mRNA transport in both anterograde and retrograde 
directions. 
 Live-cell imaging in this system using spinning-disk confocal microscopy reveals that 
processive Mbp mRNA transport occurs in both anterograde and retrograde directions with 
average speeds of approximately 0.21 µm/s and 0.16 µm/s, respectively (Fig. 7A and B), 
consistent with previously measured speeds for Mbp mRNA (4). To investigate the functional 
contribution of dynein in Mbp mRNA transport in oligodendrocytes, we pharmacologically 
inhibited dynein activity. The small molecule cell-permeable dynein inhibitor ciliobrevin D 
works by disrupting the ATPase activity of the dynein motor and has a half-minimum inhibitory 
concentration (IC50) ~5–15 µM in the cilia (41). Cells acutely treated with 15 µM ciliobrevin 
were imaged for 60-second durations for up to an hour with no observed morphology changes or 
toxicity. As early as 4 minutes after ciliobrevin treatment, Mbp mRNA net speed decreases in 
both anterograde and retrograde directions (Fig. 7A and B; N = 20 cells from 2 biological 
replicates). At around 10–15 minutes after ciliobrevin treatment, Mbp mRNA transport was 
arrested almost completely in both directions. When speeds are binned in 7-minute increments, 
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this decrease in speed is significantly different when compared to untreated cells (Fig. 7C and 
D). 
 Using faster frames rates to interrogate these possibilities, we saw as late as 11 minutes 
after ciliobrevin treatment Mbp mRNA that is engaged in bidirectional motility characterized by 
many frequent back-and-forth movements and directional switches (Fig. 7A, middle panel). 
After ciliobrevin treatment, we also observe Mbp mRNA granules with zero net motility that are 
engaged in very rapid and frequent directional switches for durations of up to one minute (Fig. 
S4D). This may represent a tug-of-war state during which anterograde and retrograde motor 
forces are roughly balanced and suggests that a single Mbp mRNA granule can associate 
simultaneously with both anterograde kinesin motors as well as retrograde dynein motors (Fig. 
7E).  
 To confirm our findings in vivo, we treated WT zebrafish with ciliobrevin D for 21 hours 
starting ~3.5 dpf. Importantly, treating at this time point permits normal OPC development so 
that we can specifically examine the role of dynein in mbp mRNA transport. Although there was 
15% mortality overall, importantly, the ciliobrevin-treated fish that were fixed at 4.5 dpf 
appeared grossly normal compared to vehicle-treated fish (Fig. S5A and B). ISH for mbp mRNA 
revealed that ciliobrevin-treated fish had a significant reduction in mbp mRNA localized to 
oligodendrocyte processes compared to vehicle-treated controls (Fig. 7 F–J). Taken together, our 
in vitro and in vivo results show that dynein inhibition leads to reduced mbp mRNA distribution. 
Chronic dynein inhibition disrupts MBP protein translation in cultured oligodendrocytes 
and disrupts myelination in zebrafish. 
In order to understand how Mbp mRNA transport inhibition can lead to myelination 
defects, we asked whether Mbp mRNA transport is necessary for local MBP protein translation. 
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We hypothesized that proper translocation of Mbp mRNA granules precedes local translation and 
recruitment of ribosomes (Fig. 8A). To test this, we treated cultured rat oligodendrocytes for 21 
hours with the dynein inhibitor ciliobrevin, then visualized Mbp mRNA localization using single 
molecule FISH (fluorescent ISH) and simultaneously immunostained for MBP protein. 
Previously, oligodendrocytes were treated acutely with 15 µM ciliobrevin for less than 1 hour for 
live-cell imaging. However, chronic treatment for 21 hours at this concentration resulted in some 
toxicity when compared to control and vehicle treated conditions (Fig. S5C). Thus, cells that had 
been differentiated for 3 days in vitro were treated for 21 hours at the non-toxic concentration of 
5 µM ciliobrevin (Fig. S5C), which had been previously used for overnight dynein inhibition in 
neurons (4). 
 Ciliobrevin-treated cells had remarkably decreased Mbp mRNA distribution and less 
MBP protein (Fig. 8B and C). Whereas Mbp mRNA granules in control cells were dispersed 
throughout the oligodendrocyte processes as distally as the cell periphery, Mbp mRNA granules 
in ciliobrevin-treated cells were restricted to the cell body and to proximal processes. Consistent 
with live-cell imaging results from acute ciliobrevin treatment, this chronic 21-hour treatment 
also demonstrates that dynein inhibition disrupts distal Mbp mRNA localization. Quantification 
of MBP protein staining revealed that only 42% of ciliobrevin-treated cells contained MBP 
protein, compared to 63% and 62% of control and vehicle-treated cells, respectively. These 
MBP-containing cells can be further binned as low expressers that have punctate MBP protein 
localization and high expressers that display pancake-like widespread MBP protein distribution. 
Binning demonstrates that while 29% and 27% of control and vehicle-treated cells are high 
expressers, only 8.5% of ciliobrevin-treated cells are high expressers. These data indicate that 
dynein inhibition leads to inefficient MBP translation.    
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3.5 Discussion 
Myelination by oligodendrocytes is critical for proper function of the nervous system. In 
a forward genetic screen in zebrafish, we identified the dynactin subunit Actr10 as a new 
regulator of myelination. actr10 mutants are lethal and display signs of impeded dynein loss of 
function in some tissues, including blindness due to photoreceptor loss and aberrant pigment 
cells with defects in melanosome motility. In the nervous system, mutants have fewer myelinated 
axons by TEM and fewer OPCs in part due to proliferation defects, phenocopying a previously 
described dynein zebrafish mutant (16). In addition, mutants exhibit less mbp mRNA in 
oligodendrocyte processes, similar to previous observations made in kinesin kif1b zebrafish 
mutants (14). Thus, we propose that proper function of the retrograde motor dynein and its 
adaptor dynactin is paradoxically required for anterograde transport of mbp mRNA. Indeed, we 
demonstrate in purified rodent oligodendrocyte cultures that acute pharmacological inhibition of 
dynein activity arrests Mbp mRNA transport in both anterograde and retrograde directions. 
Moreover, ciliobrevin treatment also decreases MBP protein levels, suggesting that mRNA 
transport is necessary for local translation of MBP. We confirmed these results in vivo in 
ciliobrevin-treated zebrafish, in which mbp mRNA distribution is perturbed in oligodendrocytes. 
The combination of our in vivo and cellular data suggests that dynein/dynactin activity is 
necessary for anterograde Mbp mRNA transport. In zebrafish, both Actr10/Arp11 loss of 
function and chronic dynein inhibition prevent proper anterograde distribution of mbp mRNA in 
oligodendrocytes. In cultured oligodendrocytes, acute dynein inhibition disrupts Mbp mRNA 
transport in both anterograde and retrograde directions. Our transport results are consistent with 
ciliobrevin treatment of cultured dorsal root ganglion neurons, which display arrest of 
mitochondrial and lysosomal axonal transport in both anterograde and retrograde directions (42, 
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43). Furthermore, our observations are consistent with earlier experiments in Drosophila 
macrophage-like S2 cells that demonstrate dynein knockdown leads to arrested transport in both 
anterograde and retrograde directions of fluorescently tagged RNA-binding protein FMRP (22). 
Our results also demonstrate that mRNA granules are highly heterogeneous, both in 
motility and in composition. We observe Mbp mRNA granules that move quickly with average 
net speeds ~0.21 and 0.16 µm/s in anterograde and retrograde directions, respectively; we also 
observe Mbp mRNA granules that have very little net motility and move bidirectionally with 
frequent directional switches. Each bidirectional mRNA granule likely associates with multiple 
opposing motors that are engaged in a “tug-of-war” in which opposing motor forces are nearly 
balanced. Since one kinesin has 7 pN of unitary force while one dynein only has 1 pN of unitary 
force, this suggests that a bidirectional mRNA granule likely associates with at least 1 kinesin 
and 6–8 dyneins. Thus, our data support a model whereby each Mbp mRNA granule 
simultaneously associates with kinesin and dynein/dynactin and the full assembly of opposing 
motors may be required to sustain transport (Fig. 7E). Though it is unclear why both kinesins and 
dyneins are simultaneously associated with individual cargos, one possibility is that the ability to 
transiently step back and forth may allow more flexibility in circumnavigating roadblocks or 
switching microtubules (44). This may be particularly important in the crowded cytoskeletal 
environment of the oligodendrocyte, in which microtubules penetrate many concentric layers of 
the dense myelin sheath (45). 
Moreover, association of different dynactin isoforms with mRNA granules may play a 
role in regulating Mbp mRNA transport as well. Co-immunoprecipitations revealed that Mbp 
mRNA granules not only associate with p150Glued, but also its shorter isoform p135, which is 
unable to bind to microtubules (40). Though a human neuronal cell line was used for the original 
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characterization of p135, we now show that p135 is also present in primary oligodendrocytes. 
Though it is still unclear what functional role p135 may play in transport regulation, a classic in 
vivo labeling study in the optic nerve demonstrated that p150Glued-associated cargos travelled 
much faster than p135-associated cargos, arriving past the optic chiasm at 2 days and 4 days after 
initial labeling, respectively (46).   
These data highlight that there is much more to learn about the composition of vertebrate 
mRNA granules, including how many motors are associated and what adaptor proteins link these 
motors to mRNAs. In neuronal axons, the RNA-binding protein La is transported in the 
anterograde direction in its native form and in the retrograde direction in its sumoylated form; 
sumoylation is required for dynein association to La and may act as a mechanism to return 
mRNA-free La protein to the nucleus by decreasing its ability to bind to mRNA (47). 
Furthermore, transport of mRNA in neurons can be stimulated in response to electrical activity 
(48, 49) and in oligodendrocytes, activation of Fyn kinase has been shown to trigger MBP 
translation (7, 8, 50). Further research on regulation at the adaptor level may yield clues on how 
environmental stimuli can trigger Mbp mRNA transport in oligodendrocytes.  
 Together, our results suggest that actr10 mutants display phenotypes similar to 
dynein/dynactin loss of function in photoreceptors, melanophores, and oligodendrocytes. 
Interestingly, recently identified human patients with mutations in dynein and dynactin primarily 
present with sensory and motor neuron symptoms and are diagnosed with Charcot-Marie-Tooth 
distal neuropathy or spinal muscular atrophy (51–60). Thus, in both humans and zebrafish, the 
nervous system is exquisitely sensitive to mutations in dynein and dynactin. Though a link 
between myelination and dynein/dynactin mutations has not been established in humans, our 
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work in zebrafish and mammalian oligodendrocytes demonstrates that dynein/dynactin function 
in Mbp mRNA transport is critical for proper myelination in vivo. 
3.6 Materials and methods 
Zebrafish lines and rearing conditions.  
All zebrafish work was done in compliance with Washington University institutional animal 
protocols, and zebrafish were housed in the Washington University zebrafish facility 
(http://zebrafish.wustl.edu). Embryos were raised in incubators at 28.5°C in egg water (5 mM 
NaCl, 0.17 mM KCl, 0.33 mM CaCl2, 0.33 mM MgSO4). ENU mutagenesis was performed 
according to standard protocols (61) and larvae were screened at 5 dpf for myelin abnormalities 
by two transgenes, tg(lhx1a:gfp) and tg(mbp:mCherry), as well as by in situ hybridization for 
mbp mRNA levels. The following transgenic and mutant zebrafish lines were used: SAT, SJD 
(62), actr10stl83, actr10nl15 (24), tg(lhx1a:gfp)(23), tg(mbp:mCherry)(a kind gift from Dave 
Lyons, University of Edinburgh), tg(neurod:egfp) (K.D. and A.V.N.), tg(olig2:dsred) (25), 
tg(sox10:mgfp) (26), tg(nkx2.2a:megpf) (1) and tg(mbp:gfp-caax) (63). 
Whole genome sequencing and mapping.  
The F2 generation of stl83 heterozygotes was outcrossed to SJD and raised. These animals were 
intercrossed and F4 progeny were screened for axonal swellings. DNA was extracted from 
phenotypically WT and mutant larvae at 5 dpf and sent to the Genome Technology Access 
Center (GTAC) at Washington University for whole genome sequencing. An in-house analysis 
pipeline (Sanchez et al. submitted) was used to determine that the mutant-to-WT allele ratio was 
highest on chromosome 20. A SNP subtraction analysis using other whole genome sequencing 
datasets narrowed the number of possible mutations down to five. The gene was confirmed by a 
complementation test using the actr10nl15 allele (24). 
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Genotyping.  
A derived cleaved amplified polymorphic sequences (dCAPS) assay was developed to genotype 
the actr10stl83 allele (http://helix.wustl.edu/dcaps/dcaps.html). An A-to-C mismatch is introduced 
in the forward primer (forward primer: 5’-GTCAGAGAACTT GCTGATACTC-3’, reverse 
primer: 5’-AGCAGTTCAGGGCAGCTTTA-3’). This causes an AvaI restriction digest site in 
the WT haplotype and digestion generates two visible WT products of 22 and 224 base pairs 
(bps), and a mutant product of 244 bps. To genotype the actr10nl15 allele, polymerase chain 
reaction (PCR) was used to amplify the first exon (forward primer: 5’-
ACCCAGCCGTTCCTCTAATG-3’, reverse primer: 5’-CCGCTCCTAAATCAA TCACC-3’). 
Mutagenesis introduced a T-to-G mutation in the start site. This inserts an HaeIII site and 
digestion results in two WT fragments of 126 and 50 bps, and three mutant fragments of 112, 50 
and 14 bps.  
In situ hybridization (ISH).  
In brief, embryos were treated with 0.003% phenylthiourea (PTU) at 24 hpf to prevent 
pigmentation. Embryos were reared in egg water with PTU until the desired age and fixed in 4% 
paraformaldehyde overnight at 4°C in 1.5 ml Eppendorf tubes with ~20 embryos per tube. A 
standard ISH protocol was then used (64) and all phenotypes were scored blindly. 
Transmission electron microscopy. 
Transmission electron microscopy (TEM) was done according to standard protocols (6). More 
detail can be found in Supplemental Information.  
Marker analysis using transgenes. 
Two transgenes, tg(olig2:dsred) and tg(sox10:mgfp), were crossed into an actr10nl15/+ 
background and grown to adulthood. Animals were intercrossed to produce double transgene 
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labeling, screened for double fluorescence and fixed at 3 dpf for OPC cross-section analysis. 
Single transgene tg(olig2:dsred) animals were used to count the number of dorsal, elongated 
olig2-labeled cells at 3 and 4 dpf. For details, see SI Materials and Methods. 
Time-lapse imaging.  
tg(nkx2.2a:megfp);actr10nl15/+ and actr10nl15/+  animals were crossed and live imaging was 
performed for up to 12 hours beginning at 57 hpf on a Zeiss LSM 880 confocal microscope. For 
details, see SI Materials and Methods. 
Melanosome aggregation.  
Control and actr10nl15/nl15 mutants were separated at 3 dpf by pigment phenotype. Larvae were 
treated with 0.5 mg/ml epinephrine (Sigma-Aldrich) dissolved in egg water. One representative 
animal from control and mutant groups was selected at random, treated with tricaine, mounted on 
an agarose mold, imaged and returned to the epinephrine treatment. This was repeated every 
approximately every 5 minutes, from 5–15 minutes, and again at 30 minutes. After 30 minutes, 
larvae were collected and genotyped. 
Noldus DanioVision assay. 
The Noldus DanioVision system was used to determine whether mutants were blind. Larvae 
were placed individually in a 96-well plate and the following protocol was used: light on 
(baseline) 0–4 minutes, light off (dark response) 4–8 minutes, light on (recovery) 8–12 minutes. 
The average distance moved from the center point during the baseline and dark response was 
calculated and analyzed for statistical significance. Two technical replicates were performed.  
Primary rat oligodendrocyte culture and electroporation.  
Oligodendrocyte precursor cells were purified from enzymatically dissociated P6–P8 Sprague-
Dawley (Charles River) rat brain cortices by immunopanning and differentiated in serum-free 
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defined medium containing T3, as previously described (38). Cells were electroporated using 
Amaxa Nucleofector (Lonza, Program O-17 for rat oligodendrocytes) with a bicistronic construct 
(pBI, Clontech) simultaneously expressing MBP 5’UTR, CDS, 3’UTR, and MS2-binding stem 
loops (24x) as well as MS2-GFP(39, 65). 
Live-cell imaging and ciliobrevin D treatment. 
Live-cell imaging was performed at the Stanford Cell Sciences Imaging Facility on a Nikon 
spinning disk confocal (TiE inverted microscope body equipped with Perfect Focus mechanism, 
Yokogawa spinning disk) with an Andor EMCCD camera inside an environmental chamber 
(37°C, CO2). Cells were treated with 15 µM ciliobrevin D (Calbiochem) and images were 
acquired at 1–3 frames per second for 60 seconds for a different cell at each time point to 
minimize photobleaching. Kymographs were generated from these movies using the Multiple 
Kymographs plug-in (FIJI, NIH) with a line width of 3 pixels. Net speed was calculated from the 
net duration and net distance of each motile event and represented as the average net speed for 
each cell. N = 2 biological replicates (2 OPC preps from 2 different animals), 10 imaging plates, 
20 cells. WT zebrafish at 3.5 dpf were separated into 6-well plates with 20 larvae per well. 
Larvae were treated with either 2.5 µM ciliobrevin D (Calbiochem) or DMSO vehicle in egg 
water for 21 hours. Larvae were fixed in 4% paraformaldehyde for ISH after 21 hours and scored 
blindly for localization of mbp mRNA in oligodendrocyte processes. 
Co-immunoprecipitations. 
1–4 million primary oligodendrocytes per condition were lysed in HEM buffer (50mM HEPES, 
1mM EDTA, 1mM MgCl2) containing 25mM NaCl, 0.5% Triton X-100, and protease inhibitors 
(Sigma, P8340). Cell lysates were incubated with Protein-G Dynabeads (Invitrogen) and co-
immunoprecipitations were performed following manufacturer’s instructions using a monoclonal 
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antibody against GFP (Clontech, JL-8). Western blots were probed with antibodies against DIC 
(Chemicon), p150Glued (BD Transduction, 610474) and Actr10 (Proteintech, rabbit polyclonal, 
20101-1-AP). 
Single Molecule FISH. 
Single Molecule FISH probes were designed against Mbp mRNA CDS (Stellaris, LGC 
Biosearch Technologies). Cells were stained according to manufacturer’s protocol. Briefly, cells 
were fixed in 4% paraformaldehyde, permeabilized in 70% ethanol for 1 hour at 4°C, hybridized 
with smFISH probes and primary antibody against MBP (Abcam, ab7349) for 4–16 hours at 
37°C, washed for 30 minutes at 37°C and then stained with secondary antibody.  
Statistical analysis. 
GraphPad Prism 7 and RStudio were used for statistical analysis. Unpaired t-tests with Welch’s 
correction were used for comparing all experiments with two variables. A one-way ANOVA was 
used to calculate the glial and neuronal TEM rescue experiments. Fisher’s exact test in R was 
used for calculating the ciliobrevin D experiments in zebrafish.  
3.7 SI Materials and methods 
Transmission electron microscopy.  
Zebrafish larvae (5 dpf) were fixed in modified Karnovsky’s solution (2% glutaraldehye, 4% 
paraformaldehyde and 0.1 M sodium cacodylate buffer, pH 7.4) using a Pelco BioWave Pro with 
Steady Temp Plus water recirculation system. To ensure accurate quantification, samples were 
cut between body segments 5–7. Preparation of tissue for analysis was performed as described 
(50). ~70-nm thin sections were cut using an ultramicrotome and mounted on copper mesh grids. 
Sections were stained using uranyl acetate and Sato’s lead stain. A Jeol JEM-1400 (Jeol USA) 
electron microscope was used to view samples and images were obtained using an AMT V601 
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digital camera. Images were analyzed using FIJI software (NIH) and all quantification was 
performed blinded to genotype. 
Spinal cord OPC quantifications  
tg(sox10:mgfp);actr10nl15/+  animals were crossed to tg(olig2:dsred);actr10nl15/+  animals. At 3 
dpf, double transgenic larvae were identified on a Zeiss fluorescent stereoscope by screening for 
dual-color fluorescence. Larvae were fixed for 30 minutes at room temperature using 4% EM-
grade paraformaldehyde diluted in 1x PBS. Larvae were then transferred to 30% sucrose for 
overnight immersion at 4°C. The next day, larvae were transected between segments 5–7. Heads 
were saved for genotyping and bodies were immersed and frozen in Tissue-Tek OCT compound 
using dry ice. Samples were sectioned at 10 µm on a cryostat and mounted on charged slides. 7 
sections per animal were imaged at 20X on an inverted Zeiss LSM 880 confocal microscope and 
OPC numbers were counted and averaged. All work was performed blinded to genotype 
Quantification of dorsal elongated OPCs. 
tg(olig2:dsred);actr10nl15/+  animals were crossed to actr10nl15/+  animals. At 3 and 4 dpf, larvae 
were screened for DsRed on a Zeiss fluorescent stereoscope. Larvae were then immobilized in 
tricaine and mounted on an agarose mold. The numbers of dorsally migrated olig2-labeled cells 
on either side of the spinal cord along the entire length of the animal were counted using a Zeiss 
fluorescent stereoscope. Quantifications were notated and animals were saved for DNA 
extraction. 
Time-lapse imaging. 
tg(nkx2.2a:megfp);actr10nl15/+ animals were crossed to actr10nl15/+  animals. Larvae were 
screened for fluorescence at 2 dpf. At ~55 hpf, mEGFP-positive embryos were immersed in 
0.8% low melting point agarose and mounted on 22x22 mm2 glass coverslips. Vacuum grease 
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was applied to a glass slide and egg water with 0.2% tricaine was used to fill the space. The 
coverslip containing mounted embryos was placed on top of the water to immerse embryos. At 
~57 hpf, larvae were imaged on an inverted Zeiss LSM 880 confocal microscope at 20X for up 
to 12 hours and Z-stacks were collected every 10 minutes. Blinded analyses were performed 
using FIJI software (NIH). Cell division times were calculated blinded to genotype from TIFF 
images of each time point.  
Rescue experiments.  
The transgenic tg(neurod:mrfp-actr10) rescue line was generated by concurrent injection of 
5kbneurod:mRFP-actr10 (12–25 pg) and transposase RNA (50–100 pg) into 1-cell stage 
embryos from an actr10nl15/+ intercross. Larvae with green hearts and mRFP fluorescence were 
grown to adulthood and genotyped for actr10nl15/+. These animals were then crossed to 
actr10nl15/+ animals and progeny were scored for germline transmission of 5kbneurod:mRFP-
actr10. Animals were again grown, genotyped for actr10nl15/+ and crossed to actr10nl15/+ for 
experiments. To generate the sox10:mRFP-actr10 construct, primers were designed to amplify 
the sox10 promoter (66) and to add Fse1 and Asc1 restriction enzyme sites to the 5’ and 3’ ends, 
respectively (forward primer: 5’GACTACGGCCGGCCGGATCCCCTTATCAGAGTCAACAT 
TCATGGATAATGAAAAAGGC-3’, reverse primer: 5’-TGGCAAGGCGCGCCACTAGTCGG 
TCCACTCGTTCTGCGGCCA-3’). The sox10 promoter fragment (insert) was amplified using a 
2X Phusion Master Mix (Thermo Scientific) and PCR purified using the QIAquick PCR 
purification kit (Qiagen). The insert and 5kbneurod:mRFP-actr10 plasmid (vector) were digested 
with Fse1 and Asc1 and the vector was subsequently treated with Antarctic phosphatase. Both 
vector and insert were visualized using gel electrophoresis and the correct bands were excised 
and gel purified. Vector and insert were ligated overnight using T4 ligase (New England 
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Biolabs). The next day, ligated product was transformed and grown overnight on antibiotic 
plates. Subsequently, colonies were grown in liquid culture overnight and mini preps were made 
the next day. 25 pg of mini prep and 100 pg of transposase RNA were simultaneously injected 
into 1-cell zebrafish embryos from tg(mbp:egfp-caax);actr10nl15/+  fish crossed to actr10nl15/+ 
fish. Injected larvae were screened for green hearts and mRFP fluorescence as early as 24 hpf. 
tg(mbp:egfp-caax) uninjected actr10nl15/nl15 mutants and mRFP-positive injected actr10nl15/nl15 
mutants were imaged on the 2-photon LSM 880 at 4 dpf. In a separate experiment, tg(mbp:egfp-
caax) uninjected actr10nl15/nl15 mutants and mRFP-positive injected actr10nl15/nl15 mutants were 
saved for TEM analysis at 5 dpf. 
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3.10 Figures 
 
Figure 1: A forward genetic screen uncovers actr10 mutants. 
(A) tg(lhx1a:gfp) marks axons in the tail of a control zebrafish larva at 4 dpf. (B) stl83 mutants 
exhibit axonal swellings in the CNS (arrows). (C) mbp ISH in a control animal at 5 dpf shows 
robust mbp mRNA levels. (D) An stl83 mutant animal exhibits reduced mbp mRNA in the 
hindbrain (arrow) and spinal cord (arrowheads). (E) Analysis of whole genome sequencing data 
revealed a higher mutant-to-WT allele ratio on chromosome 20, and SNP subtraction analysis (F) 
narrowed the number of candidate genes to 5. (G) Diagram of actr10 genomic structure shows the 
location of the nl15 mutation in exon 1 and the stl83 mutation in exon 12. (H) In a 
tg(neurod:egfp) background, the lateral line is normal in the tail of control animals at 2 dpf. (I) A 
complementation cross demonstrated that transheterozygous stl83/nl15 animals have axonal 
swellings in the PNS (actr10stl83/nl15: N = 22), which are never seen in either heterozygous or 
wildtype (WT) animals from either genotype (actr10+/+: N = 47, actr10stl83/+: N = 13, actr10nl15/+: 
N = 9) (arrows). (A, B, H, I), lateral views, dorsal up; (C and D), dorsal views, anterior up.  
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Figure 2: actr10 mutants have fewer myelinated axons in the ventral spinal cord. 
(A) Myelinated axons in a control larva in a hemi-segment of the ventral spinal cord at 5 dpf. (B) 
Pseudocoloring and higher magnification enhance visualization of control myelinated axons. (C 
and D) Myelinated axons are similarly shown in a quadrant of the ventral spinal cord in an 
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actr10nl15/nl15 mutant animal. (E and F) Myelinated axons in a control larva in a quadrant of the 
ventral spinal cord at 5 dpf. (G and H) Myelinated axons are similarly shown in a quadrant of the 
ventral spinal cord in an actr10stl83/stl83 mutant animal at 5 dpf. (I and J) Quantification revealed a 
significant difference in the number of myelinated axons in a ventral quadrant between control 
animals (N = 6) and actr10nl15/nl15 mutants (N = 4, p < 0.0006) (I) and between control animals 
(N = 8) and actr10stl83/stl83 mutants (N = 5, p < .0001) (J) at 5 dpf. Unpaired t-tests with Welch’s 
correction were used for statistical analysis. 
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Figure 3: actr10nl15/nl15 mutants have fewer OPCs.  
(A and B) Double transgenic tg(sox10:mgfp);tg(olig2:dsred) larvae were used to identify OPCs in spinal 
cord cross-sections at 3 dpf. Arrowheads mark OPCs, which are labeled by cytoplasmic DsRed and 
membrane-tagged GFP. (C) Mutants (N = 7) have significantly fewer OPCs in the spinal cord compared 
to sibling controls (N = 16, p < 0.0002). (D–G) The tg(olig2:dsred) line was used to count the number of 
olig2-labeled elongated cells in control animals (D, D’, arrows) compared to actr10nl15/nl15 mutants (E, E’, 
arrows) at 3 dpf and at 4 dpf (pictured). (F) Quantification revealed a significant difference between the 
number of olig2-labeled dorsal cells in controls (N = 48) compared to actr10nl15/nl15 mutants (N = 16, p < 
0.0067) at 3 dpf. (G) Similarly, there was also a significant difference between controls (N = 28) and 
actr10nl15/nl15 mutants (N = 16, p < 0.0001) at 4 dpf. Unpaired t-tests with Welch’s correction were used 
for statistical analysis. 
 
 76 
 
Figure 4: Cell division is delayed in actr10nl15/nl15 mutants.  
(A–E) Time-lapse imaging from ~57 hpf using the tg(nkx2.2a:megfp) line to mark OPCs allows for 
visualization of individual nkx2.2a-labeled cells that retract processes and become round in preparation 
for division (arrowhead, A). In actr10nl15/+ heterozygous control animals, the cell remains in this state for 
only two panels of 10 minutes (B and C) before becoming two cells (arrowheads, D) that divide rapidly 
(E). (F–R) In contrast, a cell from an actr10nl15/nl15 mutant animal that has already retracted its processes 
(arrowhead, F) takes over 3 hours to divide (G–R). (S) Quantification revealed a significant difference in 
either time to cell division or the end of imaging between heterozygous control animals (N = 11 cells 
from 5 animals) and mutants (N = 7 cells from 6 animals, p < 0.0194, unpaired t-test with Welch’s 
correction). See also Movies S1–S4. 
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Figure 5: Transient expression of actr10 in oligodendrocytes partially suppresses 
myelination defects in actr10nl15/nl15 mutants.  
(A–B”) Confocal images of mbp-labeled oligodendrocytes in uninjected (A) and sox10:mRFP-actr10 
(“sox10 injected”) actr10nl15/nl15 mutants (B). While uninjected actr10nl15/nl15 mutants do not exhibit RFP 
fluorescence (A’, A”), injection of sox10:mRFP-actr10 results in monomeric RFP fluorescence in 
actr10nl15/nl15 mutants (B’, B”). (C–E) TEM images show dorsal spinal cords of uninjected WT and 
actr10nl15/+ controls (C), uninjected actr10nl15/nl15 mutants (D), and sox10:mRFP-actr10-injected 
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actr10nl15/nl15 mutants (E). Myelinated axons are pseudocolored in purple. (F) Quantification shows that 
sox10-injected actr10nl15/nl15 mutants (N=6) have significantly greater numbers of myelinated axons in the 
dorsal spinal cord compared to uninjected actr10nl15/nl15 mutant siblings (N=5, p < 0.0377), although 
sox10:mRFP-actr10 injection does not restore myelination to WT control levels (N=5, p < 0.0001), 
indicative of partial rescue. One-way ANOVA with Tukey’s multiple comparisons test used for statistical 
analyses. 
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Figure 6: Dynein and dynactin are associated with Mbp mRNA granules.  
(A) ISH shows robust levels of mbp mRNA in a representative control larva at 4 dpf and higher 
magnification (B) shows mbp processes in the control (arrowheads) (N = 47/47). In contrast, an 
actr10nl15/nl15 mutant (C) has a punctate mbp phenotype and higher magnification of the same 
image (D) shows mbp positive cell bodies (arrows) but no processes (N = 18/18). (E) A lateral 
view of the brain and spinal cord of a WT animal shows mbp mRNA in processes (arrowheads) 
while actr10nl15/nl15 mutant animals (F) have cell bodies (arrows) but reduced mbp mRNA 
bearing processes. (G) A bidirectional construct expressing MS2-GFP, a RNA-binding reporter, 
as well as MBP 5'UTR, CDS, and 3'UTR tagged with MS2 stem loops was electroporated into 
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purified rat oligodendrocytes. MS2-GFP binds to stem loops to allow visualization of Mbp 
mRNA motility. (H) Primary rat oligodendrocyte expressing MS2-GFP labeled Mbp mRNA 
imaged using spinning-disk confocal microscopy shows distribution of Mbp mRNA throughout 
the oligodendrocyte processes. (I) Lysates from primary rat oligodendrocytes expressing the 
MS2-GFP labeled Mbp mRNA construct were immunoprecipitated using an anti-GFP antibody 
and probed with p150Glued, DIC (dynein intermediate chain), and Actr10/Arp11 antibodies (N = 4 
independent experiments). 
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Figure 7: Acute dynein inhibition arrests both anterograde and retrograde Mbp mRNA 
transport in cultured oligodendrocytes and perturbs mbp localization in zebrafish. 
(A) In kymographs representing 60 seconds of live-cell imaging, MS2-GFP labeled Mbp mRNA 
can be seen moving in the retrograde direction in untreated cells (top panel). Following acute 
ciliobrevin D (15 µM) addition, Mbp mRNA displays bidirectional motility characterized by 
frequent back-and-forth movement and many directional switches (middle panel). Finally, 
around 15 minutes after ciliobrevin D (15 µM) addition, most cells display arrested motility 
(bottom panel). (B) A scatter plot represents the average anterograde or retrograde net speeds for 
individual oligodendrocytes. (C and D) Anterograde or retrograde net speeds were averaged for 
each cell and binned across 27-minute time periods following ciliobrevin treatment. At 8–15 
minutes following ciliobrevin treatment, speeds significantly decreased compared to earlier time 
points. One-way ANOVA with post-hoc Tukey's test were performed. Anterograde speeds: No 
CilioD vs. 1–7 min: p = 0.109, No CilioD vs. 8–15 min: p = 0.0011, 1–7 min vs. 8–15 min: p = 
0.077. Retrograde speeds: No CilioD vs. 1–7 min: p = 0.666, No CilioD vs. 8–15 min: p = 0.106, 
1–7 min vs. 8-15min: p = 0.027. (E) A model shows that Mbp mRNA granules can move 
processively in the anterograde and retrograde directions as well as bidirectionally and that each 
Mbp mRNA granule can simultaneously bind to both kinesin and the dynein/dynactin complex. 
(F–I) mbp ISH of zebrafish larvae treated with ciliobrevin D for 21 hours. Larvae were scored as 
having strong (F), normal (G), reduced (H) or absent (I) mbp localization in oligodendrocyte 
processes (arrowheads, processes; arrows, cell bodies). (J) Quantification of phenotypic 
distribution shows that there was a significant difference in scores for DMSO (N = 71) and 
ciliobrevin D-treated larvae (N = 68), with the latter exhibiting more larvae with reduced or 
absent mbp localization in oligodendrocyte processes (p < 4.5E-14, Fisher’s exact test) (scale bar 
= 50 µM).  
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Figure 8: Chronic dynein inhibition disrupts MBP protein translation in cultured 
oligodendrocytes and disrupts myelination in zebrafish.  
(A) A model shows that transport of Mbp mRNA granules by microtubule-based motors 
precedes local translation and recruitment of ribosomes. (B) Quantification of the percentage of 
DIV3 oligodendrocytes treated for 21 hours with 5 µM ciliobrevin that express MBP protein 
demonstrate that a lower percentage of ciliobrevin-treated cells (42%) are positive for MBP 
protein compared to control cells (63%, p < 0.001) and DMSO-treated cells (62%, p < 0.001). Of 
these MBP-containing cells, only 8.5% of ciliobrevin-treated cells highly expressed MBP protein 
compared to 29% (p <0.001) and 27% (p < 0.001) in control and DMSO-treated cells. (C) Cells 
treated with 5 µM ciliobrevin for 21 hours were co-stained with smFISH probes against Mbp 
mRNA and with a monoclonal antibody against MBP protein. MBP protein images (middle 
panels) show examples of high expressers (arrows) in control cells and low expressers 
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(arrowheads) in ciliobrevin-treated cells (N = 2 biological replicates using primary cultures from 
2 different animals, 4 cover slips, 23–32 fields of view per group).  
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3.11 Supplementary figures 
 
Figure S1 (related to Fig. 1 and Fig. 2): nl15 and stl83 are alleles of actr10.  
(A) The nl15 allele is the result of a mutation in the start site (T to G), while the stl83 allele 
results from a G-to-T transition. (B) The Actr10/Arp11 amino acid sequence is highly conserved 
across species, and the glycine altered in the stl83 allele is completely conserved from zebrafish 
to human (black rectangle). (C) A dCAPs genotyping assay for stl83 inserts an AvaI restriction 
site in WT, leading to a 224 bp major band in WT used for genotyping (arrowhead) and a minor 
fragment of 22 bps. Mutants have a 244 bp fragment (asterisk). The nl15 mutation introduces an 
HaeIII site in mutants resulting in a major band at 112 bp (asterisk) and shorter bands at 50bp 
and 14bp, while WT has a major band at 126 bps (arrowhead) and a minor band of 50 bp. (D) 
Neither stl83 nor nl15 mutants develop a swim bladder. However, stl83 mutants appear 
generally healthier than nl15 mutants at 6 dpf. (E) There is no significant difference in number 
of myelinated axons in the ventral spinal cord between sibling actr10+/+ (N = 3) and actr10stl83/+ 
(N = 4) animals (p<.6120). (F) Similarly, there is no difference in number of myelinated axons 
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between sibling actr10+/+ (N = 3) and actr10nl15/+ (N = 3) animals. Unpaired t-test with Welch’s 
correction used for statistical analyses. 
 
 
 86 
 
Figure S2 (related to Fig. 6): actr10nl15/nl15 mutants have similar phenotypes to dynactin and 
dynein mutants.  
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(A, B) Photoreceptor layer analysis by DAPI staining at 3 dpf. Controls (N = 4) have a normal 
photoreceptor layer (A, arrowheads), while actr10nl15/nl15 mutants (N = 3) have a disrupted 
photoreceptor layer (B, arrowhead). (C, D) Head pigment analysis at 6 dpf. WT controls have 
normal pigmentation (C), while actr10nl15/nl15 mutants have expanded pigment (D, arrows). (E, F) 
Lateral line pigment analysis at 5 dpf. WT control animals have intermittent pigment along the 
lateral line (E), while actr10nl15/nl15 mutants have increased pigment (F, arrows). (G-I) The 
Noldus DanioVision behavioral system was used to track larval movement at 6 dpf. WT (G, N = 
23, p<.0002) and heterozygous (H, N = 36, p<.0001) controls showed a significant increase in 
movement in response to dark, while actr10nl15/nl15 mutants did not (I, N = 26, p<.9823). An 
unpaired t-test with Welch’s correction was used for statistical analysis. (J-S) Epinephrine 
treatment to assay retrograde melanosome transport. Before epinephrine treatment at 3 dpf, 
control animals (N = 19) exhibit similar pigment patterns. After 5 minutes of epinephrine 
exposure (K), melanosomes have begun to move back toward the melanophore cell body via 
retrograde transport. After 10 (L) 15 (M) and 30 minutes (N) all control animals have small 
pigment patches representative of aggregated melanosomes. Before epinephrine treatment, 
actr10nl15/nl15 mutants (N = 11) can be distinguished phenotypically from control animals by 
excessive pigment (O). After 5 (P), 10 (Q) 15 (R) and 30 (S) minutes of epinephrine treatment, 
melanosomes in mutants are still more dispersed relative to those in control animals. Note that 
representative animals were selected at random and images may be different animals. 
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Figure S3 (related to Fig. 5): Stable expression of actr10 in neurons suppresses myelination 
defects in actr10nl15/nl15 mutants.  
(A–D) Fluorescent micrographs showing tg(mbp:gfp-caax) and tg(neurod:mRFP-actr10) 
expression in zebrafish of the indicated genotypes harboring the indicated transgenes at 5 dpf. 
(A) The ventral and dorsal spinal cords are normal in WT control animal lacking the 
neurod:mRFP-actr10 transgene. (B) Large caliber swellings (arrows) are present in an 
actr10nl15/nl15 mutant lacking the neurod:mRFP-actr10 transgene. (C, D) Swellings are not 
observed in a WT control (C) and are ameliorated in actr10nl15/nl15 mutants harboring the 
neurod:mRFP-actr10 transgene (N = 15/17). (E–G) TEM images of the dorsal spinal cord show 
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myelinated axons (pseudocolored purple) in WT control animals (E)(N = 4), actr10nl15/nl15 
mutants lacking the stable neurod:mRFP-actr10 transgene (F)(N = 3), and actr10nl15/nl15 mutants 
harboring the stable neurod:mRFP-actr10 transgene (G)(N = 4). (H) Quantification shows that 
stable neuronal expression of actr10 suppresses actr10nl15/nl15 mutant myelination defects to WT 
levels (p<.9936, N.S), while there is a significant difference between control and actr10nl15/nl15 
mutants (p<.0184) and actr10nl15/nl15 mutants and actr10nl15/nl15 mutants with the neurod:mRFP-
actr10 transgene (p<.0224). 
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Figure S4 (related to Fig. 6 and Fig. 7): Co-immunoprecipitation pulls out p135 in addition 
to p150Glued.  
(A) Image of a cell expressing a control construct for MS2-GFP, which contains a nuclear 
localization sequence (NLS). In the absence of any stem loop containing constructs, such as 
MBP, MS2-GFP localizes to the nucleus. (B) Identity of the p135 band from an anti-GFP 
immunoprecipitation against MS2-GFP-associated MBP mRNA granules was confirmed by 
comparing it to the eluted band from an immunoprecipitation using an antibody targeted against 
the N-terminus of p150Glued, which contains its microtubule-binding domain. (C) Ribbon diagram 
of DCTN1 isoform 1 (p150Glued) shows a CAP-Gly microtubule-binding domain, which is 
lacking in DCTN1 isoform 2 (p135). (D) Kymograph analysis shows rapid back and forth 
movement of Mbp mRNA granules. 
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Figure S5 (related to Fig. 7): Effects of ciliobrevin D treatment on zebrafish and cultured 
oligodendrocytes.  
(A–B) DMSO and ciliobrevin D treated fish at 4.5 dpf. Compared to fish treated with DMSO for 
21 hours (A), ciliobrevin D treated fish look relatively normal. (C) Treatment of 
oligodendrocytes differentiated for 3 days in vitro with different concentrations of the dynein 
inhibitor ciliobrevin for 21 hours. Cell death was assayed by morphology using DIC microscopy; 
living cells contained continuous, non-bulbous branches and adhered to coverslips. 
Concentrations of 1 µM and 5 µM did not significantly alter the percentage of living cells while 
10 µM and 15 µM significantly decreased the percentage of living cells (n = 4 cover slips per 
group; * p = 0.023, *** p = 0.0001, one-way ANOVA). 
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Chapter 4: Investigating the role of ACTR10 
in human disease 
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Preface: 
The contents of this chapter may be adapted and reproduced at a later date in a 
published manuscript.  
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4.1 Abstract 
Precision medicine, targeting therapy to the underlying molecular cause of disease, is 
increasingly used to maximize positive outcomes in patients. To this end, better technology and 
lower costs have led to a massive increase in the use of sequencing to understand the etiology of 
human diseases. This approach has resulted in numerous studies associating new genes with 
diseases. However, validation of many of the genes found in these studies has lagged behind the 
influx of human sequencing data. The next phase in precision medicine research will be 
confirming sequencing data and establishing mechanisms for studying patient specific diseases 
in the lab. Zebrafish, already well established as an important organism for developmental 
biology, are increasingly being used in precision medicine research. 
  In a previous paper, we described uncovering a mutation in the gene actin related protein 
10 (actr10), through a forward genetic screen in zebrafish. actr10 mutants presented with myelin 
defects in the central nervous system (CNS) and we showed that this defect was due in part to 
reduced transport of mbp mRNA in oligodendrocytes, the myelinating glia of the CNS. actr10 
mutants also exhibit axonal swellings in the peripheral and central nervous systems with 
neurofilament accumulation, reminiscent of many neurological disorders. In collaboration with 
two neurologists from Washington University, we searched patient sequencing databases to 
determine if any patients with neurological disorders of unknown origin had mutations in 
ACTR10. Indeed, five families presenting with Amyotrophic Lateral Sclerosis (ALS), Charcot-
Marie-Tooth disease Type 2 (CMT2), and distal myopathy were identified as having missense 
mutations in ACTR10. Here, we focus on the ACTR10 single nucleotide polymorphism (SNP) 
identified in the CMT2 family. We generated zebrafish mutants with the patient specific ACTR10 
SNP in order to use zebrafish to model this patient specific form of CMT.    
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4.2 Introduction 
The use of whole genome sequencing (WGS), whole exome sequencing (WES), and 
genome wide association studies (GWAS) to both find new genes and to elucidate gene networks 
in human diseases has increased dramatically in recent years. Furthermore, the ability to 
sequence an individual’s genome at low cost has made precision medicine a reality for some 
diseases. However, the rapid pace of next generation sequencing has vastly outpaced researchers’ 
ability to validate and study many of the genes identified. A critical next step in advancing 
precision medicine research will be to establish pipelines for taking the many genes identified 
from these studies back to the bench for validation and further study. To this end, recent 
advances in molecular techniques in zebrafish have made them an attractive organism for 
precision medicine research.   
Zebrafish are a well-established model organism used widely in many different areas of 
research. Large clutch size, rapid embryogenesis, transparency of the early embryo, and a 
relatively short generation time are a few of the attributes that have made zebrafish so 
ubiquitous, particularly in fields such as developmental biology. Taking advantage of these traits 
in zebrafish, large-scale forward genetic screens led to the discovery of important genes 
regulating development and are still used today (1, 2) (see Chapter 2 of this dissertation). 
However, technology in zebrafish to disrupt specific genes via reverse genetics lagged behind 
what was possible in other models, such as mouse. Approaches such as TILLING relied on 
finding mutations in zebrafish populations that had been mutagenized, rather than targeting 
specific genes (3). Furthermore, antisense morpholinos have increasingly been shown to have 
off-target effects and more severe phenotypes than mutants in the targeted genes, confounding 
research (4).  
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Recent advances have brought zebrafish to the forefront of reverse genetics in model 
organisms. TALENs and CRISPR-Cas9 technology have made it feasible not only to disrupt 
genes efficiently, but also to insert nucleotides or specific sequences into the zebrafish genome 
(5). Using gene editing technology, it is now possible to introduce a single nucleotide 
polymorphism (SNP) into a gene of interest, which can be inherited by progeny. Zebrafish are 
therefore becoming increasingly suited to modeling patient specific diseases. Furthermore, the 
ability to perform transgenesis, xenografts, behavioral studies and live imaging have also made 
zebrafish incredibly useful for precision medicine research. Moreover, zebrafish can absorb 
small molecules and drugs through their skin, facilitating the use of drug screens (6). To this end, 
a recent study grafted patient specific tumors onto zebrafish, which were then treated with a 
drug, and found that not all the tumors responded in the same way (7). Zebrafish are therefore an 
important model organism that can be used to confirm sequencing data and study patient specific 
diseases in the lab. 
Zebrafish hold promise in particular for studying neurological diseases which may have 
multigenic or unknown etiology. One example of this is the complex disease Charcot-Marie-
Tooth (CMT) disease. Although there are currently 80 genes identified as causative for CMT, it 
is estimated that there remain many genes still be discovered (8). To this end, a recent paper 
described the discovery of three new CMT genes using whole exome sequencing of 40 CMT 
patients followed by tests for functional significance using morpholinos in zebrafish (9). CMT is 
a heterogenous group of progressive peripheral neuropathies that afflict one in 2,500 people, 
impacting both sensory and motor nerves (10). CMT neuropathy is broadly characterized by 
muscle weakness and atrophy in limbs beginning in the extremities (11, 12). Patients initially 
exhibit trouble walking, resulting in tripping and falling (11, 12). Patients may have difficulty 
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keeping their foot horizontal, called foot drop, or exhibit the classic neuropathic foot deformity 
“pes cavus,” which is characterized by a high arch (11, 12). In some instances, severe sensory 
loss can necessitate amputation of the afflicted foot. Although CMT is not fatal, its debilitating 
effect on patient quality of life, prevalence in the general population, and current dearth of 
treatment options make it a key candidate for precision medicine research.  
CMT neuropathy is divided broadly into two categories: CMT disease type 1, which is a 
myelinopathy originating in the myelinating Schwann cells of the PNS, and CMT disease type 2, 
which is an axonopathy originating in the axons of the PNS (13). Classical characterization of 
CMT involved testing patient nerve conduction velocities (NCVs) (14). Patients exhibiting low 
NCVs, below 38 m/s, are characterized as having CMT disease type 1, while patients with a 
normal NCV, above 38 m/s, are placed in the type 2 category (14). Since these early distinctions 
between myelinopathy and axonopathy, the classification of CMT disease has grown to include 
other characterizations, such as how the neuropathy is inherited. CMT 1 and CMT 2 can both be 
inherited in an autosomal dominant or autosomal recessive fashion (15). Other categories include 
CMT4, which is demyelinating and characterized by autosomal recessive inheritance, CMT X or 
CMT5, which is X-linked, and DI-CMT, which is inherited in a dominant intermediate manner 
(15). Currently, the number of CMT categories has expanded into nine different subgroups (16). 
Moreover, in addition to the classic Mendelian inheritance patterns, there are frequently 
instances of de novo mutations that cause CMT which, prior to the advent of low cost 
sequencing, would have gone undetected in afflicted patients (8).  
As the specific genes responsible for CMT have been identified, categorization has 
expanded to include this information. For example, the demyelinating autosomal dominant class 
of CMT disease type 1 is now subdivided into CMT1A-F. One of the most well-known genes 
 103 
involved in CMT1 encodes a critical component of the myelin sheath. PMP22 is a small, integral 
protein critical for compaction of the myelin sheath of Schwann cells and was the first protein 
identified as causative for CMT (17–20). Patients with a duplication in PMP22 are classified as 
having CMT1A. Other mutations in PMP22 are responsible for CMT1E, autosomal recessive 
CMT1, and hereditary neuropathy with pressure palsies (HNPP) (21, 22). Other genes affected in 
CMT1 include neurofilament light (NEFL), the transcription factor EGR2, and Myelin protein 
zero (MPZ) (15). PMP22, however, appears to be the gene primarily affected in demyelinating 
CMT disease. A recent study involving 17,000 patients found that 78.6% of those sequenced had 
mutations in PMP22 (23). To this end, many drug and treatment studies have targeted CMT1A 
(16). 
In CMT2, the most common mutations are in the genes MFN2 and GDAP1, both of 
which affect mitochondrial localization and transport (24–26). However, unlike in CMT1A, 
these two genes only account for 25% of the total mutations involved in CMT2 (16). Therefore, 
it is critical to continue to identify new genes that cause CMT2. An important component of 
CMT axonopathies is disruption to cytoskeletal integrity and intracellular trafficking (27). As is 
the case with many neurological disorders, the length of axons in the nervous system renders 
them acutely sensitive to transport defects (28). Thus, a primary phenotypic hallmark of CMT2 is 
disrupted transport (27). Indeed, mutations in genes involved in transport have been shown to be 
responsible for various forms of CMT2. Mutations in KIFbβ, an anterograde molecular motor 
that transports cargo from the cell body to the periphery along microtubules, were shown to be 
causative for CMT2A1 in a Japanese family (29). As in CMT1, mutations in NEFL are also 
causative for a form of CMT2, CMT2E. In a mouse model of CMT2E, axons swollen many 
times their normal diameter were shown by electron microscopy to be filled with disorganized 
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neurofilaments (30). Neurofilaments are specialized neuronal intermediate filaments that are 
critical for cytoskeletal integrity and transport. In addition to NEFL being directly mutated in 
CMT disease, abnormal neurofilament accumulation and/or disorganization is a hallmark of 
many neurodegenerative diseases, including CMT, ALS, Parkinson’s disease, and Alzheimer’s 
disease, among others (31).  
A recently characterized form of CMT2, CMT2O, was identified via exome sequencing 
of a family in which 4 generations were affected by the disease, and shown to be the result of a 
mutation in cytoplasmic dynein (32). A subsequent study of a separate afflicted family identified 
the same lesion in dynein as causative for the neuropathy (33). A mouse model of the dynein 
mutation similarly recapitulated the patient phenotypes (34). Unlike the large kinesin family of 
anterograde molecular motors, cytoplasmic dynein is the primary retrograde motor involved in 
transport in eukaryotes (35). Dynein thus requires multiple adaptors to promote facile transport 
of many different types of cargo along microtubules. One such adaptor complex is dynactin. 
Dynactin is composed of 12 different proteins, several of which have been implicated in 
neurodegenerative diseases (36). A family afflicted with motor neuron disease was found to have 
a point mutation in p150Glued, the microtubule binding component of dynactin that regulates 
microtubule stability (37–39). Follow up work in a mouse model recapitulated the degenerative 
phenotypes and demonstrated that lack of binding by p150Glued to microtubules and the protein 
EB1 played a role in the etiology (40). Another dynactin subunit, dynamitin or p50, when 
overexpressed in a mouse model results in general dynactin and dynein dysfunction leading to a 
progressive motor neuron degeneration phenotype (41). Components of the retrograde motor 
complex, including dynein, dynactin subunits and other adaptor proteins, are therefore important 
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to study for their role in neurodegenerative diseases. However, relatively little is known about 
the other proteins in the dynactin complex. 
In a large scale forward genetic screen in zebrafish, we identified a missense mutation in 
the gene actin related protein 10 (actr10), which encodes a component of the pointed end 
complex of dynactin (42). The actr10stl83 mutant identified in the screen is the result of a 
missense mutation in exon 12 out of 13 total exons. Using another allele of actr10, actr10nl15, 
which is a presumptive null, we previously demonstrated that actr10 mutants had reduced 
myelination in the CNS in part due to trafficking defects of myelin basic protein (mbp) mRNA 
(43). In collaboration with another group, we also demonstrated that actr10 has a role in 
mitochondrial trafficking in axons of the PNS which, when disrupted in the mutants, results in 
axonal swellings (44)(Appendix B of this dissertation). 
 Here, we show that actr10 mutants have defects in PNS development and myelin. 
Zebrafish homozygous for either stl83 or nl15 alleles of actr10 also exhibit reduced numbers of 
total axons in the PNS at 3 and 5 dpf. We observed axonal swelling and abnormal neurofilament 
accumulations in actr10 mutants, reminiscent of neurodegenerative diseases. These observations 
led us to wonder whether ACTR10 could have a role in human disease. To investigate this 
possibility, we worked with Drs. Matt Harms and Conrad Weihl to search sequencing databases 
for patients with neurological disorders that also had mutations in ACTR10. Five patient groups 
in total were identified: three with ALS, one with distal myopathy and one with CMT2. All 
mutations were missense mutations and corresponded to completely conserved amino acids 
between zebrafish and humans. We are currently working to test whether the patient mutation in 
ACTR10 may be contributing to the CMT2 and ALS diagnosis by knocking down Actr10 via 
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shRNA in mouse dorsal root ganglion (DRG) culture and assaying for degeneration and 
regeneration.  
Since the zebrafish actr10stl83 allele had such a severe phenotype, we hypothesized that 
the human mutations in ACTR10 might also cause a similar phenotype when recapitulated in the 
zebrafish. We found that the CMT2 allele was not present in the human population as a 
background mutation, and therefore decided to leverage the power of zebrafish to model the 
CMT2 mutation. Using TALENs, we generated a line of zebrafish with the CMT2 patient 
ACTR10 mutation. To determine if the mutant fish had a phenotype, we performed a 
complementation test between actr10CMT/+ F1 fish and actr10nl15/+ fish in a tg(neurod:egfp) 
background to screen for lateral line swellings. To our surprise, no phenotype was observed in 
the transheterozygous animals, unlike the complementation test performed previously between 
actr10stl83/+ and actr10nl15/+ fish, which yielded a strong phenotype in transheterozygous animals 
by 2 dpf. We discuss the potential reasons for the lack of an early phenotype in the Discussion 
section of this Chapter. While it is still possible that there may be an age dependent phenotype, 
and ongoing work will test this hypothesis, the potential lack of a phenotype demonstrates that 
there can be pitfalls in attempting to use model organisms to study human diseases. In this 
particular case, the complex nature of CMT2 may have precluded the ability to model the disease 
with a single mutation; rather, there may be multiple mutations in the human patient that are 
acquired over an individual’s lifetime, which eventually result in the disease diagnosis. 
Nonetheless, this work demonstrates the feasibility of reproducing human specific mutations in 
zebrafish, which was unthinkable just 10 years ago. While future studies in disease modeling 
must take into account the complexity and heterogeneity of neurodegenerative diseases, new 
advances in zebrafish techniques bode well for this work.  
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4.3 Materials and methods 
Zebrafish maintenance and husbandry 
All zebrafish used in these studies were kept in the Washington University zebrafish facility 
(zebrafish.wustl.edu). Zebrafish experiments were executed according to Washington University 
IRB standards and described in Monk lab animal protocols approved by Washington University 
(animal protocol no. 20160174; Institutional Biological & Chemical (IBC) Safety Committee 
protocol no. 10-643). Larvae were reared in egg water (5 mM NaCl, 0.17 mM KCl, 0.33 mM 
CaCl2, 0.33 mM MgSO4) at 28.5°C until 5 dpf, when they were transferred to the recirculating 
water system to be grown to adulthood. The mutant strains actr10nl15 and actr10stl83 were 
obtained from OHSU and from a forward genetic screen, respectively (43). Other lines used in 
this work include tg(neurod:egfp)(45) and tg(mbp:gfp-caax) (46). The actr10 CMT mutant strain 
was generated at Washington University using TALEN technology.  
Genotyping of actr10 mutants 
Genotyping for actr10nl15 and actr10stl83 was performed as described previously (43). To 
genotype actr10 CMT mutants, PCR was used to amplify the actr10 sequence of interest 
(forward primer: TGCAGGAGCGATATTTGGAG; reverse primer: 
CTCTTCATGAGCGGTGGA). The C-T CMT human SNP abrogated a BseR1 restriction 
enzyme site normally present in the WT sequence. Digestion of the amplified PCR product at 
37°C for two hours with the BseR1 enzyme results in an uncut mutant band of 165 bps, while the 
WT allele results in two bands of 107 and 58 bps. 
Protein alignment 
Actr10 cDNA sequences for Homo sapiens and Danio rerio were acquired using ensemble 
(https://useast.ensembl.org/index.html). Versions GRCh38.p10 for human and GRCz10 for 
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zebrafish were utilized. Sequences were added to the sequence editor ApE and the translation 
tool was used to generate the protein sequence. Sequences for human and zebrafish were aligned 
using the EMBOSS needle pairwise sequence alignment tool 
(https://www.ebi.ac.uk/Tools/psa/emboss_needle/).  
In situ hybridization 
In situ hybridization was performed according to standard protocols (47). Briefly, embryos were 
raised egg water and then treated with 0.003% phenylthiourea (PTU) beginning at 24 hpf to 
prevent pigment from forming. Larvae were grown in incubators until 5 dpf, when they were 
fixed in 4% paraformaldyde (PFA) in 1xPBS overnight at 4 °C. An in situ hybridization was then 
performed using a riboprobe against mbp mRNA (48). Larvae from these experiments were 
scored blindly and subsequently genotyped. 
Transmission electron microscopy  
For all TEM experiments, zebrafish larvae from actr10nl15/+ and actr10stl83/+ heterozygous 
intercrosses were grown in egg water until 3 or 5 dpf. All samples were cut between segments 5- 
7 and larval heads were saved for genotyping by PCR and digest, while bodies were fixed in a 
modified Karnovsky’s solution composed of 2% glutaraldehye, 4% PFA, and 0.1 M sodium 
cacodylate buffer, pH 7.4. Fixation was aided by temperature shifts in a Pelco BioWave Pro with 
Steady Temp Plus water recirculation system and proceeded according to standard protocols 
(49). The larvae used for analysis of number of myelinated and unmyelinated axons were 
mounted in epon with the cut tissue nearest the edge, while the actr10nl15 samples being used for 
analysis of axonal swellings in the CNS and neuromasts were mounted with the tail nearest the 
edge, to allow for sectioning through posterior swellings. Sections were cut on an 
ultramicrotome using a diamond knife. The zebrafish being used to examine the swellings were 
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then stained using Tol-Blue to ensure that the swellings were indeed present in the actr10nl15/nl15 
mutants. Thin ~70 nm sections were cut using an ultra diamond knife and placed onto copper 
mesh grids. Staining with uranyl acetate and Sato’s lead stain were performed according to 
standard protocols (50). Electron micrograph images were obtained using a Jeol JEM-1400 (Jeol 
USA) electron microscope and captured by an AMT V601 digital camera.  
Generation of actr10 CMT mutants 
The actr10 CMT zebrafish mutants were produced using TALEN technology. TALEN arms 
were designed using the TALEN targeter tool (https://tale-nt.cac.cornell.edu/) and generated 
using the GoldyTALEN kit (51). The left repeat variable di-residue sequence (RVD) was as 
follows: NG NN HD NG NN NG HD NG NN NI. The right RVD was as follows: NG NI NN NI 
NG NN NN NI NN NG. Additionally, the following oligonucleotide containing the CMT SNP 
(in brackets), was ordered through IDT: 
CATGAGCGGTGGAGGGGTTTTTCCAGCCTCATAGATGGAGTCGGGTGGAGA[A]GAG
CTCAGACAGCACCAGTCCGGGATGCGGCCCGTATGGTTGTAGTAAT. The reverse 
complement was used because it has been shown to insert more efficaciously after disruption by 
TALEN arms. 25-50 pg/nL total of mRNA of both TALEN arms were co-injected with 50 pg/nL 
of the oligonucleotide in a 10 µL solution containing milliQ water and 1 µL phenol red. At 24 
hpf, DNA from injected and uninjected control embryos was collected and the functionality of 
the TALEN mutagenesis was tested using the PCR and digest assay described above.  
Deep sequencing 
TALEN injected F0 animals were grown to adulthood in the Washington University zebrafish 
facility. After they were sexually mature, sperm was collected via squeezing from F0 males. 
DNA was extracted according to standard protocols. Up to 17 sperm samples were pooled into 
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PCR tubes and sent for deep sequencing at the Washington University Genome Engineering and 
iPSC Center (GEIC). Sequencing analysis revealed the SNP of interest in two out of five samples 
sent for sequencing. Sperm from the pooled animals was then collected from individual fish and 
sent again for sequencing to identify the specific F0 carrier. Sequencing identified three F0 
carriers. F0 carrier males were outcrossed to WT AB females and F1 animals were grown until 
adulthood. F1 animals were fin clipped and genotyped for the CMT mutant allele. Mutant bands 
of 165 bps were excised from the gel and DNA was collected via gel extraction using the 
QIAquick gel extraction kit. DNA was sent for Sanger sequencing to Genewiz 
(https://www.genewiz.com/en) using the forward and reverse primers used in the genotyping 
assay. F1 fish with the CMT C-T SNP were identified from sequencing.  
Regeneration assay in mouse dorsal root ganglia (DRG) 
Dorsal root ganglia were dissected from embryonic 13.5 day old mice. Neurons were plated in 
spots in 24-well plates. At DIV2, neurons were transduced with FCIV-Bclxl-IRES-GFP 
[multiplicity of infection (MOI) 10] to ensure survival of embryonic DRGs. At DIV 4, cells were 
transduced with three different shRNAs (MOI 10) targeting Actr10. shRNAs were ordered from 
Sigma-Aldrich as MISSION bacterial clones. Efficacy of Actr10 knock-down was determined by 
qPCR following shRNA addition to DRG culture. At DIV9, DRG spots were axotomized along a 
single plane using a microtome blade pressed into 8 mm chunks. Cells were allowed to 
regenerate for 48 hours before being fixed in 4% PFA and stained for SCG10, which labels 
regenerating axons. Length was measured at multiple points across the injury to determine 
regenerative growth. The regeneration experiment was performed in technical triplicate, N=4. 
Human constructs used for rescue were ordered from Genecopoeia. 
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4.4 Results  
actr10nl15/nl15 and actr10stl83/stl83 mutants have reduced mbp expression in the lateral line 
In a previously published study, we showed that actr10nl15/nl15 and actr10stl83/stl83 mutants 
had reduced expression of mbp in the hindbrain of zebrafish in addition to a punctate phenotype 
(43). Here, we show that both actr10 mutants also exhibit reduced mbp expression in the lateral 
line of the PNS (Figure 1). Zebrafish larvae from an actr10nl15/+ and actr10stl83/+ intercross were 
scored as having either “WT” or “mutant” mbp expression following in situ hybridization (ISH) 
at 5 dpf. All actr10nl15/+ and actr10+/+ animals were scored as having WT mbp expression 
(N=67/67) while all actr10nl15/nl15 mutants had mutant expression (N=27/27) (Figure 1A-B). 
Similarly, all actr10stl83/+ and actr10+/+ zebrafish had WT expression (N=30/30) while all 
actr10stl83/stl83 mutants were scored as having mutant mbp expression (N=21/21) (Figure 1C-D). 
Actr10 has previously been shown to be involved in mitochondrial trafficking, which, when 
disrupted in actr10nl15/nl15 mutants, results in swellings in peripheral axons of the lateral line 
(Appendix B). These experiments show that there are additional myelin defects not only in the 
actr10nl15/nl15 mutant, which is presumed to be a null, but also in the actr10stl83/stl83 mutants.  
actr10nl15/nl15 and actr10stl83/stl83 mutants have reduced numbers of myelinated axons at 3 and 
5 dpf compared to WT animals 
While we use mbp expression as a marker of myelinating glial cell development, it does 
not necessarily indicate that the structure of myelin is altered. To examine the ultrastructure of 
the myelin sheath, we used transmission electron microscopy (TEM) to visualize myelinated 
axons in the PNS. At 3 dpf, there were significantly fewer myelinated axons in actr10nl15/nl15 
mutants compared to actr10+/+ larvae (Figure 2A-C). TEM of the actr10stl8 allele showed similar 
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results. At 3 dpf, there was a significant reduction in number of myelinated axons in 
actr10stl83/stl83 mutants compared to actr10+/+ animals (Figure 2E-G). 
The reduction in myelinated axons persisted at 5 dpf, indicating that this defect was not a 
developmental delay. TEM at 5 dpf revealed significantly fewer axons in actr10nl15/nl15 mutants 
compared to actr10+/+ animals (Figure 2I-K). There was also a significant reduction in number 
of myelinated axons in actr10stl83/stl83 mutants compared to actr10+/+ animals (Figure 2M-O).  
actr10nl15/nl15 and actr10stl83/stl83 mutants have fewer axons at both 3 and 5 dpf. 
To understand whether the myelin defects shown by TEM were the result of axon 
defects, we also quantified total axon number in the lateral line. There was a significant decrease 
in the total number of axons in actr10ml15/nl15 mutants at 3 dpf compared to actr10+/+ animals 
(Figure 2D). Similarly, actr10stl83/stl83 mutants had fewer axons compared to actr10+/+ animals 
(Figure 2H).  
We next counted the total number of axons at 5 dpf. There were significantly fewer axons 
in actr10nl15/nl15 mutants compared to actr10+/+ animals (Figure 2L). Moreover, actr10nl15/nl15 
mutants exhibited abnormalities, including large swellings with neurofilaments and cargo 
(Figure 2J, arrowheads). In the actr10stl83 background, we also saw a decrease in total number of 
axons in mutants. There was a significant reduction in total number of axons in actr10stl83/stl83 
mutants compared to actr10+/+ animals (Figure 2P). There were also axonal abnormalities in the 
actr10stl83/stl83 mutants at this stage (Figure 2N, arrowhead). These data indicate that in addition 
to the myelin defects, there are axonal defects at both 3 dpf and 5 dpf in actr10nl15/nl15 and 
actr10stl83/stl83 mutants.  
actr10nl15/nl15 and actr10stl83/stl83 mutants exhibit neurofilament-filled axonal swellings in PNS 
and CNS axons  
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The actr10nl15 mutant was first identified in a forward genetic screen to uncover axon 
defects in the lateral line using the transgene tg(neurod:egfp)(44). At 3 dpf, swellings in the 
lateral line are visible in actr10nl15/nl15 mutants, which are not present in control animals (Figure 
3). Neither actr10nl15/+ nor actr10+/+ animals ever exhibited swellings, and were there therefore 
combined as controls (Figure 3). Previously, we showed that these large swellings were the result 
of stalled mitochondria in axon terminals of neuromasts, which are sensory structures along the 
lateral line which aid fish in sensing water movements (44). Upon further inspection, we found 
that in addition to the mitochondria, there is an excess of neurofilaments in the swellings not 
observed in control animals (Figure 3).   
We also previously showed that there were additional large caliber swellings in the CNS, 
which we hypothesized were in the Mauthner axon (43). By using a construct in which actr10 
tagged with mRFP was driven by the neurod promoter, we were able to rescue axon defects in 
both the CNS and in the PNS (43). At 5 dpf, the large caliber swellings can be visualized in both 
actr10nl15/nl15 and actr10stl83/stl83 mutants using the tg(mbp:egfp-caax) line (Figure 4). Swellings 
are never observed in WT or heterozygous animals of either genotype (Figure 4). We wondered 
whether these swellings were similarly filled with neurofilaments. Therefore, we examined 
actr10nl15 animals using TEM. All actr10+/+ animals examined had normal Mauthner axons 
(Figure 4I-K). In contrast, all mutant animals imaged had abnormal neurofilament accumulation 
in the Mauthner axon (Figure 4L-N). Furthermore, all mutants exhibited cargo accumulation that 
appeared to be degenerating (Figure 4M). We also observed axons other than the Mauthner with 
neurofilament accumulation (arrows, Figure 4M). In some instances, the Mauthner axon was 
swollen to many times its normal size (Figure 4O-Q).  
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Neurofilament accumulation is a hallmark of many neurological disorders, including 
ALS, Parkinson’s disease, and Charcot Marie Tooth disease. Furthermore, a mouse model of 
CMT type 2E was shown to exhibit giant axons filled with neurofilaments, very similar to the 
actr10nl15/nl15 mutant. We therefore wondered whether ACTR10 mutations might play a role in 
human neurological disorders. 
Human patients with missense mutations in ACTR10 have neurological disorders 
Working with Dr. Matt Harms, who has since moved to Columbia University, and Dr. 
Conrad Weihl from Washington University School of Medicine, Department of Neurology, we 
obtained sequencing data from patients with neurological disorders that also had mutations in 
ACTR10. Sequencing identified ACTR10 mutations in three patients with ALS, one patient with 
distal myopathy, and one patient with CMT2 (Figure 5A). While one ALS patient had a C9orf72 
mutation that was causative for the disease, the cause of disease for the other patients was 
unknown. All ACTR10 mutations were missense and all patients were heterozygous for the 
mutant allele (Figure 5A). This fits with the zebrafish data that both actr10 alleles are lethal 
when homozygous (43). Moreover, a recent study of humans with homozygous mutations in 
Iceland did not find any humans that had homozygous mutations in ACTR10, indicating that this 
gene may be necessary for human survival (52). All of the human ACTR10 missense alleles 
identified via sequencing were in completely conserved amino acids between humans and 
zebrafish (Figure 5B) and were also relatively close to the actr10stl83 allele, which has a severe 
phenotype (Figure 5B).  
Using the Exome Aggregation Consortium (ExAC) browser, it was found that the 
patients with CMT2 and distal myopathy had ACTR10 mutations that have not been identified in 
the general population, meaning that they are not common background mutations. As a result of 
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this finding, and from our investigation of actr10nl15 and actr10stl83 phenotypes, we decided to 
pursue the CMT2 mutant allele to understand whether this could have a role in the patient 
disease. In order to study the patient specific ACTR10 mutation, we decided to generate zebrafish 
mutants with the patient disease.   
An actr10CMT/+ complementation cross with actr10nl15/+ fish does not result in a mutant 
phenotype 
 To generate a zebrafish strain with the patient specific mutation, we used TALEN 
technology. The human SNP is the result of a C-T nucleotide change that causes a proline to 
serine amino acid change at amino acid 393 (Figure 5B). We injected TALEN mRNA targeting 
the actr10 locus near the codon encoding the amino acid 393 affected by the missense mutation 
in human, as well as an oligonucleotide containing the patient specific nucleotide into 1-cell 
stage zebrafish larvae. The human SNP is the result of a C-T nucleotide change that causes a 
proline to serine amino acid change at amino acid 393 (Figure 5B). In the zebrafish, we were 
able to generate this nucleotide change in F0 embryos (Figure 5C). We designed a PCR-based 
genotyping assay in which the mutant nucleotide alters a restriction enzyme binding site, 
resulting in the mutant allele having a larger band (Figure 5D).  
We grew up the F0 fish with the CMT mutation to adulthood and then outcrossed several 
founders to another strain of zebrafish to produce the F1 generation. After the F1 fish reached 
adulthood, we found that many F1 animals were indeed heterozygous for the CMT humanized 
allele (actr10CMT/+). We then performed a complementation test with the actr10nl15/+ animals 
harboring the tg(neurod:eGFP) transgene to determine if the actr10CMT mutation causes a 
phenotype. Previously, the complementation cross between actr10nl15/+ and actr10stl83/+ produced 
a strong swelling phenotype in the lateral line by 2 dpf, as visualized by tg(neurod:eGFP) (43). 
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However, the complementation cross with the actr10CMT/+ allele did not produce larvae with a 
lateral line phenotype by 5 dpf, as 12 larvae, which had been scored as WT, were 
transheterozygous animals (Figure 6).  
4.5 Discussion 
Here, we demonstrated that two actr10 mutant alleles in zebrafish resulted in reduced 
myelination in the PNS, as well as reduced numbers of axons and a neurodegenerative 
phenotype, including neurofilament accumulation in axonal swellings. These phenotypes led us 
to wonder whether there might be human conditions caused by ACTR10 mutations. Working 
with two neurologists, we identified five different groups of human patients with the diseases 
ALS, distal myopathy, and CMT2, that had missense mutations in ACTR10. All of the mutations 
were in completely conserved amino acids between zebrafish and human. Although the 
mutations were far in the protein sequence, they were in a relatively similar position to the 
actr10stl83 mutation, which was also a missense mutation resulting in a single amino acid change. 
Since the actr10stl83 had such a severe phenotype, we hypothesized that the other human ACTR10 
mutations might produce a similar phenotype in zebrafish. Furthermore, using the ExAC 
browser, we found that no humans have been identified with the CMT2 mutation, meaning that it 
is likely not a common background SNP. Therefore, we decided to generate a “humanized” 
zebrafish line containing the patient specific SNP. 
In order to identify whether the actr10CMT line had a phenotype, our first step was to 
perform a complementation test, which had been done previously between actr10nl15 and 
actr10stl83 to demonstrate that the stl83 phenotype was indeed the result of an actr10 mutation. 
However, when we performed the complementation cross between actr10nl15/+ and actr10CMT/+ 
animals, there was no observable phenotype in the transheterozygous larvae by tg(neurod:egfp) 
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at 3 dpf. In the original complementation cross, the swelling phenotype was obvious by 2 dpf. 
The larvae from the complementation cross were grown until 5 dpf to observe if there might be 
subtler defects. However, at 5 dpf, all larvae were scored as having a WT phenotype. The first 
possibility for this lack of phenotype is that there may be an age-dependent phenotype that is not 
present at early stages. Another possibility is that the phenotype is subtle and cannot be observed 
via transgene analysis, but may require other methods, such as TEM. 
However, if experiments are performed to test the two possibilities listed above, and there 
is still no phenotype, there could be several reasons to explain this observation. The first is that 
the actr10stl83 mutation may be in a unique and important domain necessary for the Actr10 
protein to be produced properly, while the actr10CMT mutation may be in a less important 
domain. Furthermore, the actr10stl83 mutation causes a glycine to tryptophan amino acid change, 
a drastic change which might affect the folding of Actr10 and prevent it from being processed 
properly.  
The lack of phenotype in the larval zebrafish does not preclude the possibility that the 
missense mutation in the human patient may still have a role in CMT2 disease. Although the 
mutation occurs in a completely conserved amino acid, the protein sequence between human and 
zebrafish ACTR10 is ~75% conserved and there are amino acid differences between the two 
species. Therefore, the CMT mutation could be more important in humans than it is in zebrafish. 
This brings up an important point which will have to be addressed in order for human disease 
research in zebrafish to proceed: zebrafish and human genes can have divergent protein 
sequences, and in many cases, zebrafish can possess multiple copies of a human gene.  
Another possibility is that the human disease phenotype is the result of multiple 
mutations in different genes over the course of the patient’s life. Many neurological disorders in 
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particular are considered multigenic and are unlikely to be the result of one mutation. To this 
end, the human CMT2 patient was heterozygous for the ACTR10 mutation, while the actr10 
zebrafish mutants only exhibit defects when the animals are homozygous for the CMT mutation. 
In zebrafish, complete loss of actr10 is lethal, as it likely is in humans, and the reason actr10 
homozygous zebrafish mutants are able to live until ~day 7 is likely due to maternal deposition 
of WT actr10 mRNA in the egg. It was unlikely that there would be a dominant CMT phenotype 
in the zebrafish, since neither actr10nl15/+ nor actr10stl83/+ animals exhibited any defects. 
Therefore, if the human ACTR10 mutation does not directly cause the disease phenotype, the 
mutation could function in conjunction with other mutations. Addressing the multigenic nature 
of many human diseases will be another hurdle to overcome in order to effectively create animal 
models of patient specific diseases.  
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4.6 Figures  
 
Figure 1: actr10nl15/nl15 and actr10stl83/stl83 mutants have reduced mbp expression in the PNS. 
(A) A lateral view of a control zebrafish larva at 5 dpf shows normal mbp expression along the 
lateral line (arrowhead)(N=67/67) in contrast to an actr10nl15/nl15 mutant (B), which exhibits 
reduced mbp expression (arrowhead)(N=27/27). (C) Similarly, in the actr10stl83 background, a 
WT control zebrafish shows normal levels of mbp (arrowhead)(N=30/30) while an actr10stl83/stl83 
mutant (D) has reduced peripheral mbp expression (arrowhead)(N=21/21). 
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Figure 2: actr10nl15/nl15 and actr10stl83/stl83 mutants have axonal and myelin defects.  
TEM images of the lateral line of actr10+/+ (WT, A), and actr10nl15/nl15 (MUT, B) zebrafish 
larvae at 3 dpf show myelinated axons (pseudocolored) and unmyelinated axons (asterisks). (C) 
Quantification shows a significant difference in the number of myelinated axons between WT 
(N= 4) and MUT (N= 7, p<0.00534) (D) There is also a significant difference in the number of 
total axons (p<0.00486). TEM images of actr10+/+ (WT, E), and actr10stl83/stl83 (MUT, F) 
zebrafish larvae are similarly pseudocolored to show myelinated axons and naked axons 
(asterisks). (G) There is a significant reduction in myelinated axons between WT (N=6) and 
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MUT (N=6, p<1.68457e-7)). (H) There were also significantly fewer axons in MUT compared to 
WT (p<0.04974). TEM images at 5 dpf of actr10+/+ (WT, I), and actr10nl15/nl15 (MUT, J) show 
myelinated axons pseudocolored in blue. (J) The actr10nl15/nl15 mutant shows neurofilament 
accumulation and abnormal degeneration and swelling at 5 dpf (arrowheads, N=4/6) (K) 
Quantification of number of myelinated axons shows a significant decrease in MUT (N=6) 
compared to WT (N=4, p<8.71309e-7). (L) At 5 dpf, there is also a significant decrease in 
number of total axons between MUT and WT (p<4.51358e-5). TEM images of actr10+/+ (WT, 
M), and actr10stl83/stl83 (MUT, N) zebrafish larvae at 5 dpf show myelinated axons 
(pseudocolored) and unmyelinated axons (asterisks). (N) actr10stl83/stl83 mutants exhibit 
degenerated or abnormal axons (arrowhead, N=4/6). (O) Myelin defects persist at 5 dpf, with a 
significant reduction between WT (N=3) and MUT (N=6, p<0.03255). (P) At 5dpf, there are 
significantly fewer axons in MUT compared to WT (p<5.46213e-6). *p<0.05. **p<0.01, 
***p<0.001, ****p<0.0001. A two-sided student’s t-test in R was used for quantification.  
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Figure 3: actr10nl15/nl15 mutants exhibit swellings in the lateral line and neurofilament 
accumulation in neuromasts.  
Both control, which includes both actr10+/+ and actr10nl15/+ animals (A), and actr10nl15/nl15 
mutants (B) appear grossly normal by brightfield microscopy at 3 dpf. (C) However, using 
fluorescent microscopy to observe tg(neurod:egfp) expression demonstrates that while the lateral 
line in control animals is normal, actr10nl15/nl15 mutants (D) have visible swellings (arrows, WT: 
N=14/14, actr10nl15/+:N=34/34, actr10nl15/nl15:N=25/25). (E) TEM of an actr10+/+ animal shows a 
normal neuromast (N=3/3). (F) A higher magnification shows the absence of swellings. (G) An 
actr10nl15/nl15 mutant, however, shows a large caliber swelling (box, N=4/4). (H) A higher 
magnification image shows that the swelling is filled with neurofilaments (arrowheads).  
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Figure 4: actr10 mutants exhibit swelling in the large caliber Mauthner axon and 
neurofilament accumulation.  
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(A-D) Brightfield images of control animals and actr10 mutants demonstrate that the WT 
controls (A, C) are grossly healthier at 5 dpf compared to actr10 mutants (B, D). (E) A lateral 
view of the zebrafish spinal cord in a control animal shows normal tg(mbp:egfp-caax) expression 
(WT: N=4/4, actr10nl15/+: N=7/7), whereas in an actr10nl15/nl15 mutant (F) there are large caliber 
swellings (arrowheads, actr10nl15/nl15: N=7/7 ). Similarly, a control animal from the actr10stl83 
background shows normal expression (G, WT: N=2/2, actr10stl83/+: N=9/9) while an 
actr10stl83/stl83 mutant (H) exhibits similar swellings (arrowheads, actr10stl83/stl83: N=10/10). (I) 
An electron micrograph of a quadrant of the ventral spinal cord from an actr10+/+ (WT) 
zebrafish taken shows neuronal cell bodies (asterisks) and the large caliber myelinated Mauthner 
axon (arrow). (J) A higher magnification image shows myelinated axons (pseudocolored blue) as 
well as the myelinated large caliber Mauthner axon (arrow). (K) All WT animals had normal 
Mauthner axons without neurofilament accumulation (N=4/4) (L). An EM image from an 
actr10nl15/nl15 mutant animal shows no myelinated axons and a swollen Mauthner axon (arrow). 
(M) A higher magnification image reveals that the swollen Mauthner, in addition to other axons, 
is filled with neurofilaments (arrows). Additionally, there are swellings that appear to be filled 
with mitochondria and other cargo (arrowhead). (N) Neurofilaments are visualized in the swollen 
Mauthner. All mutants examined had neurofilament accumulations in axons (5/5). (O) Another 
actr10nl15/nl15 mutant shows an extreme swelling of the Mauthner axon. This correlates with the 
large caliber swellings observed in actr10nl15/nl15 and actr10stl83/stl83 mutants. (P-Q) Higher 
magnification images show the accumulated neurofilaments in the swollen Mauthner axon 
(arrow). 
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Figure 5: Generation of a humanized zebrafish strain with a patient specific actr10 
mutation.  
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(A) Table shows sequencing information from 5 patient families diagnosed with ALS, distal 
myopathy and CMT2 that also have missense mutations in ACTR10. (B) A protein sequence 
comparison between human and zebrafish shows the location of the human ACTR10 mutations 
as well as the location of the stl83 mutation. All mutations are in completely conserved amino 
acids. (C) A sequence comparison between WT zebrafish DNA and the CMT sequence shows 
the C-T nucleotide change that results in the proline to serine amino acid change. (D) A gel 
image of the CMT genotyping assay shows the 165 bp mutant band, which is not cut by the 
restriction enzyme BseR1. The WT sequence is cut by the enzyme, resulting in two fragments of 
lengths 107 and 58 bps.  
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Figure 6: Transheterozygous actr10nl15/+ ; actr10CMT/+ zebrafish do not have an axonal 
swelling phenotype at 5 dpf.  
(A) A brightfield image shows a zebrafish larva at 5 dpf. (B) All zebrafish scored from the 
complementation cross had a WT phenotype by tg(neurod:egfp), including 12 transheterozygous 
animals.  
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Figure 7: Actr10 knockdown in mouse DRG culture results in a regeneration defect.  
(A) Three different shRNA constructs demonstrated efficient knockdown of Actr10 by qPCR. 
(B) Axon regeneration (arrow) in DRG spot culture (arrowhead) after axotomy was normal when 
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a control shRNA was used. (C) Knocking down Actr10 with shRNA decreased regeneration. (D) 
The regeneration phenotype was not rescued with addition of a WT ACTR10 construct. (E) 
Quantification shows decreased regeneration after shRNA Actr10 knock down, which is not 
rescued by WT, ALS or CMT constructs.  
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Chapter 5: Conclusions and future directions 
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5.1 Conclusions and future directions 
Starting with a large-scale forward genetic screen in zebrafish, I identified a mutant 
exhibiting myelin defects in the central and peripheral nervous systems (Chapter 2). I used a 
whole genome sequencing approach to determine that the gene responsible for the mutant 
phenotype was in actin related protein 10 (actr10) (Chapter 2, Chapter 3, Appendix A). I found 
through studying the zebrafish actr10 mutant, and also using oligodendrocyte cell culture, that 
dynein and dynactin are required for the anterograde movement of mbp mRNA granules 
(Chapter 3). In addition to this role in oligodendrocytes, a role for actr10 specifically in 
mitochondrial retrograde transport was identified in peripheral nervous system axons (Appendix 
B). I demonstrated that actr10 zebrafish mutants exhibit neurodegenerative phenotypes and I 
worked with neurologists at Washington University to identify patients with neurodegenerative 
diseases who also had mutations in ACTR10. One patient in particular, who had been diagnosed 
with Charcot-Marie-Tooth disease type 2, had an ACTR10 mutation that was not identified in the 
ExAC browser, indicating it was not a common human background mutation. I therefore decided 
to generate a zebrafish line with the CMT2 patient ACTR10 SNP. This was done successfully 
using TALEN technology. However, I did not observe a neuronal mutant phenotype when I did a 
complementation cross between actr10nl15/+ and actr10CMT/+ heterozygotes.  
In order to determine whether the CMT allele produces a phenotype, the next step will be 
to outcross F1 actr10CMT/+ animals to produce the F2 generation, which will then be intercrossed 
to look for a phenotype in homozygous mutants. Another future direction to fully explore the 
actr10CMT allele will be to determine if there are age-dependent phenotypes. Since the patient 
with CMT2 did not present with the disease until middle age, this is an important experiment that 
could explain the lack of an early defect. To test whether age could play a role in the zebrafish 
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phenotype, actr10CMT/+ F2 animals will be intercrossed to produce WT, heterozygous, and 
homozygous actr10CMT/CMT mutants. All viable genotypes will be grown to adulthood (~1-year-
old). TEM on zebrafish maxillary barbels will be done to determine if there are myelin or axonal 
defects at this later stage.  
Finally, we are currently collaborating with the lab of Dr. Valeria Cavalli to test whether 
loss of Actr10 function in mouse dorsal root ganglia (DRG) culture results in regeneration and/or 
degeneration phenotypes. Thus far, we have knocked down Actr10 in mouse using shRNA 
(Figure 7A). A regeneration assay in which axons from DRG spot culture are cut found that there 
was a regeneration defect in the Actr10 knockdown condition (Figure 7B, C). When we 
attempted to rescue the phenotype with a human ACTR10 construct containing the ALS and 
CMT2 mutations, there was no rescue (Figure 7D, E). However, there was also no rescue of the 
phenotype when we added a WT ACTR10 construct (Figure 7E). This preliminary data is 
therefore inconclusive due to the lack of rescue by WT ACTR10. Future directions will be to 
determine why the WT ACTR10 construct did not rescue and to perform the assay again to 
conclude if the ALS and CMT2 ACTR10 human constructs do not rescue. Additional future 
directions will be to test the degenerative phenotype after knocking down Actr10 in mouse DRG 
culture and to examine the actr10CMT/CMT mutant zebrafish in the context of peripheral nerve 
injury. These experiments in mouse will contribute to a more complete modeling of the human 
diseases. 
Although it is too early to irrefutably determine whether the "humanized" zebrafish 
model was successful, this project has demonstrated some of the constraints with human disease 
modeling in animal models, and in zebrafish in particular. Future work must address issues such 
as the multigenicity of human diseases, the differences between zebrafish and human proteins, 
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and the potential for age related phenotypes not obvious at early larval stages, when the majority 
of zebrafish research is performed. However, the current rapid pace of innovation makes it quite 
likely that modeling of patient specific diseases in zebrafish will be a reality in the not too distant 
future.   In conclusion, I used a variety of genetic tools in zebrafish to study neural development. 
Using a forward genetics approach, I identified new factors involved in myelination, including a 
mutation in actr10 that results in defects in transport of an mRNA critical for myelination by 
oligodendrocytes. By using a reverse genetics approach, I generated a zebrafish strain with a 
human ACTR10 mutation to model a neurological disorder. This dissertation demonstrates the 
breadth of research possible using zebrafish to investigate the mechanisms of key developmental 
processes. 
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Appendix A: Whole genome sequencing-
based mapping and candidate identification 
of mutations from fixed zebrafish tissue 
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Preface: 
 
This chapter has been reproduced and adapted in its entirety from the following 
published manuscript: 
 
Sanchez NE*, Harty BL*, O’Reilly-Pol T, Ackerman SD, Herbert AL, Holmgren 
M, Johnson SL, Gray RS, Monk KR. (2017) Whole genome sequencing-based 
mapping and candidate identification of mutations from fixed zebrafish tissue. G3 
7(10):3415-3425.  
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A.1 Abstract 
As forward genetic screens in zebrafish become more common, the number of mutants 
that cannot be identified by gross morphology or through transgenic approaches, such as many 
nervous system defects, has also increased. Screening for these difficult to visualize phenotypes 
demands techniques such as whole-mount in situ hybridization (WISH) or antibody staining, 
which require tissue fixation. To date, fixed tissue has not been amenable for generating libraries 
for whole genome sequencing (WGS). Here, we describe a method for utilizing genomic DNA 
from fixed tissue and a bioinformatics suite for WGS-based mapping of zebrafish mutants. We 
tested our protocol using two known zebrafish mutant alleles, gpr126st49 and egr2bfh227, both of 
which cause myelin defects. As further proof of concept we mapped a novel mutation, stl64, 
identified in a zebrafish WISH screen for myelination defects. We linked stl64 to chromosome 1 
and identified a candidate nonsense mutation in the F-box and WD repeat domain containing 7 
(fbxw7) gene. Importantly, stl64 mutants phenocopy previously described fbxw7vu56 mutants, and 
knock-down of fbxw7 in wild-type animals produced similar defects, demonstrating that stl64 
disrupts fbxw7. Together, these data show that our mapping protocol can map and identify 
causative lesions in mutant screens which require tissue fixation for phenotypic analysis. 
A.2 Introduction 
Zebrafish (Danio rerio) have emerged as an ideal model organism for both genetic and 
chemical screens due to their vertebrate anatomy and physiology, large clutch sizes, fully 
sequenced genome, transparency during development, and ease of maintenance. Forward genetic 
screens in zebrafish have uncovered many new mutant alleles that disrupt key regulators of a 
wide variety of developmental and cellular biological processes (Driever et al. 1996; Haffter et 
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al. 1996). However, the rate at which new mutants are generated has not been matched by the 
rate of linking a mutant phenotype to a specific causative lesion, which has created a backlog of 
unmapped mutants. Traditional PCR-based mapping methods are extremely time consuming, 
taking months or even years (Talbot & Schier 1998; Geisler et al. 2007; Zhou & Zon 2011). 
With the relatively recent advent of next-generation sequencing approaches such as whole 
genome sequencing (WGS) and RNA-sequencing, a phenotype can be linked with a genomic 
region or a specific mutation in a matter of days or weeks (Bowen et al. 2012; Leshchiner et al. 
2012; Obholzer et al. 2012; Voz et al. 2012; Miller et al. 2013). 
However, while mapping with WGS can allow rapid identification of causative 
mutations, this technology to date has only been applied to screens wherein phenotypes can be 
easily identified by gross anatomical observation or by fluorescent transgenes, which allow 
genomic DNA (gDNA) extraction from fresh tissue. To our knowledge, WGS-based mapping 
protocols have not been applied to screening strategies that require tissue fixation such as whole-
mount in situ hybridization (WISH) or antibody staining. In these strategies, the phenotypes can 
only be identified after the samples have been fixed and have undergone a variety of other 
chemical manipulations, which compromise not only the ability to extract sufficient amounts of 
gDNA, but also the quality of gDNA obtained. 
One good example of a biological process that is difficult to screen without tissue fixation 
is myelination. Myelin is a multilamellar, lipid rich membrane that is it iteratively wrapped 
around neuronal axon segments. It is produced by oligodendrocytes in the central nervous system 
(CNS) and Schwann cells in the peripheral nervous system (PNS). Myelin is a jawed vertebrate 
innovation (Zalc et al. 2008) and as such, zebrafish are the most tractable model organism to 
screen for genes involved in the formation of myelin and the development of the myelinating glia 
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(Kazakova et al. 2006; Pogoda et al. 2006). However, while disruptions to myelinating glia result 
in debilitating symptoms in a wide variety of neurological disorders in humans, disruptions to 
genes specifically affecting myelination do not typically result in gross morphological 
abnormalities during early zebrafish development. Further, although there are transgenic lines 
that label myelinating glia, changes in myelination can be difficult to assess by simple transgenic 
screening, especially in the PNS. Therefore, one common approach to screen for myelination 
defects in both the CNS and PNS has been to assess the expression of myelin basic protein (mbp) 
by WISH or antibody staining (Kazakova et al. 2006; Pogoda et al. 2006).  
 Here we describe methods for extracting gDNA from zebrafish larvae after WISH and 
present a WGS and bulked segregate analysis (BSA) based approach to link mutant phenotypes 
identified in forward genetic screens to a genomic region and identify possible causative 
mutations. We validated our approach using known mutations and report a novel mutation 
uncovered in a forward genetic screen for regulators of myelination.  
A.3 Results 
The specialized glia that produce myelin provide vital trophic support to ensheathed 
axons, while the myelin sheath itself protects axons and allows for saltatory conduction of action 
potentials (Nave 2010). The first forward genetic screens in zebrafish for disruptions in 
myelinating glial cell development utilized WISH to assess changes in the levels or patterns of 
mbp expression in the CNS and PNS (Pogoda et al. 2006; Kazakova et al. 2006). Over the years, 
as the causative mutations for these mutant phenotypes were identified, the study of these genes 
has contributed tremendously to the understanding of the development of myelinating glia. 
However, there are still many aspects of myelinating glial cell development and myelination that 
remain mysterious.  
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 Therefore, to identify novel regulators of oligodendrocyte and Schwann cell 
development, we conducted a large-scale three-generation forward genetic screen in zebrafish. 
The genomes of 80 adult male zebrafish were randomly mutagenized with N-ethyl-N-nitrosourea 
(ENU) to produce the founder generation. We then drove these mutations to homozygosity and 
assessed the third generation (F3) progeny for changes in mbp expression patterns in the CNS 
and PNS by WISH using a riboprobe for mbp (Brösamle & Halpern 2002). The extensive tissue 
fixation and chemical manipulation of these samples precluded known WGS-based methods for 
mapping putative causative mutations for any phenotypes recovered. Therefore, to take 
advantage of the power and speed of WGS in mapping mutations, we developed a WGS-BSA 
pipeline using gDNA isolated from fixed tissue.  
The WGS-BSA pipeline accurately maps the st49 allele to gpr126 using gDNA from fresh 
tissue 
To establish our pipeline, we first sequenced a known mutation that results in phenotypes 
easily observed by gross morphology so that we could test the ability of our WGS analysis 
scheme to correctly identify a causative lesion. The st49 mutant allele was uncovered in a 
forward genetic screen in zebrafish for mutants with developmentally disrupted mbp expression 
(Pogoda et al. 2006). The causative mutation was later identified through traditional PCR-based 
linkage mapping and Sanger sequencing of genes in the linked area as a T to A transition 
resulting in a nonsense mutation in the gene adgrg6/gpr126 (Monk et al. 2009). Importantly, in 
addition to decreased mbp expression in the PNS observed by WISH, at 5 days post-fertilization 
(dpf), gpr126st49/st49 animals display a swollen ear phenotype (Fig 1A-B) that readily 
distinguishes mutant animals from their wild-type and heterozygous siblings in living larvae 
(Monk et al. 2009; Geng et al. 2013). We took advantage of this obvious morphological defect to 
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collect a pool of phenotypically mutant larvae with swollen ears and a pool of siblings that 
displayed phenotypically normal ears (N=30 larvae per pool). 
We then extracted gDNA from each pool and submitted both samples to the Genome 
Technology Access Center (GTAC) at Washington University for WGS on a single lane of the 
Illumina HiSeq3000. Sequencing reads for both pools were aligned to the Zv9 genome build of 
the zebrafish genome using Novoalign (Howe et al. 2013) (Table 1), and variants (SNPs, 
insertions, and deletions) were called using SAMtools (Li et al. 2009; Li 2011) and annotated 
using snpEFF (Cingolani et al. 2012). Our sequence analysis pipeline consists of three different 
custom Perl scripts that can be run locally on any workstation and easily tailored to specific 
circumstances. Henceforth, these scripts will be referred to as “ChromSplit,” “Allele Ratio 
Calculator (ARC),” and “SNPfilter.”  
For both sibling and mutant datasets, we used the ChromSplit script to split each variant 
in the BED file based on genomic position into separate files for each of the 25 zebrafish 
chromosomes. Mitochondrial DNA and variants currently assigned to genomic scaffolds were 
excluded. The second script, ARC, then used the 50 individual chromosome files – 25 sibling 
and 25 mutant – to group variants into non-overlapping bins based on chromosomal position and 
calculate the mutant allele frequency (MAF) in each bin. As a starting point, we set the bin size 
to 200 kilobases (kb). In total, 6,735 bins of a 200 kb size were generated containing at least one 
SNP with the variant allele being seen in some frequency in both the sibling and mutant pools. 
Finally, using ARC we compared the MAF for each bin between siblings and mutants to 
calculate the ratio of homozygosity between these two groups. Any bins with fewer than 10 
SNPs were subsequently removed due to the outsized ability of any outliers to affect the 
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calculated ratios. In this instance, 6,531 bins had 10 or more SNPs with variant alleles seen in 
both the mutant and sibling st49 pools data. 
To determine the specific chromosome linked to the mutant phenotype, we graphed the 
mutant/sibling allele ratios for all bins by genomic position and looked for regions of high 
homozygosity as seen by sequential bins with an allele ratio of approximately 2. For a variant 
that is homozygous in the mutant pool and with perfect Mendelian ratios in the sibling pool, the 
theoretical expected allele ratio/mapping score is 3 at single bp resolution. We expect our 
mapping scores to approach this limit but rarely, if ever, reach it because we utilize a non-
overlapping bin size of 200 kb to calculate the mapping score. The overall allele ratio/mapping 
score is reduced in the individual bins because we are using a large bin filled, in some cases, with 
hundreds of SNPs from highly heterogenous genetic backgrounds several generations removed 
from isogenic mapping strains. Additionally, we do not control for the genotypic ratio in the 
sibling pool, thus in practice we observe allele ratios closer to 2 for bins with high rates of 
homozygosity. When graphing the mutant/sibling allele ratios of all the bins across the entire 
genome for st49 mutants, there was a clear peak at chromosome 20, indicating linkage to the 
swollen ear phenotype (Fig 1C). When viewing only chromosome 20, three distinct regions 
displayed the highest levels of SNP ratio imbalances between the mutant and sibling pools, 
indicating linkage of these regions to the mutant phenotype used to sort the pools. These three 
distinct regions were centered around chromosomal positions 12 MB, 25 MB, and 39 MB (Fig 
1D). 
Finally, we used SNPfilter to eliminate variants in protein-coding sequences that had 
been previously annotated by SNPFisher (Butler et al. 2015), a database of SNPs observed in 
non-mutagenized zebrafish. This process eliminated SNPs that were present in WT populations 
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of zebrafish, and therefore were unlikely to cause our phenotype of interest. All SNPs annotated 
by SNPeff as protein coding that resulted in non-synonymous amino acid changes and that were 
verified to be homozygous in the mutants but not siblings using the integrative genomics viewer 
(IGV) (Thorvaldsdóttir et al. 2013; Robinson et al. 2011) were considered putative causative 
lesions. The st49 mutant pool had 71,791 SNPs annotated by SNPeff (Table 2) as coding SNPs. 
After filtering out known SNPs, 35,730 SNPs remained. Only 29 SNPs fall into any of the three 
intervals linked to the st49 mutant phenotype (Fig 1E-G). Of all the SNPs that pass all filtering, 
the predicted most deleterious SNP was a T to A nonsense mutation in gpr126, which is the 
causal mutation for the gpr126st49 allele (Monk et al. 2009). 
The WGS-BSA pipeline accurately maps the fh227 allele to egr2b using gDNA from fixed 
tissue 
Our WGS analysis pipeline accurately predicted the st49 allele to be a nonsense mutation 
in gpr126, but the gDNA used for WGS was from fresh tissue. To determine if we could use the 
same process to map mutants from our WISH-based forward genetic screen, we tested our 
pipeline using a mutation known to disrupt mbp expression in the PNS by WISH. The fh227 
allele was discovered through targeting induced local lesions in genomes (TILLING) (Moens et 
al. 2008) for mutations in egr2b (krox20) and is a C to A point mutation that leads to a premature 
termination codon (PTC) (Monk et al. 2009). egr2bfh227 mutants display severely decreased mbp 
expression in the posterior lateral line nerve (pLLN) of zebrafish (Monk et al. 2009). Zebrafish 
genotyped as egr2bfh227/+ were intercrossed and WISH was performed on the resulting progeny at 
5 dpf using an mbp riboprobe. Individuals were pooled based on the mbp expression phenotype – 
either phenotypically wild-type (Fig 2A; N=33) or reduced mbp expression (Fig 2B; N=33).  
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To extract gDNA from fixed WISH larvae with high yields, we modified the animal 
tissue (column-based) protocol included with the Qiagen DNeasy Blood & Tissue kit. Two of 
these modifications were incubating 10 minutes at 56°C in ATL buffer and again when samples 
are in AL buffer. Per the manufacturer, the ATL and AL buffers occasionally generate 
precipitates that can be prevented by brief warming at 56°C. Therefore, we added short 
incubations as precautions given the precious nature of the samples. To increase gDNA yield, we 
made two additional modifications – the Proteinase K digestion was increased from 30 minutes 
to 3 hours, and the elution incubation was lengthened to at least 20 minutes. We found that using 
the recommended digestion and elution times resulted in at least 10-fold lower yield. Thus, since 
many non-column-based gDNA extraction protocols for a variety of animal tissues involve 
Proteinase K digestion steps of 12 hours or more, we increased the digestion time to 3 hours and 
elution time to >20 minutes and saw a dramatic improvement in gDNA yield (from ~2-10ng/ul 
to ~75-150ng/ul). Digestion times greater than 3 hours did not continue to notably increase yield.  
All samples were submitted for WGS using the same specifications as described above to 
map st49. We also subjected the fh227 WGS data to the same analysis paradigm as outlined for 
st49. In total, 6,783 bins of a 200 kb size were generated for the fh227 pools, 6,725 of which 
contained 10 or more SNPs. We then graphed the mutant/sibling allele ratio by genomic position 
and found a clear peak of homozygosity on chromosome 12, indicating linkage to the fh227 
phenotype (Fig 2C). When viewing only chromosome 12, the most divergent region between 
mutant and sibling pools, and thus most linked to the fh227 phenotype, is a single distinct 
genomic region centered around the 10 MB mark (Fig 2D).  
The fh227 mutant pool had 167,060 SNPs annotated by SNPeff as coding SNPs (Table 
2). After filtering out known SNPs, 81,832 SNPs remained. Notably, only 21 SNPs fell into the 
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interval linked to the fh227 mutant phenotype (Fig 2E). Of all SNPs that passed all filtering, the 
predicted most deleterious SNP was a nonsense mutation in egr2b, which is the known causal 
mutation for the fh227 allele (Monk et al. 2009). 
The WGS-BSA pipeline accurately maps the novel stl64 mutation to fbxw7 
We have demonstrated that we can utilize gDNA from fixed tissue and successfully 
perform WGS with that DNA. We have also shown that we can use BSA to link a phenotype to a 
specific genomic region, and through SNP filtering, we can identify the specific causative 
mutation. To demonstrate that we can successfully map a novel allele, we ran one of the first 
mutants from our screen though the WGS-BSA pipeline. This mutant allele, provisionally 
designated stl64, displayed striking overexpression of mbp in the CNS when compared to 
siblings at 5 dpf (Fig 3A-B).  
To determine the causative lesion in the stl64 mutants, we crossed stl64 carriers and used 
WISH with an mbp riboprobe to identify mutants. As before, we pooled the larvae into two 
groups based on their mbp expression phenotype – normal mbp levels (Fig 3A; N = 23) and 
enhanced mbp expression (Fig 3B; N=26). gDNA from both samples was submitted for WGS on 
the Illumina HiSeq2500 as described above for the st49 and fh227 alleles. Sequencing reads for 
both pools were aligned using Novoalign to the same Zv9 genome build of the zebrafish genome 
as was used to map st49 and fh227 (Table 1). SNPs were again called and annotated using 
SAMtools and snpEFF. In total, 6,790 bins of a 200 kb size were generated for the stl64 pools, of 
which 6,746 bins contained 10 or more SNPs. The mutant/sibling allele ratios for stl64 were 
highest on chromosome 1 (Fig 3C). Closer inspection of chromosome 1 showed that the ratios of 
SNPs in the mutant and sibling pools were most different, and thus most highly linked, at a 
single distinct region centered around chromosomal position 23 MB (Fig 3D).   
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The stl64 mutant pool had ~155,550 SNPs annotated by SNPeff as coding SNPs (Table 
2), 84,553 of which remained after filtering out known SNPs. Of those 84,553 SNPs, only 3 
SNPs fell into the interval linked to the stl64 mutant phenotype, were protein coding, and were 
verified in IGV as homozygous in the mutant pool but not in the sibling pool (Fig 3E). Among 
these 3 SNPs, the predicted most deleterious SNP was a C to A transition resulting in a PTC in 
fbxw7. 
Previously, zebrafish fbxw7vu56 mutants were shown to possess an increased number of 
oligodendrocytes and to display hypermyelination in the CNS (Snyder et al. 2012; Kearns et al. 
2015). To determine if the overexpression of mbp in the CNS of stl64 mutants was similarly due 
to increased oligodendrocyte numbers, we performed WISH using a riboprobe against nkx2.2a, 
which marks the oligodendrocyte lineage. At 65 hours post-fertilization (hpf), stl64 mutants 
displayed more nkx2.2a positive cells in the spinal cord than their WT siblings (Fig 4A-B). 
Further, ultrastructural analyses by transmission electron microscopy (TEM) revealed increased 
numbers of myelinated axons as well as thicker myelin in the spinal cords of stl64 mutants at 8 
dpf (Fig 4 C-J). To further test if fbxw7 regulates myelination we employed an established 
antisense oligonucleotide morpholino (MO) (Snyder et al. 2012) to reduce fbxw7 levels in WT 
embryos. We then assessed mbp expression by WISH, and found that larvae injected with low 
doses of the fbxw7-MO displayed increased mpb expression (Figure 4K-L). Together, our WGS 
mapping using fixed-tissues, the phenotypic similarities of stl64 and fbxw7vu56 mutants, and our 
fbxw7-MO analyses strongly support that the stl64 mutation represents a new allele of the fbxw7 
gene. 
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A.4 Discussion  
Here, we have described a WGS-BSA pipeline for identifying the causative mutations for 
phenotypes discovered in zebrafish forward genetic screening strategies requiring fixed tissue. 
We tested this protocol by mapping two alleles, gpr126st49 and egr2bfh227, known to disrupt 
myelination. Furthermore, we successfully mapped a novel allele, stl64, generated in a WISH-
based forward genetic screen, to a nonsense mutation in the gene fbxw7.  
In validating the WGS-BSA pipeline, the importance of genetic variation in the lines 
sequenced became clear with the sequencing of the gpr126st49 pools. There were three linkage 
peaks for the gpr126st49 pools compared to only a single linkage peak in the egr2bfh227 and 
fbxw7stl64 pools. We believe this is due to the crossing history of each line. The egr2bfh227 line 
was maintained on an AB* (ZFIN ID: ZDB-GENO-960809-7) background with intermittent 
outcrossing to the wild-caught, IND line (ZFIN ID: ZDB-GENO-980210-28). Similarly, the 
screen that generated the fbxw7stl64 allele started on the SAT background (ZFIN ID: ZDB-
GENO-100413-1) before being outcrossed to SJD (ZFIN ID: ZDB-GENO-990308-9) (Johnson 
et al. 1996) and other fish with mixed backgrounds (pigment mutants and transgenes) before 
sequencing. The outcrossing of both the egr2bfh227 and fbxw7stl64 lines drove down the level of 
homozygosity across their respective genomes and allowed the difference in ratio between the 
sibling and mutants pools to be more easily observed. In contrast, the gpr126st49 line in our lab 
has been maintained exclusively on the AB* background without intermittent outcrossing. This 
difference in crossing history has driven up the level of homozygosity and led to three distinct 
regions of the genome being linked to the st49 phenotype. This large linkage peak underscores 
the importance of performing at least one outcross before collecting mutants for pooled 
sequencing. 
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It was also apparent from our analyses that coverage of the genome when using WGS 
was especially important for filtering of putatively causative SNPs. For st49, in the middle of the 
third linked region on chromosome 20 (spanning 37.4 Mb to 41.6 Mb), 8 bins had fewer than 10 
SNPs fall into them and were subsequently filtered out. This differs from both the fh227 and 
stl64 sequencing, which had hundreds of SNPs across the entire region. The loss of the 8 bins in 
the middle of the region likely suppressed the expected signal from the true gpr126st49 mutation, 
contributing to the generally broad linkage observed. Additionally, when verifying the 
homozygosity of the gpr126st49 allele in the mutant sequencing, a single read was all that covered 
the mutation in the st49 sibling pool, further underscoring the importance of coverage depth in 
calling variants. Based on the sequencing described here, a target of 100 million mapped reads is 
the minimal target recommended for future experiments. 
We have shown that linking a genomic region to a phenotype using our WGS-BSA 
approach is relatively robust and is able to overcome excessive inbreeding and relatively low 
coverage; however, determining if a specific mutation from the linked region is causative has 
several important caveats. The filtering methods described here are specific to defining coding 
variants introduced by mutagenesis and are not applicable to all scenarios. For example, in the 
case of an allele that was simply an endogenous, rare, recessive mutation driven to homozygosity 
in the process of the screen, the SNPFisher database of naturally occurring variants would be 
inappropriate to use as a filter. Similarly, if the responsible mutation is in a regulatory region, 
limiting SNPs to only those designated as coding by SNPeff is similarly inappropriate. In both 
these cases, SNPs previously observed as homozygous should still be removed, but the 
SNPFisher database should not be included. 
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In the case where an allele’s causative mutation is a nonsynonymous mutation introduced 
through mutagenesis, as opposed to the three nonsense mutations described here, we propose a 
schema to prioritize the most likely causative mutation. Highest priority should be given to 
mutations affecting splice sites or out of frame insertions and deletions (INDELS). Below that, 
priority should be given to nonsynonymous SNPs that disrupt protein domains or cause shifts in 
polarity or hydrophobicity between amino acid side chains. The mutation with the highest 
probability to be causative should be confirmed by creation of a second allele and 
complementation testing.  
Despite the caveats regarding coverage, outcrossing, and SNP filtering, our demonstrated 
ability to extract gDNA from fixed tissue in order to map and characterize mutations is 
important. Using WGS with BSA over traditional PCR-based mapping methods can dramatically 
shrink the time required to map some mutants. Including fixed tissue as a DNA source for this 
procedure opens up this approach for a cadre of mutants not easily identified by gross 
morphological changes. As a result, many new genes may be discovered from existing mutants 
and new screens can be envisioned involving these types of screens using fixed zebrafish tissues. 
We note that our protocol to obtain high-quality gDNA from fixed tissue can be paired with any 
number of useful pipelines already described to define causative lesions by WGS (e.g., Henke et 
al. 2013). 
In conclusion, as WGS has increased the speed by which mutants discovered in forward 
genetic screens can be linked to a causative region and mapped to a specific lesion, the inability 
to use WGS to map alleles that need to be phenotyped using fixed tissue has held back the 
mapping of an entire class of alleles. To address this hurdle, we created a WGS-BSA pipeline for 
sequencing and analysis of gDNA extracted from pools of fixed or fresh tissue. This pipeline 
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compares areas of the genome between mutant and sibling pools to calculate the ratios of variant 
to reference alleles for that specific region. Furthermore, filtering out natural variants and 
variants previously observed as homozygous from the list of predicted protein coding variants in 
the linked regions allows for an accurate attribution of causality to a specific mutation. Using this 
WGS-based mapping pipeline, we correctly identified the previously described mutations, 
gpr126st49 and egr2bfh227, when gDNA was extracted from pools of either fresh or fixed tissue, 
respectively. To test the ability of the WGS-BSA pipeline to map a novel mutant, we used this 
pipeline to identify the causative lesion in an unidentified CNS hypermyelination mutant, 
designated stl64, from our WISH-based forward genetic screen. We found that stl64 was most 
strongly linked to a 3 Mb region of chromosome 1, with the most deleterious mutation being a C 
to A transition leading to a premature termination codon in the gene fbxw7. Importantly, stl64 
mutants phenocopy the CNS myelination defects observed in a previously described mutation in 
the same gene, fbxw7vu56. Finally, loss of fbxw7 in WT zebrafish larvae resulted in similar 
overexpression of mbp, further supporting the conclusion that stl64 disrupts the gene fbxw7. 
These experiments demonstrate that our new pipeline can successfully identify causative lesions 
for mutants that can only be analyzed using fixed tissue preparations. We believe that this 
pipeline can be easily applied to extract gDNA from pooled fixed or fresh tissue for WGS with 
BSA to determine the protein coding causative mutation in zebrafish screen mutants. 
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A.5 Figures and tables 
 
Figure 1: The st49 allele is accurately mapped to chromosome 20 and gpr126 using gDNA 
extracted from fresh tissue. 
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Dorsal views of phenotypically wild-type (A) and gpr126st49/st49 (B) zebrafish show the 
characteristically enlarged ears (arrowheads) of mutants at 5 days post-fertilization (dpf). When 
the ratio of variant to reference alleles in the mutant pool is compared to the sibling pool and 
graphed across the whole genome for gpr126st49, there is a clear spike on chromosome 20 for the 
gpr126st49 mutation (Box) (C). This spike indicates linkage of the region to the trait used to sort 
the mutant and sibling pools. gpr126st49 is linked to three separate regions on chromosome 20 
(Arrows) (D). Linkage map of the gpr126st49 allele showing the 3 different regions of 
chromosome 20 linked to the expanded ear phenotype that was used to sort the mutant and 
sibling pools. Between all 3 linked regions there are 29 different protein coding, homozygous, 
non-synonymous SNPs (E-G). The single introduced stop is the mutation responsible for the 
gpr126st49 mutant phenotype. 
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Figure 2: The fh227 allele is accurately mapped to chromosome 12 and egr2b using gDNA 
extracted from fixed tissue. 
Dorsal view of mbp expression in 5 dpf zebrafish using WISH and the mbp riboprobe shows 
phenotypically normal expression (purple) of mbp along the pLLNs (arrowheads) (A) compared 
to severely reduced mbp expression along the pLLN (arrowheads) in egr2bfh227/ fh227 mutants (B). 
When the ratio of variant to reference alleles in the mutant pool is compared to the sibling pool 
and graphed across the whole genome for egr2bfh227, a clear spike on chromosome 12 is observed 
(Box) (C). This spike indicates genotypic linkage to the trait used to sort the mutant and sibling 
pools. When looking at chromosome 12, egr2bfh227 is linked to a single region centered around 
10 Mb (Arrow) (D). Linkage map of the egr2bfh227 allele showing the 21 different homozygous, 
non-synonymous, protein coding SNPs in the single chromosome 12 region linked to the 
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decreased mbp expression in the PNS that was used to sort the mutant and sibling pools (E).  The 
single introduced stop is the mutation responsible for the egr2bfh227 mutant phenotype. 
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Figure 3: The stl64 phenotype is linked to chromosome 1 and is likely caused by a nonsense 
mutation in fbxw7. 
Dorsal views of 5 dpf zebrafish showing mbp expression by WISH using the mbp riboprobe. 
Normal expression in the CNS (arrowhead) by phenotypically wild-type siblings (A) compared 
to the dramatic overexpression of mbp in the stl64 mutants (B) shows increased mbp expression 
in the stl64 mutants. When the ratio of alleles in the mutant pool compared to the sibling pool is 
graphed across the whole genome for the stl64 allele, a clear spike on chromosome 1 (Box) is 
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observed for stl64 (C). This spike indicates genomic linkage to the trait used to sort the mutant 
and sibling pools. When viewing chromosome 1, stl64 is linked to a single region of the 
chromosome centered around 24 Mb (Arrow) (D). Linkage map of the stl64 allele showing the 
three protein coding, homozygous, non-synonymous SNP linked to the increased mbp expression 
in the CNS that was used to sort the mutant and sibling pools. The most deleterious SNP is the 
introduced stop codon in fbxw7 (E). 
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Figure 4: The fbxw7stl64 allele phenocopies the fbxw7vu56 allele. 
stl64 mutants display more nkx2.2a+ cells in the dorsal spinal cord (SpC) relative to their WT 
siblings at 65 hours post-fertilization (hpf) (A,B). TEM analysis of the ventral (C-F) and dorsal 
(G-J) SpC at 8 dpf shows that fbxw7stl64 mutants have more myelinated axons in the dorsal SpC 
(I) and thicker myelin in both regions (F, J). Transient morpholino (MO) knockdown of fbxw7 in 
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WT embryos results in mbp overexpression at 65 hpf compared to control injected siblings (K, 
L). Error bars are S.D. ** = p < 0.01, *** = p < 0.001, NS = not significant.  
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Table 1: WGS Coverage of the gpr126, egr2b and stl64 Pools. 
Coverage statistics for each pool sequenced. Mapped reads are counted as mapped when an 
individual read is mapped to the genome without regard for its pairs. Aligned pairs are counted 
as only those reads where both reads of the pair were able to be aligned. All alignment 
calculations are in regard to the ability of Novoalign to map a read accurately. Coverage 
calculations are based off the actual depth of coverage across the Zv9 build of the zebrafish 
genome. 
 
  
Total 
Mapped 
Reads 
Total 
Aligned 
Read Pairs 
% Genome 
≥ 5x 
% Genome 
≥ 10x 
gpr126st49 Siblings 63,359,360 27,209,088 67.34% 49.39% 
gpr126st49 Mutants 58,637,164 24,936,351 66.59% 49.37% 
egr2bfh227 Siblings 95,221,594 44,326,398 74.86% 46.83% 
egr2bfh227 Mutants 93,143,924 43,264,449 74.86% 47.31% 
stl64 Siblings 99,225,270 41,977,069 65.45% 20.94% 
stl64 Mutants 116,915,836 49,043,710 69.69% 30.12% 
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Table 2: Number of Exonic SNPs and INDELS in the gpr126, egr2b and stl64 Pools. 
Number of mutations, by SNPs and INDELS, to the reference genome (Zv9) for all pools 
sequenced. 
  
Number of Exome 
SNPS 
Number of Exome 
INDELS 
gpr126st49 Siblings 74,146 1,843 
gpr126st49 Mutants 66,055 1,798 
egr2bfh227 Siblings 153,942 2,862 
egr2bfh227 Mutants 155,256 2,884 
stl64 Siblings 126,026 2,644 
stl64 Mutants 160,112 3,275 
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A.6 Methods 
Zebrafish Husbandry and Genotyping 
All Danio rerio stocks were maintained in the Washington University Zebrafish Consortium 
facility (http://zebrafish.wustl.edu/husbandry.htm). Embryos were collected from paired matings 
and raised in egg water (5 mM NaCl, 0.17 mM KCl, 0.33 mM CaCl2, 0.33 mM MgSO4) at 
28.5°C. At 5 dpf, larvae were transitioned to a rotifer-based diet for 10-14 days before 
incorporating flake food and flowing water. Traditional morphological markers were used to 
stage embryos (Kimmel et al. 1995). When necessary for WISH, development of pigment was 
prevented by adding 0.003% phenylthiourea (PTU) to egg water around 24 hpf and maintained 
until fixation at 5 dpf. All animal experiments were performed in compliance with Washington 
University’s institutional animal protocols. 
Forward Genetic Screen 
A standard three-generation forward genetic screen was performed in zebrafish using the 
chemical mutagen, N-ethyl-N-nitrosourea (ENU) (Mullins et al. 1994; Solnica-Krezel et al. 
1994). Briefly, adult WT (SAT strain) males were mutagenized using 3-3.5 mM ENU over the 
course of 4-6 weeks, allowed to recover for 1 month, and then crossed to WT (SAT) females, 
resulting in the F1 generation (Draper et al. 2004). Each F1 individual was then outcrossed to a 
double transgenic line [tg(lhx1a:egfp) (Swanhart et al. 2010); tg(mbp:mcherry-CAAX) (kind gift 
from Dave Lyons, University of Edinburgh), on a mixed-strain WT background], which marked 
a subset of neurons (lhx1a) and all myelinating glia (mbp). This cross produced F2 families, 
which were raised together and then intercrossed to drive putative mutations to homozygosity in 
the F3 progeny. Clutches of F3 larvae that showed altered mbp promoter expression by transgene 
were selected for verification using WISH to directly assess mpb expression. When initial 
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transgenic screening proved to be inconsistent, all subsequent screening was done exclusively by 
WISH using the mbp riboprobe. 
Whole Mount in situ hybridization (WISH) 
We used standard protocols (Thisse & Thisse 2008) to perform WISH on zebrafish larva. After 
24 hpf, embryos were raised in egg water with 0.003% PTU to prevent the development of 
pigment. At the desired developmental stages, pools of 25-40 larvae were anesthetized and then 
fixed in 4% paraformaldehyde (PFA) for 2 hours at room temperature or 4° C overnight with 
gentle agitation. After fixation, samples were then dehydrated in 100% methanol overnight at -
20°C. Following dehydration, embryos were washed in 0.2% PBS-Tween (PBSTw), 
permeabilized with proteinase K (20 mg/µl diluted 1:1000 in 0.2% PBSTw), and incubated with 
digoxygenin-labeled riboprobe overnight at 65° C in hybridization buffer (50% formamide). 
Following probe treatment, embryos were washed and then blocked for at least 1 hour at room 
temperature in a solution of 2% blocking reagent made in maleic acid buffer with 0.2% triton 
(MABTr) supplemented with 10% normal sheep serum. Samples were then incubated overnight 
at 4° C in primary antibody (Anti-Dig, Fab fragments (1:2000); Roche, Pleasanton, CA) diluted 
in blocking solution, with gentle agitation. Following primary antibody treatment, embryos were 
repeatedly washed in MABTr, and developed by alkaline phosphatase reaction. Embryos were 
then post-fixed in 4% PFA, passaged through increasing concentrations of glycerol, and stored 
long-term in 70% glycerol at 4° C, protected from light. The mbp (Brösamle & Halpern 2002) 
and nkx2.2a (Barth & Wilson 1995) riboprobes have been previously described. All scoring was 
performed blinded to genotype.  
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Genotyping egr2bfh227 and fbxw7stl64 
DNA for genotyping was extracted by adding 50 µl of fish lysis buffer (10 mM pH 8 Tris, 1 mM 
EDTA 0.3% tween and 0.3% glycerol) to tissue. After cooling from a 10 minute digestion at 98° 
C, 10 µl of 10 mg/ml proteinase K was added to each sample and all samples were digested for 
12 hours at 55°C. The proteinase K was inactivated by incubating at 98° C before storing the 
DNA for later use.  This process tended to provide low amounts of fragmented gDNA that was 
sufficient for genotyping but not sufficient for WGS. 
The egr2bfh227 allele was genotyped by using the following primers 5’-
GAGGACTTTCGCTCTTTTTG-3’ and 5’-TCGGACGAACTTACCAGACAC-3’, which 
amplified a 228 base pair (bp) region including the egr2bfh227 mutation. These primers were 
redesigned from those described in Monk et al. (2009) to better amplify the smaller size 
fragments of gDNA that typically were extracted from fixed tissue. A 40 cycle PCR with 60° C 
annealing temperature and 45 second extension time was performed on all samples. To assay the 
egr2bfh227 mutation status, disrupts of an NsiI restriction site was used as described previously 
(Monk et al. 2009). PCR amplicons were digested with the NsiI enzyme (New England 
Biosciences, Ipswich, MA) for 2 hours at 37° C, and then heat inactivated for 20 minutes at 65° 
C. The sizes of digested products were visualized using a 3% agarose gel with ethidium bromide. 
Samples with two bands at 161 and 67 bps were scored as egr2b+/+ (wildtype), a single uncut 
band at 228 bp was scored as egr2bfh227/fh227 (mutant), individuals with all three size bands were 
called egr2bfh227/+ (heterozygous). 
The fbxw7stl64 mutation was genotyped using the following primers: 5’-
CTCTCCAGTGTGACCAGGTT-3’ and 5’-GCTCTCAGGTCCTCACAAGC-3’, which amplify 
a 147 bp region surrounding the stl64 lesion. PCR was performed for 40 cycles with an 
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annealing temperature of 55° C and an extension time of 45 seconds. The stl64 mutation disrupts 
a Hpy188I restriction site, so this disruption was used to genotype individual fish. PCR 
amplicons were digested with the Hpy188I enzyme (New England Biosciences) for at least 1-2 
hours at 37° C, and then heat inactivated at 65° C for 20 minutes. Products sizes were visualized 
on a 2-2.5% agarose gel with ethidium bromide. A thick band around 75 bp was scored as 
fbxw7+/+ (wildtype), a single uncut band at 147 bp was scored as fbxw7stl64/stl64 (mutant), and 
individuals with both size products were called fbxw7stl64/+ (heterozygous). 
Genomic DNA Extractions from Fresh Tissue 
Pools of anaesthetized fish in egg water were collected in a 1.5 ml tube, and as much liquid as 
possible was removed from each tube. 500 µl of fish lysis buffer was added, and the tubes were 
heated at 98° C for 10 minutes before cooling. Next, 5 µl of 20 mg/ml proteinase k was added, 
and all tubes were incubated overnight at 55° C with gentle agitation. After digestion, the 
samples were spun in a centrifuge at 17,900 x g for 1 minute. The resulting supernatant was 
moved to a new tube and 500 µl of 100% isopropanol was added. The samples and isopropanol 
were incubated overnight at -20° C then spun for 15 minutes at 17900 x g at room temperature. 
After centrifuging, the supernatant was removed and 500 µl of 70% ethanol was added. This 
mixture was then incubated at room temperature for at least 5 minutes before as much liquid as 
possible was removed with a pipette. Finally, the sample was air dried and the resulting pellet 
was suspended in TE for later use. 
Genomic DNA Extractions from Fixed Tissue 
For egr2bfh227 mutants, after mbp WISH was completed, zebrafish larvae were passaged into 
70% glycerol and scored for mbp expression. Mutant animals were separated from their 
phenotypically wild-type siblings, and phenotypically wild-type and mutant larvae were pooled 
 168 
separately. These pools were then backed out of glycerol by replacing the 70% glycerol with 
50% glycerol for 5 minutes and then replacing the 50% glycerol with 30% glycerol for another 5 
minutes. The 30% glycerol was then replaced with PBSTw. On the other hand, stl64 mutants 
were not passaged into glycerol before scoring and pooling, and were instead pooled directly into 
PBSTw. For both egr2bfh227 and stl64 mutants, all samples were washed at least three times in 
PBSTw. Finally, as much PBSTw as possible was removed, and gDNA was extracted using the 
DNeasy Blood & Tissue (Qiagen cat# 69506) kit with four key modifications to the 
manufacturer’s protocol.  
These four modifications substantially increased our gDNA yield; specifically, we: (1) 
incubated for 10 minutes at 56° C when the samples are in the ATL buffer; (2) incubated a 
minimum of 3 hours at 200 rpm during the proteinase k digestion; (3) incubated for 10 minutes 
at 56° C when the samples were in AL buffer; (4) incubated at least 20 minutes (can go longer; 
e.g., >90 minutes) after the buffer AE is added before centrifuging for 2 minutes. Additionally, 
we found that it is of paramount importance to use a fresh kit, ideally less than three months old, 
to process samples. Using older kits resulted in significantly decreased or in failed extraction. 
Whole Genome Sequencing (WGS) 
All gDNA was extracted and submitted to the Genome Technology Access Center (GTAC) at 
Washington University for WGS. Quantification of concentration and integrity of all genomic 
DNA, was determined by using Qubit (ThermoFisher) and Tapestation (Agilent), respectively. 
All samples submitted had a minimum of 1 µg of gDNA. Each sample was barcoded, pooled, 
and paired-end sequencing was done in a single lane of a HiSeq2500 or 3000 (Illumina). After 
demultiplexing, all reads were aligned using Novoalign (Novocraft). From the alignments, SNPs 
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and INDELS were called using SAMtools (Li et al. 2009; Li 2011), and any effects to protein 
coding genes were predicted using snpEFF (Cingolani et al. 2012). 
Bulked Segregate Analysis 
There are three custom Perl scripts referred to as “ChromSplit,” “Allele Ratio Calculator 
(ARC),” and “SNPfilter” that link mapping and filtering of causal variants. ChromSplit takes the 
bam file generated in the process of aligning the reads to the genome and splits them into two 
files per chromosome. The first contains all SNPs called and the second contains all INDELS 
observed. SNPs and INDELS observed in the mitochondrial genome or on unattached 
chromosomal scaffolds are discarded prior to linkage mapping. ARC tiles bins of custom size 
across the different chromosomes and fills each bin with the ratio of mutant to reference allele 
for all SNPs observed in both the mutant and sibling pools. When all SNPs are sorted into their 
appropriate bins, the ratio of mutant to reference allele is calculated for the whole bin and that 
ratio is compared between the mutant and sibling pools. The mutant to sibling pool ratio for each 
bin is generated by ARC. 
With the output of ARC, all bins with less than 10 SNPs are thrown out because of the 
outsized effect that a single SNP can have. To determine a linked chromosome, the ratios of the 
mutant and sibling bins are graphed and the highest peak that approaches a ratio of two indicates 
the linked chromosome. To identify the region of a single chromosome is most linked to the 
phenotype used to sort pools, all bins from that chromosome were sorted by their ratios. The 20 
bins with the highest ratios are selected, and any area where those selected bins are clustered is 
the region of the chromosome most closely linked to the phenotype.  
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SNP Filtering and Prioritization 
The SNPfilter script takes the output from the SNPeff program and sorts out all SNPs and 
INDELS previously observed in unmutagenized strains as well as SNPs and INDELS previously 
observed as homozygous that are not causative. The database of variants from unmutagenized 
lines used here was the SNPFisher database (Butler et al. 2015). SNPfilter was written to use the 
SNPFisher database as a base while adding the homozygous SNPs observed in the SNPeff files 
being filtered to the database of known SNPs for future filtering. In this way, as SNPfilter is run 
on more samples, its ability to filter out non-causative SNPs and INDELS increases. Any SNPs 
not removed by SNPfilter that are homozygous and non-synonymous are candidates for the 
phenotype used to sort the mutant and sibling pools.  
Transmission electron microscopy (TEM) 
TEM was performed between body segments 5-7 of 8.5 dpf zebrafish larvae using established 
protocols employing microwave assistance (Czopka & Lyons 2011). In brief, individual larval 
trunks were fixed in modified Karnovsky’s fixative (4% PFA, 2% glutaraldehyde, 0.1M sodium 
cacodylate, pH 7.4) via microwave assistance and then overnight at 4° C. After genotyping and 
pooling samples with the same genotypes, samples were washed with 0.1M sodium cacodylate 
and post-fixed for 1 hour in 2% osmium tetroxide in 0.1M sodium cacodylate and 0.1M 
imidazole. Samples were then washed with ultrapure water and stained with saturated uranyl 
acetate. Larvae were dehydrated using increasing concentrations of ethanol then 100% acetone, 
and finally were infiltrated overnight with a 1:1 acetone:EPON mix at room temperature using 
gentle agitation of the tubes. The next day, samples were transferred to 100% EPON, while 
allowing any residual acetone to fully evaporate. Finally, individual larvae were embedded in 
100% EPON and baked at least 48 hours at 65° C.   
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When the EPON was solid, excess material was trimmed off each block and thin (70 nm) 
sections were mounted on copper mesh grids (Electron Microscopy Sciences, Hatfield, PA). 
Grids were stained again with saturated uranyl acetate for an hour, rinsed with ultrapure water, 
and then stained with Sato’s lead stain for 6 minutes. Grids were imaged using a Jeol (JEM-
1400) electron microscope and images were collected using an AMT V601 digital camera. All 
images were analyzed using the FIJI module of Image J and Adobe Photoshop.  
Morpholino Injections 
A morpholino targeting fbxw7 has been previously described and validated (Snyder et al. 2012). 
For injections, the morpholino was diluted in ultrapure water supplemented with phenol-red dye 
(10%) to obtain a final concentration of 2.5 µg/µl. Embryos were injected at or before the 1-cell 
stage with 2.5 ng of morpholino in a total volume of 2 nl. To control for potential adverse effects 
of the injections, control siblings were also injected with an equal volume of phenol-red dye 
diluted 1:10 in ultrapure water. Finally, we scored morpholino and control-injected animals by 
mbp WISH. All scoring was performed blind to treatment. 
Data Access 
.bed files produced during sequencing the stl64 mutation, the three Perl scripts, and a guide to 
using these scripts are freely available (https://zenodo.org/record/843605).  
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retrograde transport in axons 
  
 178 
Preface: 
 
This chapter has been reproduced and adapted in its entirety from the following 
published manuscript: 
 
Drerup CM, Herbert AL, Monk KR, Nechiporuk AV. (2017) Regulation of 
mitochondria-dynactin interaction and mitochondrial retrograde transport in axons. 
Elife 6.  
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B.1 Abstract 
Mitochondrial transport in axons is critical for neural circuit health and function. While 
several proteins have been found that modulate bidirectional mitochondrial motility, factors that 
regulate unidirectional mitochondrial transport have been harder to identify. In a genetic screen, 
we found a zebrafish strain in which mitochondria fail to attach to the dynein retrograde motor. 
This strain carries a loss-of-function mutation in actr10, a member of the dynein-
associated complex dynactin. The abnormal axon morphology and mitochondrial retrograde 
transport defects observed in actr10 mutants are distinct from dynein and dynactin mutant axonal 
phenotypes. In addition, Actr10 lacking the dynactin binding domain maintains its ability to bind 
mitochondria, arguing for a role for Actr10 in dynactin-mitochondria interaction. Finally, genetic 
interaction studies implicated Drp1 as a partner in Actr10-dependent mitochondrial retrograde 
transport. Together, this work identifies Actr10 as a factor necessary for dynactin-mitochondria 
interaction, enhancing our understanding of how mitochondria properly localize in axons. 
B.2 Introduction 
Mitochondrial transport in axons is critical for the formation and function of the nervous 
system. This organelle generates the ATP necessary for energy demanding functions in all cells, 
but neurons are especially reliant on mitochondria to maintain their electrically polarized state. 
After depolarization, ATP-dependent ion pumps are employed to repolarize the cell and prepare 
it for another action potential. It is estimated that at rest alone, neurons use 4.7 billion molecules 
of ATP per second (Zhu et al., 2012). Because of this large ATP requirement, mitochondria need 
to be properly localized to regions of high ion influx, such as at synapses (reviewed in Schwarz, 
2013). In addition to their critical role in cellular metabolism, mitochondria also regulate local 
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calcium ion levels (Werth and Thayer, 1994). Calcium efflux from intracellular stores mediates 
synaptic activity. During inactivity, this ion needs to be contained in intracellular compartments 
as high cytoplasmic calcium levels correlate with axonal degeneration (Avery et al., 2012; 
Vargas et al., 2015; Yang et al.,  2013). The proper localization of mitochondria to sites of high 
ATP consumption and calcium ion flux requires active transport. 
In addition to maintaining axon health, mitochondrial motility is also necessary to 
maintain mitochondrial health and function. Mitochondria undergo fission-fusion dynamics that 
facilitate both the replenishment of proteins in this organelle and the maintenance of 
mitochondrial DNA quantity and integrity (reviewed in Scheibye-Knudsen et al., 2015).  
Interrupted mitochondrial fission or fusion has been linked to loss of mitochondrial DNA, loss of 
oxidative potential, and mitophagy. Axonal transport of mitochondria is tightly linked to 
mitochondrial dynamics as mitochondrial fusion requires the coalescence of mitochondria and 
fission requires the active separation of dividing organelles. The relationship between 
mitochondrial dynamics and transport is also apparent at the molecular level: Mitofusin, an 
essential protein for mitochondrial fusion, participates in the anterograde transport of this 
organelle as well (Misko et al., 2010). Furthermore, manipulation of the dynamin-like protein 
Drp1, necessary for mitochondrial fission, impacts the localization of mitochondria (Smirnova et 
al., 2001; Varadi et al., 2004). The mechanistic bases for these relationships are still largely 
unclear. 
Elegant work in Drosophila, C. elegans, and cultured neurons has begun to elucidate the 
mechanisms of mitochondrial axonal transport. The primary anterograde mitochondrial motor, 
Kinesin-1, attaches to mitochondria via the proteins Miro (RhoT1/2; Guo et al., 2005) and 
Milton (TRAK1/2; Glater et al., 2006; Stowers et al., 2002). Miro contains calcium sensitive EF 
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hands that, when exposed to high levels of this ion, change their confirmation, resulting in the 
uncoupling of the Kinesin-1 motor from microtubules (Saotome et al., 2008; Wang and Schwarz, 
2009). This mechanism, in conjunction with mitochondrial tethering factors (Kang et al., 2008), 
allows mitochondrial congregation at sites of high synaptic activity. The Miro/Milton transport 
machinery is not specific for anterograde transport, however, as loss of either protein impacts 
anterograde and retrograde mitochondrial movement (Guo et al., 2005; Saotome et al., 2008). 
Therefore, how mitochondria are specifically moved in a unidirectional manner by either the 
Kinesin or Dynein motor protein complex is not well understood. 
Retrograde mitochondrial transport is known to depend on the cytoplasmic dynein 
complex (Pilling et al., 2006; Schnapp and Reese, 1989). The core dynein motor (reviewed in 
Holzbaur and Vallee, 1994) is oftentimes associated with dynactin, itself a multi-protein 
complex, during retrograde axonal transport. Dynactin, specifically its p150 subunit, has been 
shown to facilitate dynein processivity and also serves as an anchor for dynein at microtubule 
plus ends, facilitating cargo loading (Lloyd et al., 2012; Moughamian and Holzbaur, 2012; 
Schroer, 2004). The dynactin accessory complex is attached to dynein through interaction of 
p150 with the tails of the dynein intermediate chains (Vaughan and Vallee, 1995). In addition to 
p150, dynactin contains two actin-related proteins, Arp1 and Actr10 (also known as Arp11; 
Eckley et al., 1999; Eckley and Schroer, 2003).  Together with p25, p62 and p27, Actr10 is a part 
of the dynactin pointed end complex which is predicted to be in an ideal location for cargo 
binding (Yeh et al., 2012). Structural work suggests that one key function for Actr10 is capping 
the actin-like Arp1 filament, to regulate filament length and facilitate attachment of other pointed 
end proteins (Urnavicius et al., 2015); however, this does not preclude an additional role for 
Actr10 in cargo attachment to the dynein complex, a function which has not been explored. 
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In a forward genetic screen for mediators of retrograde axonal transport, we identified a 
strain with a loss-of-function mutation in Actr10. actr10nl15 mutants (hereafter referred to as 
actr10) display axon terminal swellings in the central and peripheral nervous systems indicative 
of retrograde transport abnormalities. Analysis of cargo localization and movement in the actr10 
mutant revealed clustering of mitochondria, but not other cargos analyzed, at microtubule plus 
ends due to failed retrograde mitochondrial movement. This phenotype was vastly different from 
loss of either Dynein heavy chain or p150, potentially indicating a unique function for Actr10 in 
mitochondrial retrograde movement. Furthermore, we demonstrated that abnormal mitochondrial 
movement in actr10 mutants is due to failed attachment of mitochondria to the dynein-dynactin 
complex in the absence of Actr10. Importantly, Actr10 engineered to lack the dynactin binding 
domain maintains mitochondrial interaction, hinting at a specific role for Actr10 in mediating 
dynactin-mitochondria interaction. Finally, we provide biochemical and genetic evidence that 
Drp1, a Dynamin-related protein previously implicated in microtubule minus end-directed 
mitochondrial movement (Smirnova  et  al.,  1998), partners with Actr10 in mitochondrial 
retrograde transport. Together our data support a model in which Actr10 functions to scaffold 
mitochondria to the dynein-dynactin complex for retrograde transport in axons. 
B.3 Results 
Mitochondria accumulate in actr10 mutant axon terminals due to failed retrograde 
transport 
We used the zebrafish posterior lateral line (pLL) system to identify novel mediators of 
retrograde cargo transport in axons (Drerup and Nechiporuk, 2013). pLL axons develop early 
(axon extension is complete by 2 days post-fertilization (dpf) and synapse formation occurs by 4 
dpf), are superficially localized and are largely planar, making them an ideal system for in vivo 
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observations and manipulations (Figure 1A; Ghysen and Dambly-Chaudière, 2004; Metcalfe, 
1985; Metcalfe et al., 1985). Using an ENU-based forward genetic screen, we isolated a larval-
lethal, recessive mutant strain with large swellings in pLL axon terminals (Figure 1B). 
RNAmapper analysis (Miller et al., 2013) identified the causal mutation as a single nucleotide 
change (T to G) in the start codon of actr10. We confirmed actr10 as the affected gene using 
RNA-mediated rescue of axon terminal swellings and by performing TALEN- (Transcription 
Activator Like Effector Nuclease) mediated disruption of the first exon of actr10, which 
phenocopied the mutant axon terminal swellings (Figure 1C–F). 
Axonal swellings, like those observed in actr10 mutants, can arise due to a number of 
intracellular abnormalities, including disruptions in retrograde cargo transport (Drerup and 
Nechiporuk, 2013;Martin et al., 1999). To determine if a particular cargo was accumulating in 
actr10 mutant axon terminals, indicative of impaired retrograde movement, we performed 
immunolabeling on mutants and wildtype siblings at 4 dpf with antibodies against various axonal 
cargos. This revealed an accumulation of Cytochrome c, a mitochondrial protein, in actr10 axon 
terminals (Figure 2A,B,E). To confirm mitochondrial accumulation in mutant axon terminals, 
mitochondria were labeled in neurons with TagRFP by zygotic injection of a plasmid containing 
a mitochondrial targeting sequence tagged with this fluorescent protein (5kbneurod:mito-
TagRFP). actr10 mutants displayed mitochondrial accumulation in pLL axon terminals (Figure 
2C,D). Other known pLL axon retrograde cargos, including those labeled by Lamp1 (Lysosome 
associated membrane protein1; late endosome/lysosome marker) and phosphorylated c-Jun N-
Terminal Kinase (pJNK) did not accumulate (Figure 2F–K; Drerup and Nechiporuk, 2013).  
Expression of wildtype Actr10 using zygotic injection of in vitro synthesized mRNA rescued 
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mitochondrial accumulation in actr10 mutants (Figure 2L–O), confirming that Actr10 is 
necessary for proper mitochondrial positioning. 
As our immunolabeling experiments were not exhaustive for every possible cargo in 
axons, we undertook transmission electron microscopy (TEM) analyses of pLL axon terminals to 
determine if mitochondria are the predominant cargo mislocalized in actr10 mutants. This 
experiment demonstrated mitochondria are highly enriched in the axon terminal swellings of 
actr10 mutants compared to other intracellular structures (Figure 3A,B; n = 3 wildtypes, n = 4 
mutants). Together, our immunolabeling and TEM analyses showing mitochondrial 
accumulation in axon terminals could indicate interrupted retrograde mitochondrial transport in 
actr10 mutants. 
To determine if mitochondrial retrograde transport was disrupted in actr10 mutants,  
mitochondria in single pLL axons were tagged with TagRFP using 5kbneurod:mito-TagRFP 
plasmid injection and organelle movement was visualized by confocal microscopy (Figure  
4A,B). Kymograph analysis demonstrated a 37% and 39% reduction in the distance moved by 
mitochondria in the anterograde and retrograde directions respectively in actr10 mutants but no 
change in mitochondrial transport velocity (Figure 4C–F). Despite the decrease in anterograde 
transport distance, the frequency of anterograde mitochondrial transport was unchanged in 
actr10 mutants. We also analyzed reversal frequency to determine if there was a defect in 
directional persistence of mitochondrial transport in actr10 mutants but found no difference in 
the proportion of mitochondria that reversed direction during our imaging sessions (wildtype:   
0.011 ± 0.008; actr10 mutants: 0.000 ± 0.009; ANOVA; p=0.4003). In contrast, both the 
frequency of retrograde mitochondrial transport and the proportion of mitochondria moving in 
the retrograde direction were dramatically decreased in actr10 mutants (Figure 4G,H). As 
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velocity of movement was largely normal, these data suggest a role for Actr10 in the attachment 
of mitochondria to the retrograde motor for transport. 
Actr10 functions autonomously in neurons to regulate axon morphology and mitochondrial 
localization 
actr10 is ubiquitously expressed, albeit enriched in the nervous system during larval  
stages (Figure 5A–C). As neuronal activity and the presence of growth factors can modulate 
mitochondrial transport (Chada and Hollenbeck, 2004; Chen and Sheng, 2013), it was possible 
that changes in the axonal environment in actr10 mutants could alter mitochondrial movement. 
This led us to ask if Actr10 functions autonomously in axons to regulate mitochondrial transport. 
To test for a neuron-specific function for Actr10 in mitochondrial localization, we expressed 
monomeric red fluorescent protein (mRFP) tagged Actr10 in individual pLL neurons using 
zygotic injection of a 5kbneurod:mRFP-actr10 DNA plasmid and assessed axon terminals. 
While mRFP-Actr10 expression in wild-type axons had no apparent effects (Figure 5D;  n = 6 in 
3 biological replicates), it rescued axon terminal morphology and mitochondrial localization in 
all mutants analyzed (Figure 5E–G; n = 5 mutants in 3 biological replicates). These experi- 
ments confirmed a neuron-specific function for Actr10 in mitochondrial localization in axons. 
Dynein localization and motility does not rely on Actr10 
Previous work on Actr10 function assayed mitotic spindle positioning during cell 
division in cultured fibroblasts and nuclear positioning in fungi to show that Actr10 depletion 
phenocopied dynein loss of function (Lee et al., 2001; Yeh et al., 2012; Zhang et al., 2008). In 
association with structural work implicating Actr10 in Arp1 filament capping (Urnavicius et al., 
2015), these data could imply that loss of Actr10 impacts dynactin integrity and, subsequently, 
all dynein function. However, the aforementioned work could also be interpreted to mean that 
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appropriate dynactin-nuclear membrane interaction requires Actr10 function. Supporting this 
possibility, Actr10 has been shown to regulate dynactin-membrane association (Clark and Rose, 
2006). With this data in mind, we next wanted to determine if loss of Actr10 phenocopied dynein 
or dynactin loss of function in mature neurons, the cell type that displayed specific defects in 
mitochondrial retrograde transport in our studies. First, we analyzed the localization of dynein 
and dynactin in actr10 mutant axons at 4 dpf. Neither Dynein heavy chain (DHC) nor p150 were 
significantly mislocalized in actr10 mutants, though we did observe a trend of increased DHC in 
actr10 mutant axon terminals (Figure 6A–F). Next, to determine if dynein was able to move in 
the retrograde direction, we assayed dynein motility by tagging the core motor complex using 
expression of an mRFP tagged variant of dynein light intermediate chain (5kbneurod: 
dync1li1V2-mRFP; Figure 6G,H). Kymograph analysis revealed no change in the parameters of 
retrograde dynein movement, though we did note a 42% reduction in the distance and a 26% 
reduction in the velocity of anterograde dynein transport. Despite these defects in anterograde 
dynein transport, there was no change in the proportion of dynein-positive puncta moving in the 
anterograde or retrograde direction in actr10 mutants at 4 dpf (Figure 6I–M). Additionally, we 
analyzed reversal frequency to determine if there was a defect in persistence of dynein 
movement in actr10 mutants but found no difference in the average number of puncta that 
reversed direction during our imaging sessions (wildtype: 1.62/100 mm*min ±0.37; actr10 
mutants: 1.74/100 mm*min ±0.44; ANOVA; p=0.844). These experiments demonstrated that 
loss of Actr10 does not impede dynein-dynactin complex localization or dynein retrograde 
movement in axons. 
We then analyzed the stability of dynein-dynactin interaction using co-
immunoprecipitation from whole larval extracts. Immunoprecipitation of endogenous proteins 
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was not possible due to lack of zebrafish-specific antibodies, so we turned to overexpression of 
tagged dynein components using zygotic injection of in vitro synthesized mRNA. First, we 
confirmed that a GFP tagged version of dynein intermediate chain 2b (i2b), a core dynein 
protein, could integrate into the motor complex. mRNA encoding i2b-GFP was injected into 
zygotes and anti-GFP antibodies were used to immunoprecipitate the complex. Extracts were 
subjected to western blot analysis and probed with anti-DHC antibodies. i2b-GFP can integrate 
into the core dynein complex (Figure 6N). We then used this approach to determine if loss of 
Actr10 impacts dynein-dynactin interaction. i2b-GFP was expressed in actr10 mutants and wild-
type siblings and larval extracts were subjected to GFP-based immunoprecipitation at 4 dpf. 
Western blot of larval extracts revealed no change in p150 interaction with the core dynein motor 
(Figure 6O). Together, these experiments confirmed that loss of Actr10 does not impact dynein-
dynactin interaction. 
To further explore the effect of loss of Actr10 on retrograde cargo transport, we analyzed 
the movement of additional dynein cargos in axons. First, we visualized peroxisome transport in 
lateral line axons. Kymograph analysis of peroxisome transport at 4 dpf demonstrated small 
changes in anterograde transport velocity and distance of retrograde transport bouts (Figure 7A–
G). A slight, but not significant decrease in the proportion of peroxisomes moving in the 
retrograde was apparent as well (Figure 7G; ANOVA; p=0.07). Upon further investigation, we 
found that previous studies revealed a surprising relationship between mitochondria and 
peroxisomes, including a large number of shared membrane proteins, such as Drp1 (reviewed in 
Schrader, 2006). Our work implicates Drp1 in Actr10-dependent mitochondrial localization (see 
Figure 12), making the impact of Actr10 loss of function on peroxisome transport complex. 
Therefore, we analyzed the transport of a third cargo, Lamp1-labeled vesicles, which are 
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composed of late endosomes and lysosomes. Analysis of Lamp1-positive vesicle movement at 4 
dpf demonstrated that this cargo is transported normally in actr10 mutant axons (Figure 7H–L). 
These live imaging experiments, in conjunction with the immunolabeling of known retrograde 
cargos (Figure 2) and our TEM studies (Figure 3), argue that loss of Actr10 does not hinder the 
transport of all dynein-dependent, retrograde cargos in axons. 
Since we observed small changes in retrograde peroxisome transport, we wanted to 
further investigate the relationship between loss of Actr10 and loss of dynein/dynactin. To do 
this, we analyzed the ability of DHC and p150 null mutants to phenocopy actr10 mutants. First, 
we compared actr10 mutants to a previously isolated zebrafish DHC mutant, dync1h1mw20 
(hereafter referred to as dync1h1; Insinna et al., 2010). Unlike actr10 mutants (see Figure 1), 
dync1h1 mutants displayed rapid degeneration of pLL axons by 4 dpf, with pLL nerves 
extending less than half-way to the tail at this time-point (Figure 8A,B). Mitochondria do 
accumulate in distal axons of dync1h1 mutants, as expected with global disruption of retrograde 
transport (Figure 8F,G). The disparity between actr10 and dync1h1 mutant axonal phenotypes 
argues that loss of Actr10 does not impact all dynein function in axons. 
We then compared the actr10 mutant phenotype to loss of dynein-dynactin interaction 
using zebrafish p150 mutants. There are two orthologs of p150 in zebrafish, p150a and p150b. 
These paralogues are highly similar at the amino acid level but have slightly different expression 
patterns: while both are ubiquitously expressed, p150b is enriched in developing (1 and 2 dpf) 
and mature (4 dpf) neurons while p150a is enriched only in mature neurons 4 dpf (Figure 9A–F). 
To determine whether loss of p150 phenocopies the actr10 mutant, we assayed single and double 
p150 mutants using a p150a mutant described previously (Del Bene et al., 2008; Wehman et al., 
2005) and a novel p150b mutant we engineered (p150bnl16). Loss of p150a alone has no 
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discernable effect on axons or mitochondrial localization (Figure 8C,H). We used CRISPR-Cas9 
technology (Hwang et al., 2013) to create a deletion in exon 3 of p150b, which resulted in a 
frame-shift and premature stop site. p150b single mutants are indistinguishable from wild-type 
siblings at 4 dpf, with normal axon terminals and no abnormalities in mitochondrial localization 
(Figure 8D,I). This strain does not have the small eye phenotype observed in dync1h1 and p150a 
mutants (Figure 8A–D; Del Bene et al., 2008; Insinna et al., 2010; Wehman et al., 2005). Unlike 
single p150 mutants, p150a/b mutants are phenotypically similar to dync1h1 mutants, with 
truncated pLL axons and mitochondrial accumulation at axon ends (Figure 8E,J). This confirms 
the reliance of mitochondria on the dynein-dynactin complex for retrograde movement and 
demonstrates that actr10 mutants do not phenocopy the axon truncation phenotype of dynein or 
dynactin loss of function mutants. 
We then analyzed the effect of p150 loss of function on mitochondrial transport in pLL 
axons. Mitochondria were tagged with TagRFP using zygotic injection of the 5kbneurod:mito-
TagRFP plasmid and kymograph analysis was performed on videos acquired through live 
imaging (Figure 8K-N). Unlike loss of Actr10, p150a/b double mutants had an almost complete 
cessation of mitochondrial movement in the anterograde and retrograde directions (Figure 
8N,O). In addition, we noted a dramatic loss of mitochondria from the central portion of axons in 
p150a/b double mutants, likely because of the strong defect in anterograde mitochondrial 
transport (Figure 8P). Analyses of transport parameters revealed no change in the distance or 
velocity of the residual mitochondrial movement in either direction (Figure 8Q,R). The dramatic 
loss of all mitochondrial movement in p150a/b mutants, specifically reductions in both the 
anterograde and retrograde pools, is not observed in actr10 mutants, which have only a reduction 
in the retrograde mitochondrial pool (see Figure 4). Furthermore, two cargos known to localize 
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normally in actr10 mutants, pJNK and Lamp1 (see Figure 2), accumulate in in p150a/b mutant 
axon terminals (Figure 10A–D), indicating that the retrograde transport of these cargos is 
perturbed by loss of dynein-dynactin interaction. Therefore, our phenotypic, in vivo transport, 
immunolabeling and biochemical data fail to support the argument that loss of Actr10 impacts all 
dynein-dynactin function in axons and, instead, supports a specific requirement for Actr10 in 
mitochondrial retrograde transport in this neuronal compartment. 
Mitochondria fail to attach to the dynein-dynactin complex in actr10 mutants 
The specific effect of Actr10 depletion on retrograde mitochondrial transport frequency 
led us to ask if Actr10 is necessary to attach this organelle to the dynein motor complex. We 
addressed this question using mitochondrial fractionation from whole larvae (Figure 11A; 
Prudent et al., 2013). Analysis of fractions revealed equal levels of p150 in the input and heavy 
fractions between wildtype and actr10 mutants. Strikingly, in actr10 mutants, p150 was largely 
lost from the mitochondrial fraction with a concomitant increase of p150 to the light fraction, 
which contains all cellular components not pelleted under low centrifugation speeds (Figure 
11B,C). This result demonstrates the necessity of Actr10 for mitochondrial attachment to 
dynactin. 
To better define the mechanism of dynactin-Actr10-mitochondrial interaction, we 
identified the domain in Actr10 necessary for association with the dynactin complex using 
immunoprecipitation of deletion constructs (overlapping deletion of 40 amino acid regions) from 
HEK293T cells. Whereas Actr10△7–△10 deletions showed reduced binding to dynactin, 
Actr10△7 most consistently failed to immunoprecipitate dynactin in all experiments (Figure 
11E,F; n = 4). As this result was somewhat variable in HEK cells, we confirmed the necessity of 
this domain for Actr10-dynactin interaction in vivo using immunoprecipitation of Actr10 and 
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Actr10△7 from embryo lysates. This revealed a loss of interaction between Actr10△7 and 
dynactin, demonstrating the reliance of Actr10 on this region for interaction with dynactin 
(Figure 11G; n = 3). Finally, if Actr10 is a part of the scaffold necessary for mitochondria-
dynactin interaction, a separate mitochondrial binding domain likely exists in Actr10. If this is 
the case, Actr10 lacking the dynactin binding domain should maintain its interaction with 
mitochondria. To address this, we assayed the ability of Actr10△7 to bind mitochondria using 
mitochondrial fractionation. mRFP-Actr10 and mRFP-Actr10△7, expressed using zygotic 
microinjection of respective mRNAs, were both present in the mitochondrial fractionation 
(Figure 11D,H; n = 2), arguing that separate protein domains exist in Actr10 which are necessary 
for interaction with dynactin and mitochondria. This data supports a role for Actr10 in binding 
mitochondria to dynactin for retrograde mitochondrial transport. 
Drp1 functions with Actr10 in mitochondrial retrograde transport 
It is unlikely that Actr10 binds directly to mitochondria as it does not have predicted 
transmembrane or other membrane-associated domains. Rather, similar to Kinesin-1-
mitochondrial attachment, there are likely partner proteins that facilitate this interaction (Glater 
et al., 2006; Guo et al., 2005). Literature searches revealed a particularly strong association 
between Drp1 (Dynamin related protein 1), a GTPase associated with mitochondrial fission, and 
mitochondrial localization. Specifically, a lysine to alanine mutation at amino acid 38 in Drp1 
(mimicking a constitutively GDP-bound form) causes clustering of mitochondria in the 
perinuclear region of fibroblasts in a microtubule-dependent manner (Smirnova et al., 2001; 
Varadi et al., 2004). Using immunoprecipitation, we demonstrated that Drp1 interacts with 
Actr10, with strongly enhanced interaction between Actr10 and the Drp1K38A variant (Figure 
12A; n = 3 replicates in independent experiments; (Smirnova et al., 2001, 1998). 
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Next, we asked whether Drp1 works with Actr10 to regulate mitochondrial retrograde 
transport in vivo. To address this, we examined the genetic interaction between Drp1 and Actr10 
in mitochondrial localization in pLL neurons. We reasoned that if Drp1 and Actr10 function in 
the same pathway, Drp1 manipulation would impact the location of mitochondria in wildtype but 
not actr10 mutant axons. We expressed Drp1-mRFP, Drp1K38A-mRFP, and cytoplasmic mRFP 
(control) in pLL neurons using injection of a plasmid encoding the respective open reading frame 
under an inducible promotor. Mitochondria were labeled by 5kbneurod:mito-EGFP co-injection. 
In wild-type larvae, expression of Drp1K38A-mRFP caused mitochondrial clustering in the 
perinuclear region, phenotypically similar to the results observed in cultured fibroblasts (Figure 
12B,C; Smirnova et al., 2001; Varadi et al., 2004). In contrast, Drp1K38A-mRFP expression did 
not alter mitochondrial localization in actr10 mutant pLL neurons (Figure 12D,E). If Drp1K38A 
mediates retrograde mitochondrial movement, we predicted its expression would induce 
movement of mitochondria from the proximal axon into the cell body, leading to loss of 
mitochondrial occupation of the axon. Indeed, expression of Drp1K38A caused a substantial 
decrease in the number of mitochondria per micron in wildtype but not actr10 mutant axons 
(Figure 12F–J). Notably, actr10 mutants already have reduced mitochondrial occupation of pLL 
axons which could impact the fraction of mitochondria capable of motility in this assay. More 
definitive analyses of Drp1’s role in Actr10-dependent mitochondrial motility will be the subject 
of continued investigation. Together, the biochemical and genetic interaction between Actr10 
and Drp1K38A support a model in which Drp1, in its GDP-bound state, modulates dynein- based 
mitochondrial localization via an Actr10-dependent mechanism. 
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B.4 Discussion 
Using genetics, immunolabeling, biochemistry, and in vivo imaging of cargo movement, 
we have identified Actr10 as a mediator of retrograde mitochondrial transport. In the absence of 
this dynactin pointed end protein, mitochondrial retrograde transport frequency is selectively 
disrupted, leading to accumulation of this organelle in axon terminals. Importantly, the 
anterograde transport of mitochondria, the localization and transport of other cargos assayed, the 
localization of dynein-dynactin components as well as dynein retrograde movement are all 
largely intact in the absence of Actr10, arguing for a role for Actr10 in mitochondrial retrograde 
transport in axons. Additionally, Actr10 maintains its ability to interact with mitochondria 
without being incorporated into the dynactin complex, suggesting a specific role for this protein 
in linking this organelle to the retrograde motor. Finally, we demonstrated that Actr10, perhaps 
through interaction with Drp1, links mitochondria to the dynactin complex. Our study brings us a 
step closer to understanding how unidirectional mitochondrial transport is mediated in axons to 
maintain a functional neural circuit. 
Actr10s role in mitochondrial retrograde transport 
We provide multiple pieces of evidence supporting a function for Actr10 in 
mitochondrial transport. First, mitochondria are the only cargo analyzed whose localization or 
retrograde transport is significantly perturbed with loss of Actr10. If dynein-mediated cargo 
movement was generally disrupted, other cargos, including lysosomes and dynein itself, would 
fail to move in the retrograde direction as well. Second, the axonal phenotype of dynactin and 
dynein loss-of-function mutants is vastly different from actr10 mutants: dync1h1 and p150a/b 
mutants display pLL nerve degeneration at 4 dpf while actr10 mutants do not. Third, loss of 
dynactin-dynein interaction in p150a/b mutants impedes all mitochondrial transport, a phenotype 
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that is not observed in actr10 mutants. Fourth, neither the localization of dynein and dynactin nor 
the retrograde movement of dynein are perturbed with loss of Actr10. Lastly, we identified a 
domain in Actr10 (△7) that is essential for interaction with the dynactin complex but 
inconsequential for interaction with mitochondria. This piece of data is critical as it demonstrates 
that Actr10 can interact with this organelle independently of dynactin, arguing for a direct role 
for this protein in mitochondria-dynactin interaction. Together, our data argue that Actr10 is 
necessary for dynactin-dependent, retrograde transport of mitochondria in axons. 
Actr10 could directly link mitochondria to dynactin or potentially facilitate this 
interaction through other dynactin pointed end proteins, such as p62. p62 is of particular interest 
in this regard as it is predicted to rely on Actr10 for binding to the dynactin complex (Urnavicius 
et al., 2015). Based on our current data, we cannot rule out a role for this protein in 
mitochondrial transport. Furthermore, Actr10 interacting proteins, including p62, could have 
additional impacts on mitochondrial transport parameters, including transport distance. As noted 
above, actr10 mutants have slight deficits in the distance moved by mitochondria in both the 
anterograde and retrograde directions. While we cannot definitively ascertain the underlying 
mechanism of this disruption, at least three possibilities exist. First, bidirectional transport 
distance could be affected by the abnormal localization of mitochondria. Mitochondrial 
localization directly affects local levels of ATP, which in turn could compromise the processive 
activity of ATP-dependent motors necessary for long distance transport. Another possibility is 
local deficits in mitochondrial activity: if mitochondrial health is compromised, this could 
account for the bidirectional transport deficits of mitochondria. Finally, it is possible that Actr10 
or its interacting proteins, such as p62, regulate motor engagement. It is largely thought that 
cargos typically have anterograde and retrograde motors attached simultaneously and direction 
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of transport is attributed to regulation of motor engagement. More frequent oscillations in motor 
engagement due to loss of Actr10 or Actr10 interactors could account for the shortened distances 
moved by mitochondria in both directions. At this point, we do not have a full explanation for 
these transport parameter alterations but they are a topic of continued interest. 
Multiple roles for Actr10 in the cell 
Our data does not preclude a function for Actr10 in the retrograde transport of additional 
cargos in axons or other roles for Actr10, which could vary based on a number of factors 
including cell type and developmental stage. Of particular interest is a potential role for Actr10 
in peroxisome transport through interaction with Drp1. While we did not find a statistically 
significant difference in the proportion of peroxisomes moving in the retrograde direction, there 
was a trend towards a decrease in this population. As Drp1 is known to localize to peroxisome 
membranes as well (Schrader, 2006), it will be interesting to further explore the interplay 
between these proteins and the transport of these highly related organelles. In addition to cargo 
transport, one predicted function for Actr10, based on structural and biochemical data, is in 
capping the Arp1 filament (Urnavicius et al., 2015). In support of this role, knockdown of Actr10 
using siRNA in Cos7 cells resulted in dissociation of the dynactin complex pointed end (Yeh et 
al., 2012). Additionally, studies in the fungi neurospora and aspergillus demonstrated that loss of 
Actr10 phenocopies the abnormal nuclear positioning observed with loss of dynein (Lee et al., 
2001; Zhang et al., 2008). Similarly, zebrafish actr10 mutants display the small eye phenotype 
observed in dync1h1 and p150a mutants (see Figure 8 and Del Bene et al., 2008; Insinna et al., 
2010). Finally, similar to loss of p150, knockdown of Actr10 resulted in multipolar spindle 
formation in Cos7 cells (Yeh et al., 2012). Together, these data could imply that Actr10 is in fact 
necessary for all dynein-dynactin activity through stabilizing the Arp1 filament; however, they 
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could also be interpreted to mean that Actr10 is necessary for regulation of Arp1-membrane 
interaction. Indeed, Actr10 has been shown to regulate Arp1-membrane interaction (Clark and 
Rose, 2006) and the zebrafish eye phenotype in the p150a mutant is due to a defect in 
interkinetic nuclear migration (Del Bene et al., 2008). This type of function for Actr10 could also 
explain the nuclear positioning defect in the actr10 loss of function studies in fungi (Lee et al., 
2001; Zhang et al., 2008). Therefore, rather than purely serving a stabilizing role for the dynactin 
complex, Actr10 may modulate both Arp1 interaction with the nuclear membrane and 
mitochondria-dynactin binding in axons. How these functions are disparately regulated in 
different cell types, in different cellular compartments and/or at varying developmental stages is 
still unclear. 
Given the previous data implicating Actr10 in Arp1 capping and subsequent dynactin 
stability and dynein function (Urnavicius et al., 2015; Yeh et al., 2012; Zhang et al., 2008), we 
were presented with the challenge of confirming that Actr10 has a specific function in 
mitochondrial retrograde transport and reconciling our work with these previous studies. As 
outlined above, our evidence for a role for Actr10 in mitochondrial transport specifically 
includes: (1) actr10 mutant axons are not phenotypically identical to dync1h1 or p150 mutants; 
(2) mitochondrial retrograde, but not anterograde, transport is disrupted in actr10 mutants while 
all mitochondrial movement is inhibited in p150a/b mutants; and (3) localization and transport of 
all other cargos are not disrupted in actr10 mutants. Together, these results argue that loss of 
Actr10 does not impact all dynein-dynactin function. In addition, a variant of Actr10 lacking the 
dynactin binding domain retains its ability to interact with mitochondria, further substantiating a 
direct role for this protein in mitochondria-dynactin interaction. Together, our data argue that 
Actr10 participates in mitochondrial attachment to the retrograde motor protein complex in 
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neurons in addition to potentially facilitating Arp1 capping and nuclear positioning in other 
contexts. 
Drp1 and Actr10 function together to regulate mitochondrial retrograde transport 
The interaction between Drp1 and Actr10 in mitochondrial retrograde transport may 
provide a link between mitochondrial movement and mitochondrial fission. Originally, we 
investigated the role of Drp1 in retrograde mitochondrial transport as previous studies revealed 
the unique ability of this GTPase to elicit mitochondrial localization to microtubule minus ends 
(Smirnova et al., 2001, 1998). Upon further investigation, it became apparent that a select 
number of proteins implicated in mitochondrial fission and fusion, including Drp1, have been 
shown to be essential for mitochondrial transport. Specifically, the fusion-related protein 
Mitofusin binds to the Miro-Milton complex and is necessary for mitochondrial movement 
(Misko et al., 2010). Similar to Miro and Milton, loss of Mitofusin results in decreased 
anterograde and retrograde mitochondrial transport in cultured neurons (Misko et al., 2010). 
Interestingly, the inner mitochondrial membrane protein Opa1, also necessary for mitochondrial 
fusion, does not participate in transport (Misko et al., 2010). Thus, eliminating mitochondrial 
fusion itself does not impact mitochondrial movement; rather mitochondrial outer membrane 
proteins may have dual roles in fusion-fission dynamics and transport. 
Similarly, our work in conjunction with other studies supports the argument that Drp1 
participates in both mitochondrial fission and retrograde mitochondrial transport. Drp1 
translocates to mitochondria where it can bind to receptors Fis1 and Mff (LosonLosón et al., 
2013). In its GTP-bound form, it then oligomerizes, forming a constrictable collar necessary for 
fission during which GTP is exchanged for GDP (Ingerman et al., 2005). We found that a Drp1 
variant incapable of binding GTP stimulates mitochondrial accumulation at the nuclear 
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periphery, linking fission with transport. Our genetic interaction data suggest that Actr10 
functions with Drp1 in this process, though further experiments are necessary to confirm this. 
Rather than Actr10 working with Drp1 to regulate mitochondrial localization, it is also possible 
that loss of Actr10 results a decrease in the motile pool of mitochondria in axons upon which 
Drp1K38A could work. We cannot differentiate between these possibilities at this point. 
Nevertheless, given the intriguing data generated here, it is tempting to speculate that, upon the 
GTP-GDP transition, not only do mitochondria undergo fission but Drp1 also recruits the 
retrograde motor protein complex through interaction with Actr10 to facilitate separation of these 
daughter mitochondria. The precise nature of Drp1-Actr10 interaction and the role of this 
interaction in mitochondrial retrograde transport is a subject of current investigation. 
B.5 Conclusions 
The coordinated regulation of mitochondrial transport is necessary for the formation and 
maintenance of active neural circuits. Our work identifies Actr10 as a crucial protein for 
mitochondrial interaction with the dynein-dynactin complex, regulating retrograde transport. In 
addition, we argue that the role of Actr10 is specific and not due to a general loss of dynactin 
stability or dynein function. The strongest pieces of evidence supporting this assertion are the 
ability of Actr10 to bind mitochondria in the absence of dynactin and the disparate nature of the 
actr10-dync1h1 and actr10-p150a/b mutant phenotypes in axons. In addition, we identified 
Drp1, a GTPase implicated in mitochondrial fission, as an Actr10 interactor with a potential role 
in mitochondrial retrograde transport. Together with previous studies on mitochondrial motility, 
a complex picture is emerging in which mitochondrial transport and fission/fusion are dependent 
on a core group of proteins, with an independent set of proteins regulating mitochondrial 
docking. In conclusion, further work is crucial to understanding how mitochondrial transport and 
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dynamics are orchestrated in axons, which will ultimately allow us to better understand how this 
critical organelle is positioned and maintained. As mitochondrial transport and dynamics have 
been implicated in neurological disorders, a more complete mechanistic understanding of their 
regulation will provide insight into disease pathology. 
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B.6 Figures 
 
Figure 1. actr10 mutants have swollen axon terminals.  
(A) Wild-type larva (pigment free) at 4 dpf carrying the neurod:egfp BAC transgene. By 4 dpf, 
pLL axons are fully extended and functional synapses have formed with hair cells of primary 
neuromasts. (B) actr10 mutant axons fully extend but terminals display large swellings. Posterior 
lateral line ganglion (pLLg) and innervation of the third neuromast (NM3) are indicated. Insets 
in (A) and (B) show magnified NM3 axon terminals. Arrows in inset point to swellings. 
Asterisks label areas of the pLL nerve obscured by pigment in the mutant. (C) The mutant axon 
terminal swelling phenotype can be suppressed by exogenous expression of mRFP-Actr10 in a 
dose-dependent manner. Proportion of mutants with axon terminal swellings is depicted. (D–F) 
Injection of TALENS targeting exon 1 of the actr10 genomic locus phenocopies the actr10 
mutant axon terminal swelling phenotype in F0 injected larvae (arrows). Axons are labeled by 
the neurod:egfp BAC transgene (white). Scale bars in A, B = 100 µm 
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Figure 2: Loss of Actr10 causes mitochondrial accumulation in swollen axon terminals.  
(A,B) At 4 dpf, swollen axon terminals in actr10 mutants (B) have high levels of Cytochrome c 
immunolabeling (arrow; NM3 shown) relative to a wildtype sibling (A). (C,D) TagRFP-labeled 
mitochondria accumulate in actr10 mutant (arrow), but not wildtype, axon terminals at 4 dpf. (E) 
Mean fluorescence intensity (background subtracted) of Cytochrome C in axon terminals of A 
and B. (F,G) Mean fluorescence intensity (background subtracted) in axon terminals of H-K 
show comparable levels of Lamp1 and pJNK fluorescence intensity between wildtype and actr10 
mutant terminals (ANOVA; mean ± SEM shown). (H–K) Lamp1 and pJNK immunolabeling in 
NM3 axon terminals (arrows). Lamp1 and pJNK are in red in (H–K) and white in H’-K’. (L–O) 
Mitochondrial accumulation in mutant axon terminals, assayed using Cytochrome c 
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immunolabeling (white), can be suppressed by mRNA-mediated expression of mRFP-Actr10. 
Arrows point to axon terminal regions for comparison. Scale bars = 10 µm. 
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Figure 3: TEM analysis of axon terminal swellings reveal mitochondrial accumulation. 
 (A) Wild-type axon terminals innervating lateral line neuromasts showed no swellings (N = 3). 
(B) All neuromasts assayed in actr10 mutants had mitochondrial laden axon terminal swellings 
(N = 4). A’ and B’ are higher magnification views of the areas outlined in A and B. Arrowheads 
in B’ point to mitochondria. 
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Figure 4: Mitochondrial retrograde transport is specifically disrupted in actr10 mutants.  
(A,B) Stills from Videos 1 and 2 of mitochondrial transport in single pLL axons of a wildtype 
(A) and actr10 mutant (B). Yellow and red arrowheads point to mitochondria moving in the 
anterograde and retrograde directions respectively. (C,D) Kymograph analyses of mitochondrial 
transport in wildtype (C) and actr10 mutants (D). (E,F) Distance and velocity of mitochondrial 
transport in actr10 mutants (Ant-anterograde; Ret-retrograde; ANOVA). (G) The number of 
mitochondria moving in the retrograde direction is significantly reduced in actr10 mutants 
(ANOVA; p<0001). (H) The proportion of mitochondria moving in the retrograde, but not 
anterograde, direction is reduced in actr10 mutants (ANOVA with post-hoc contrasts; p<0.01). 
Scale bars = 10 µm. Error bars represent mean ± SEM. Number of larvae assayed (biological 
replicates) is indicated on graphs. 
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Figure 5: Actr10 functions cell autonomously in axons.  
(A–C) Expression of actr10 mRNA was assayed using in situ hybridization with DIG-labeled 
riboprobes and alkaline phosphatase-mediated NBT/BCIP precipitation. actr10 is ubiquitously 
expressed at all time points tested, with elevated expression in the nervous system at later stages 
(3 and 5 dpf). Arrows point to the pLL ganglion in B and C. (D) Neuronal mRFP-Actr10 
expression does not alter axon morphology or mitochondrial localization in wildtype larvae at 4 
dpf. Mitochondria were visualized by Cytochrome c immunolabeling in NM3 axon terminals. 
(E) Uninjected actr10 mutants have high levels of Cytochrome c immunolabling in NM3 axon 
terminals at 4 dpf. (F) mRFP-Actr10 expression in actr10 mutant neurons suppressed axon 
terminal swellings and mitochondrial accumulation. Yellow arrowhead points to the region of 
the axon terminal expressing mRFP-Actr10. Note that mRFP-Actr10 negative axon terminals 
(red arrowhead) display axonal swelling and high levels of Cytochrome c labeling. Lines in D”, 
E” and F” indicate regions used for line scan analysis. (G) Line scans show that mRFP-Actr10 
expression rescues Cytochrome c levels in actr10 mutant axons (compare pink/red and yellow 
lines). Pigment cells (*) obscure some nerves. Scale bars = 10 µm. 
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Figure 6: Dynein-dynactin localization and retrograde movement are intact in actr10 
mutants.  
(A,B) Dynein heavy chain (DHC) immunolabeling demonstrates normal DHC localization in 
NM3 axon terminals of actr10 mutants at 4 dpf. (C,D) p150 is normally localized in NM3 axon 
terminals of actr10 mutants at 4 dpf. (E,F) Analyses of mean fluorescence intensity in axon 
terminals (background subtracted) showed comparable fluorescence intensity between mutant 
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and wildtype siblings (ANOVA; mean ± SEM shown). (G,H) Stills from dynein time-lapse 
imaging sessions (Videos 3 and 4) in wildtype and actr10 mutant pLL axons at 4 dpf. 
Arrowheads indicate retrograde dynein movement. (I,J) Kymograph analyses of dynein transport 
in wildtype (I) and actr10 mutants (J). (K–M) Retrograde dynein transport parameters, including 
the proportion of dynein-labeled vesicles (K), distance moved by vesicles (L) and velocity of 
movement (M) are unaffected in actr10 mutants (ANOVA; mean ± SEM shown). A reduction of 
anterograde dynein-positive puncta distance and velocity was noted (ANOVA; mean ± SEM 
shown). (N) Dynein intermediated chain 2b fused to GFP (i2b-GFP) interacts with the core 
dynein complex. Immunoprecipitation of i2b-GFP from whole embryo extracts followed by 
DHC western (top). Whole embryo lysate controls for i2b-GFP (middle; top band not present in 
wildtype) and DHC (bottom). Bead only (no 1˚) immunoprecipitation controls shown. (O) The 
core dynein complex labeled by i2b-GFP can immunoprecipitate p150 from whole larval lysates 
derived from wildtype and actr10 mutant larvae at 4 dpf (top). Whole larval lysate control for 
i2b-GFP (middle) and p150 (bottom). Bead only (no 1˚) and uninjected wildtype 
immunoprecipitation controls shown. Scale bars = 10 µm. Number of larvae assayed is indicated 
on graphs. 
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Figure 7: Peroxisome and Lamp1 vesicle transport in actr10 mutants at 4 dpf.  
(A,B) Stills from peroxisome imaging sessions at 4 dpf from Videos 5 and 6. Yellow and red 
arrowheads point to anterograde and retrograde peroxisome movement respectively. (C,D) 
Kymographs analyses of peroxisome transport in wildtype (C) and actr10 mutants (D). (E–G) 
Peroxisome transport parameters were similar between actr10 mutants and wildtype siblings, 
though a slight reduction in retrograde distance and anterograde velocity were noted (ANOVA; 
mean ± SEM shown). The proportion of peroxisomes moving in the retrograde direction was 
reduced as well, though not significantly (ANOVA; mean ± SEM shown; p=0.07). (H,I) 
Kymographs of Lamp-labeled vesicle movement at 4dpf. (J–L) Lamp1 vesicles were transported 
similarly between wildtype and actr10 mutants. An increase in the proportion of these vesicles in 
mutants that were stationary during imaging was noted (p<0.01; ANOVA; mean ± SEM shown). 
Number of larvae assayed is indicated on graphs. Scale bars = 10 µm. 
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Figure 8: dync1h1 and p150a/b mutants fail to phenocopy actr10 mutants. 
(A) Wildtype larva at 4 dpf with full pLL axon extension into the tail. End of pLL nerve 
indicated by arrowhead. (B) Loss of DHC in dync1h1 mutants results in pLL axon degeneration, 
leading to a truncated pLL nerve at 4 dpf. Small eyes are also apparent (red dotted line), as has 
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been reported previously. (C) p150a mutants have small eyes (red outline) but pLL nerves are 
identical to wildtype siblings. (D) p150b mutants at 4 dpf with normal pLL nerves and no change 
in eye diameter. (E) p150a/b double mutants have truncated, thin pLL nerves with swellings 
along the length of axons and in terminals and are indistinguishable from dync1h1 mutants. 
p150a/b mutants also show small eyes similar to dync1h1 and p150a mutants. (F,G) dync1h1 
mutants display axon terminal swellings and mitochondrial accumulation compared to wildtype 
controls at 4 dpf. Arrows point to mitochondria rich, axonal swellings. Mitochondria are labeled 
by expression of mito-TagRFP (red on top F-J, white below F’-J’). (H,I) p150a and p150b single 
mutants have axon terminal morphology and mitochondrial localization in axon terminals similar 
to wildtype siblings. (J) Loss of both p150 paralogues (p150a/b; J) results in swollen axon 
terminals with increased mitochondrial density similar to dync1h1 mutants (G). (K–N) 
Kymograph analyses of mitochondrial transport in p150 mutants. (O) The proportion of 
mitochondria moving in both the anterograde and retrograde direction in pLL axons is 
significantly decreased in p150a/b double mutants (ANOVA with Tukey HSD post-hoc 
contrasts). (P) The number of mitochondria in pLL axons is decreased in p150a mutants 
compared to wildtype siblings (ANOVA with Tukey HSD post-hoc contrasts; *p<0.05). The 
number of mitochondria in pLL axons of p150a/b double mutants is dramatically reduced 
compared to wildtype siblings (ANOVA with Tukey HSD post-hoc contrasts; mean±SEM 
shown). (Q,R) Distance and velocity of limited residual mitochondrial movement is not 
significantly altered in p150a/b mutants compared to wildtype siblings (ANOVA with Tukey 
HSD post-hoc contrasts; mean ± SEM shown). Scale bars in A-E = 100 µm. Scale bars in F-J = 
10 mm. Number of larvae assayed is indicated on graphs. 
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Figure 9: p150a and p150b expression in zebrafish embryos and larvae.  
(A,C,E,E’) p150a in situ hybridization shows ubiquitous expression at 1 and 2 dpf, with a slight 
enrichment in neurons of the pLL ganglion at 4 dpf. (B,D,F,F’) p150b is enriched in developing 
neurons with low level expression ubiquitously at all stages assayed. pLL and anterior lateral line 
ganglia are indicated by an arrowhead or arrow respectively in all. *=ear. Higher magnification 
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views of the ear, pLL ganglia, and anterior lateral line ganglia shown in insets in B’, D’, E’, and 
F’. Scale bars in A-F = 100 µm. Scale bars in B’ and D’-F’=20 µm. 
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Figure 10: pJNK and Lamp1 accumulate in p150a/b pLL axon terminals.  
(A,B) pJNK accumulates in axon terminals at 4 dpf in p150a/b double mutants. NM3 shown. 
(C,D) Lamp1 accumulates in NM4 axon terminals at 5 dpf in p150a/b double mutants. Arrows 
point to axon terminals in wildtype and p150a/b double mutants in all. Axons are labeled by the 
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neurod:egfp BAC transgene (green). Lamp1 and pJNK are show in red in A-D and white in A’-
D’. Scale bars = 10 µm. 
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Figure 11: Actr10 is essential for mitochondria-dynactin interaction. 
 (A) Schematic of whole embryo mitochondrial fractionation. (B) While the level of p150 in the 
input and heavy fractions are comparable between wildtype and actr10 mutants, p150 is shifted 
from the mitochondrial to light fraction in actr10 mutants. ATPβ western blot from the same 
extracts (bottom) serves as a mitochondrial loading control. (C) Quantification of p150 intensity 
(normalized to mitochondrial loading) in actr10 mutants relative to wildtype. (D) Quantification 
of p150 intensity (normalized to mitochondrial loading) in mRFP-Actr10△7expressing embryos 
relative to those expressing mRFP-Actr10. (E) Schematic and sequence of the 47 region in 
Actr10. (F) Immunoprecipitation of EGFP-Actr10 deletion constructs from HEK293T cells 
identified the △7 region as critical for Actr10’s interaction with the dynactin complex (n = 4 
replicates). (G) In zebrafish embryos, mRFP-Actr10△7, expressed by zygotic injection of in 
vitro synthesized mRNA, was unable to interact with dynactin (top). mRFP-Actr10 and mRFP-
Actr10△7 (middle) and p150 (bottom) are all present at similar levels. Bead only (no 1˚) 
immunoprecipitation controls shown. (H) Actr10△7 is able to interact with mitochondria in 
zebrafish embryos as assayed by mitochondrial fractionation. ATPβ mitochondrial loading 
control (bottom). 
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Figure 12: Drp1 functions with Actr10 in mitochondrial retrograde transport.  
(A) EGFP-Actr10 interacts with myc-Drp1 in HEK293T cells. The K38A mutation in Drp1 
strengthens this interaction (n = 3 replicates). (B,C) Expression of Drp1K38A-mRFP causes 
mitochondrial clustering in wildtype pLL neuron cell bodies at 4 dpf compared to an mRFP only 
control (B). (D,E) Though mitochondrial morphology is abnormal in actr10 mutant pLL neuron 
cell bodies (D), expression of Drp1K38A-mRFP does not cause clustering of this organelle (E). 
(F–I) While expression of Drp1K38A-mRFP in wildtype larvae causes loss of mitochondria from 
the proximal axon compared to mRFP only controls (F,G), mitochondrial number is unaffected 
by Drp1K38A-mRFP expression in actr10 mutants (H,I). Arrowheads point to mitochondria in 
mRFP-expressing axons. Mitochondria are labeled by expression of a mitochondrial targeting 
sequence tagged with EGFP (5kbneurod:mito-EGFP; green in B-I, white in B-I’). (J) 
Quantification of mitochondrial number normalized to mitochondrial size in the proximal axon 
(ANOVA with post-hoc contrasts; mean ± SEM shown). Scale bars = 10 µm. Number of larvae 
assayed is indicated on graphs. 
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B.7 Materials and methods 
Zebrafish husbandry and strains 
Adult *AB and WIK strains were maintained at 28.5˚C and spawned according to standard 
protocols (Westerfield, 2000). ENU mutagenesis and mutant screening were performed as 
described previously (Mullins et al., 1994). Additional strains used include: 
TgBAC(neurod:egfp)nl1 (Obholzer et al., 2008), actr10nl15, dync1h1mw20 (Insinna et al., 2010), 
p150a (also known as moks309; (Del Bene et al., 2008; Wehman et al., 2005), and p150bnl16. 
RNA-seq based identification of the actr10nl15 mutation and genotyping 
RNAseq-based mapping was performed according to established protocols (Miller et al., 2013). 
actr10 heterozygotes (*AB background) were crossed to WIKs to generate a mapping strain. 
Heterozygous F1 hybrids were identified using pair wise crosses. Eighty wildtypes/heterozygotes 
and 80 actr10 mutants were obtained from a single mapping pair. These larvae were lysed at 4 
dpf in Trizol according to the manufacturer’s protocol. mRNA was extracted in 
phenol:chloroform:isoamyl alcohol and twice in chloroform before the pellet was redissolved in 
20 mL of RNase/DNase free water. Sequencing was performed by the OHSU Massively parallel 
sequencing core on an Illumina HiSeq2000, generating approximately 30 million reads per 
condition. From this RNAseq data, RNA-mapper identified a single nucleotide change in the 
start codon of the actr10 gene in the actr10nl15 mutant pool. The mutation (validated by 
sequencing and restriction digest of individual samples) completely segregated with the mutant 
phenotype. For experiments, actr10 mutants were identified by genotyping according to the 
following protocol: PCR amplification of the region around exon 1 of the actr10 locus resulted 
in a 374 bp product (forward primer: 5’-CTGTTTTCGGATGAACTGCCTG; reverse primer: 5’-
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AGATGCTCTTCGTCTTCTGGCTA. The actr10 mutation inserts a HaeIII cut site. Digestion 
with HaeIII generates wildtype (209 bp) and actr10 mutant (195 bp) bands. 
Cloning the zebrafish ortholog of actr10, plasmid production, TALEN synthesis, and 
mRNA synthesis 
The full-length open reading frame of actr10 was cloned from a 2 dpf zebrafish cDNA library 
and ligated into the pSC-A-amp/kan vector (Agilent Technologies; forward primer: 5’-
AAATGCCCTTG TTTGAA; reverse primer: 5’-TTTCTCAGTGGAGAAGG). All expression 
and mRNA synthesis vectors were constructed using Gateway compatible cloning as described 
(Kwan et al., 2007). For Actr10 expression, the Actr10 open reading frame was PCR amplified 
with BP arms and inserted into the Gateway compatible 3’-entry vector pDONRP2R-P3 (forward 
primer: 5’-ggggacaagtttgtacaaaaaagcaggctAAATGCCCTTGTTTGAA; reverse primer: 5’-
ggggaccactttgtacaagaaagctgggtaTTTCTCAG TGGAGAAGG). Other constructs used included: 
5kbneurod:mito-TagRFP (modified from (Fang et al., 2012); 5kbneurod:mRFP-dync1li1V2 
(Drerup and Nechiporuk, 2013); Hsp701:mRFP- polyA; Hsp701:Drp1-mRFP; 
Hsp701:Drp1K38A-mRFP; and CMV/SP6:EGFP-dync1i2b. They were constructed as described 
here. The zebrafish dync1i2b ortholog was cloned into the pDONRP2P3 3’ entry vector using 
BP-competent primers (forward primer: 5’-ggggacagctttcttgtacaaagtggAGA 
TGGCTCCCGTTTTAGAGAAG; reverse primer: 5’-
ggggacaactttgtataataaagttgtTCATGCCTCGTTC TCTGTC) and a 2 dpf zebrafish cDNA library. 
The zebrafish Drp1 ortholog was cloned from 2 dpf cDNA, sequence verified, and cloned into 
the pDONR221 middle entry vector using BP cloning (forward primer: 5’-
GGGGACAAGTTTGTACAAAAAAGCAGGCTTCAACGCGATGGAGGCTCTTA;reverse 
primer: 5’-GGGGACCACTTTGTACAAGAAAGCTGGGTACCACAAGTGCGTC). To 
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generate Drp1K38A, the middle entry vector was mutated to change Lysine 38 to Alanine (forward 
primer: 5’- CGCAGAGTAGCGGGGCGAGTTCAG; reverse primer: 5’-
CCAAAACTGAACTCGCCCCGCTAC). All expression plasmids were constructed by LR 
cloning using the 5kbneurod (Mo and Nicolson, 2011), CMV/SP6, or Hsp701 5’ entry vectors  
and the pDestTol2pA2 destination vector. mRNA was synthesized using the SP6 mMessage 
Machine kit (Life Technologies). TALENs targeting exon 1 of actr10 were designed using 
freeware (http://www.talendesign.org) and synthesized as described (Dahlem et al., 2012); Tal1 
target: AATTTCTGCTGATAAAATGC; Tal2 target: GGGCAGCGGAGGAGA). 
Generation of the p150nl16 mutant and genotyping 
The p150bnl16 mutant was generated using CRISPR/Cas9-mediated genome editing as described 
(Hwang et al., 2013; Shah et al., 2015). Guide RNA targeting exon 3 (GGCGAGGGCAGCGC 
TCCCAC) of the p150b locus was produced using a PCR-mediated scaffold method as described 
(Gagnon et al., 2014). Cas9 mRNA (Chang et al., 2013) was produced using the SP6 mMessage 
machine kit. Zygotes derived from p150a (moks309) heterozygous outcrosses were injected with 
10 pg guide RNA and 100 pg Cas9 mRNA at the one cell stage. Progeny were raised until 
adulthood and outcrossed to wildtypes to generate larvae. Larvae were genotyped using PCR 
amplification of the exon 3 locus (forward primer: 5’-CGTGAGTGAGCTCTTGGTCTG; 
reverse primer: 5’-GCGTCTATAACCATGTTTGACCTTG) and cut with MwoI to identify 
insertions/deletions. Changes to the guide RNA target result in loss of the MwoI cut site in 
p150b mutants: wildtype (164 bp + 64 bp) from p150b mutants (224 bp). 
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In situ hybridization and antibody labeling 
In situ hybridization and antibody labeling were done according to established protocols (Drerup 
and Nechiporuk, 2013). The actr10 open reading frame was used for in situ hybridization. An 
~800 base pair portion the 3’UTR of p150a and p150b were used for in situ hybridization of 
these paralogues. Antibodies used were: a-Dynein heavy chain (Protein Tech; #12345–1-AP); a-
p150 (BD Transduction Laboratories; #610473); a-Lamp1 (Iowa Hybridoma Bank, #1D4B); a-
pJNK (Cell Signaling Technology, #9251S); a-GFP (Aves Labs Inc., #GFP-1020); a-DsRed 
(Clontech, #632496); a-Cyto- chrome c (BD Biosciences, #556432); a-GFP (Fisher Scientific, 
#A-11122); a-c-myc (Santa Cruz, #sc-40); and a-ATPb (Abcam; #ab128743). 
Cell culture, immunoprecipitation and mitochondrial fractionation 
HEK293T cells (Sigma Aldrich; #12022001; identity authenticated by STR-PCR) were cultured 
according to standard protocols in DMEM with 50 U/mL Pen-Strep. Cells tested mycoplasma 
free (MycoAlert Mycoplasma Detection Kit; Lonza; L07-218). This human cell line was used for 
its transfection ease and results were confirmed in vivo. Transfection was done in a 6-well plate 
using 2.5 mg total DNA and 5 mL of Lipofectamine2000 per well according to manufacturer’s 
protocols (Thermo Fisher;#11668027). The mammalian GFP-Actr10 clone was used previously 
(Yeh et al., 2012) and obtained from Addgene (plasmid #51398). Drp1-myc and Drp1K38A-myc 
expression constructs were previously described (Smirnova et al., 2001). GFP-Actr10 deletion 
constructs were made using the QuikChange II XL Site-Directed Mutagenesis kit (Agilent, 
#200521). 
Mitochondrial fractionation was performed according to established protocols (Prudent et 
al., 2013). Briefly, for each biological replicate 100 wildtype/heterozygous or actr10nl15 mutant 
larvae were disrupted in 700 mL MB buffer (210 mM mannitol, 70 mM sucrose, 1 mM EDTA, 
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10 mM HEPES pH = 7.5 and protease inhibitors) using a 26 gauge needle. After removal of the 
input fraction, lysates were subjected to increasing centrifugation speeds to fractionate 
mitochondria from a heavy and light fractions. The mitochondrial fraction was washed once in 
fresh MB buffer prior to addition of Laemmli buffer to the pellet and heat denaturation. Extracts 
were run on a 10% acrylamide gel, transferred to PVDF membrane, and incubated with 
antibodies prior to developing with the West Pico Substrate (Thermo Fisher; #34080). After 
initial development, membranes were washed in water and PBS/0.1% Tween prior to incubation 
with the a-ATPb antibody 
In vivo analysis of axonal transport 
Axonal transport analyses were done as described (Drerup and Nechiporuk, 2013). Briefly, 
zygotes were injected with plasmids to express cargos of interest tagged with fluorescent 
proteins. At 4 dpf, larvae (each a biological replicate) were screened for pLL ganglion expression 
of cargo fusions and imaged using a 63X/NA1.2 water objective on an FV1000 confocal 
microscope (Olympus). All imaging was done in a single z-plane, allowing acquisition at 2–4 
frames per second, as required by the Nyquist sampling theorem (Nyquist, 1928). Kymograph 
analyses of cargo movement were performed using Metamorph (Molecular Devices). 
Transmission electron microscopy 
Zebrafish larvae at 5 dpf were fixed and prepared for TEM analysis using standard protocols 
(Czopka and Lyons, 2011). Samples were embedded and sectioned from the tail of the larvae. An 
ultramicrotome was used to cut 1000 nm sections, which were then stained with Toluidine Blue 
to ensure the presence of neuromasts. Subsequently, 70 nm sections were cut and placed on 
copper mesh grids. Grids were stained with uranyl acetate for one hour and then each grid was 
cleaned with milliQ water for 45 s. The next day, grids were stained with Sato’s lead stain for 15 
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min and again cleaned with milliQ water. The Washington University Center for Cellular 
Imaging Jeol JEM- 1400 (Jeol USA) electron microscope was used to observe samples and an 
AMT V601 camera captured images. 
Image and statistical analyses 
Volumetric analyses to determine mean fluorescence intensity of immunolabeling was done 
using Imaris (Bitplane). For this analysis, a surface rendering was done using expression of the 
neurod:egfp transgene in axon terminals and the mean fluorescence intensity was determined. 
Background from the same channel was subtracted prior to analysis. For quantification of 
western blots, mean intensity of was determined for signal and background using ImageJ. 
Statistical analyses were done in JMP. Prior to parametric analyses, data normality and variance 
were determined. Parametric data was analyzed using ANOVAs with Tukey-Kramer HSD 
contrasts for multiple comparisons. Non-parametric data was analyzed using Wilcoxon/Kruskal 
Wallis Tests. Image analyses and figure preparation was done using ImageJ, Adobe Photoshop, 
and Adobe Illustrator. 
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